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I  
Preface 
 
 
 
 
The study of new molecules able to selectively and stably interact with DNA 
and RNA is a field of great interest in consideration all the possible applications in 
medicine. In the last years, many studies have been conducted aimed to the 
explanation of epigenetic modifications (DNA methylation, histone modification and 
expression   of   non-coding   RNA   molecules,   as   microRNA)   important   in   the 
mechanisms  of  gene  regulation;  in  fact  this  is  one  of  the  main  steps  for 
understanding the biology in both human conditions, normal and pathological, and for 
the development of new bioactive molecules. RNA has been the preferred target of 
long-standing studies aimed at the discovery of molecules able to block gene 
expression in a sequence selective way. 
During the past few years, molecular biologists have discovered hundreds of 
gene sequences that encode small RNA molecules, the microRNAs (miRNAs), 21 to 
25 nucleotides in length, which are involved in the post-transcriptional regulation of 
gene expression. Indeed, there are hints that the level of some miRNAs is altered in 
cancer and in other pathologies; for instance, miRNAs regulate cancer-promoting 
genes, playing a pivotal role in cancer onset and progression. Briefly, microRNAs 
recognizing a target sequence in the 3'UTR of the mRNA target, and based on the 
partial or total complementarity of the sequences, they bind to mRNA leading to the 
inhibition of translation or degradation of the mRNA, respectively. Furthermore, in the 
pathogenesis of tumors, miRs play a double role; in fact, if it interferes with an mRNA 
coding for a tumor-suppressor protein, it become "oncogenes", applying itself as a 
target for anticancer therapy. 
Synthetic oligonucleotides or analogues acting as competitors by binding to 
miRNA have been proposed as novel potential drugs. Among the most efficient 
molecules proposed for these applications are the PNAs. Peptide nucleic acids 
(PNAs) are oligonucleotide analogues with a polyamide backbone and are very 
promising tools for binding RNA, since they have a higher affinity for RNA than DNA, 
are stable to nucleases and are very specific. Their use as therapeutic agents have 
been proposed since early studies and recent advancements in cellular delivery 
systems; anti-gene and antisense strategies make them good candidates for drug 
development. 
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In this contest, we have selected the miR-221 as target for the ours novel 
engineered PNAs; miR-221 have been shown to be overexpressed in many different 
types of tumor, as glioblastoma, hepatocarcinoma, prostate and breast cancer; 
moreover, it had been shown to be associated to the suppressor of p27kip1, a cell 
cycle inhibitor and tumor suppressor protein. In fact, it had been found that in the 
3’UTR of p27kip1 mRNA there are at least two binding sites for miR-221. 
 
The major limit of the PNAs technology is the low cellular uptake, in particular 
on eukaryotic cells; in order to solve this problem, several approaches have been 
proposed; our PNAs presents modifications of the backbone with positive charged 
groups; in fact it has been demonstrated that these modifications are able to enhance 
cellular uptake and consequently PNA efficiency. Another modification that we have 
insert in the PNAs employed in our experiments is to link to PNAs a polyarginine (R) 
tails, based on the observation that this cell-membrane penetrating oligopeptides are 
able to facilitate uptake of conjugated molecules. 
The anti-miR-221 PNAs (PNA-a221 and Rpep-PNA-a221) proposed in this 
PhD thesis were synthetized by Prof. Corradini, Prof. Marchelli and collaborators at 
University of Parma, Department of Organic and Industrial Chemistry. They first 
designed the synthesis of new class of uracil dimers by substitution of amide linker 
on C(5) with more flexible methylamine linker, obtaining the 5-methylamino uracil. 
This reaction intermediate had been used for the synthesis of the 5-methylazidouracil 
PNA monomer. The R8 peptide was linked to the N-term of PNA, following the 
synthesis on solid phase. 
The  results  presented  in  this  PhD  Thesis  clearly  show  that:  (a)  the 
polyarginine-PNA conjugated anti-miR-221 is efficient internalized in the target cell 
lines without any transfection reagents; (b) targeting miR-221 by PNA resulted in a 
lowering of level of miR-221 and up-regulation of p27kip1 mRNA and protein in breast 
cancer MDA-MB-231 cell line. On the other hand, protocols of medicinal chemistry 
finalized to the design and the production of the final form of bioactive molecules, 
generate intermediates during chemical synthesis that, at least in theory, might retain 
effects on biological function. Therefore, in order to maximize the production of 
bioactive agents, all the synthetic intermediates deserve attention at least in a first 
screening. 
 
In our case, the uracil dimers derivatives, employed during the synthesis of 
 
PNA-anti-miR-221 were considered; in addition we also considered the C(5) uracil 
III  
modified monomers, used as starting molecules for the synthesis of dimers. As a first 
explorative investigation, we analyzed the possible antitumor activity of their analogs, 
possibly associated, as found in several other antitumor agents, with activation of 
terminal erythroid differentiation. We have first evaluated the antiproliferative and 
induction of erythroid differentiation activities of dimers; our results are published in 
Accetta et al. (2009) and briefly described in the Introduction Part 1 of this PhD 
Thesis. We have demonstrated for the first time that this kind of uracil derivatives can 
be considered to be a new class of erythroid differentiation inducers. 
Following this initial results, we have analyzed also the C(5) uracil derivative 
monomers; we present the Results Part 1 of this thesis. We have focused our 
attention in particular on Compound 9, which between all, has proved to be a potent 
erythroid inducer on K562 cell line. In this respect, it’s widely demonstrated that 
inducers of K562 erythroid differentiation are often in erythroid cell isolated from beta- 
thalassemia patients. 
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URACIL DERIVATIVED SHOWING 
ANTIPROLIFERATIVE AND ERYTHROID DIFFERENTIATION 
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- INTRODUCTION - 
 
 
 
 
 
1.1 Pyrimidine 
 
 
Pyrimidine is a heterocyclic aromatic organic compound similar to benzene 
and pyridine, containing two nitrogen atoms at positions 1 and 3 of the six-member 
ring, as shows in Figure 1 (Gilchrist et al., 1997). Three nucleobases found in nucleic 
acids, cytosine (C), thymine (T), and uracil (U), are pyrimidine derivatives. In DNA 
and RNA, these bases form hydrogen bonds with their complementary purines. Thus, 
in  DNA, the purines adenine (A) and guanine (G) pair up with the pyrimidines 
thymine (T) and cytosine (C), respectively. 
 
 
 
 
 
 
Figure 1. Chemical structure of natural pyrimidine 
 
 
 
 
 
The pyrimidine system is a very important pharmacophor core of naturally 
occurring and synthetic bioactive compounds (Lagoja et al., 2005); the potential of 
pyrimidine compounds is linked to the possibility of being used as antagonists in the 
biosynthetic pathways of pyrimidine nucleobases or in other important processes, by 
competing for the same binding sites of naturally occurring compounds. 
 
 
 
 
1.1.1 Biological activity of pyrimidine derivatives 
 
 
A series of modified pyrimidines were and are currently used as drugs. For 
example, fluoropyrimidine drugs such as 5-fluorouracil (5-FU) and capecitabine are a 
mainstay in the treatment of numerous solid tumors, alone or as part of combination 
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therapies. Despite the high interpatient pharmacokinetic variability and the cytotoxic 
effect, 5-FU is currently used in cancer therapeutics, in particular for colorectal and 
gastric cancer (Mercier et al., 2006). 
Azidothymidine (AZT) was the first applied drug for HIV treatment. AZT is 
phosphorylated by intracellular kinases to AZT-5'- triphosphate (AZT-5’-3P), which is 
the active metabolite. AZT-5’-3P is able to interferes with the RNA-dependent-DNA- 
polymerase (reverse transcriptase), acts as viral inhibitor. It can also be incorporated 
into the growing viral DNA, acting as a terminator signal. 
Another example, bacimethrin (4-amino-5-hydroxymethyl-2- 
methoxypyrimidine) is known as the simplest pyrimidine antibiotics, acting as 
antagonist on bacterial thiamine biosynthesis (Reddick et al., 2001). 
In literature it is also reported that uracils derivatives are potentially biologically active 
compounds. For examples, oxime libraries based on dimeric uracil derivatives have 
been  proposed for  the  development of  uracil  DNA glycosylase (UNG) inhibitors 
(Jiang et al., 2005). As described by Maruyama et al., 1,3-disubstituted uracil 
derivatives  have  shown  an  antiviral  activity  against  HIV-1  and  human 
cytomegalovirus (HCMV), probably interacting with the amino acid residues of HIV-1 
reverse transcriptase (Maruyama et al., 2007). 
Another class of molecules, obtained by Isobe et al., the N(1)- and N(3)-uracil 
derivatives, have shown an anti-inflammatory activities via inhibition of the picryl 
chloride-induced contact hypersensitivity reaction (CHR) in mice. These activities 
were essentially equipotent with that of tacrolimus, a strong immunosuppressant. 
(Isobe et al., 2003). Another pyrimidine analogs, 1-Benzyl derivatives of 5- 
(arylamino)-uracil, exhibit promising inhibitory activity against HIV-1 in CEM-SS 
culture, and activity anti-EBV in АKАТА cell culture. (Mikhail et al., 2010). 
 
 
 
 
1.1.2 C(5)-substituted uracil derivatives 
 
 
The pyrimidine bases of RNA are uracil (U) and cytosine (C), while thymine (T) 
and C are used for DNA. The C(5) position of C and U is unsubstituted, whereas the 
C(5) of T is substituted with a Me group. Miller et al. hypothesized that various C(5)- 
substituted uracil derivatives were formed during chemical evolution, and that C(5)- 
substituted U derivatives may have played important roles in the transition from an 
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“RNA world” to a “DNA-RNA-protein world” (Robertson et al., 1995). Several C(5) 
uracil derivatives have been described as cytostatic and antiviral compounds; 
Gazivoda et al., have evaluated the antitumoral and antiviral activities of a new class 
of C(5) aryl, alkenyl, and alkynyl substituted uracil derivatives. In particular the 5- 
(phenylethynyl)uracil-2,3-di-O-benzylated l-ascorbic acid derivative have shown 
selective inhibitory effect toward all tumor cell lines except for cervical carcinoma 
(HeLa), pancreatic carcinoma (MiaPaCa-2), laryngeal carcinoma (Hep-2), and colon 
carcinoma (SW 620), and no cytotoxicity to normal human fibroblast (WI 38); while 
5-propynyl substituted uracil derivative of l-ascorbic acid   have shown inhibitory 
activity against vesicular stomatitis virus, Coxsackie B4 virus and Sindbis viruses 
(Gazivoda et al., 2007). 
Following our general project, aimed at the synthesis of oligonucleotide 
analogues, in particular PNA, with modifications able to improve their binding activity 
(Sforza et al., 2007; Corradini et al., 2007. Corradini, Marchelli and collaborators 
have designed some uracil dimers, using C(5) modified uracil derivatives, connected 
with a spacer through the 5-positions (Figure 2). 
 
 
 
 
 
 
Figure 2. General scheme of uracil dimers 
 
 
 
 
 
 
1.1.3 Synthesis of 5-carboxamido uracil dimers 
 
 
N1-Alkylated uracil derivatives were synthesized from isoorotic acid (uracil-5- 
carboxylic acid) or thymine. The carboxylic acid derivatives were condensed with 
diamines in order to produce dimeric compounds or with monoamines in order to 
obtain reference monomeric compounds. Some of the derivatives, in particular the 
uracil dimers, were the first to be tested in our laboratories for the erythroid 
differentiation  activity.  In   the   retrosynthetic  design,   Prof.   Corradini   and   his 
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collaborators have used as starting material either isoorotic acid (5 uracilcarboxylic 
acid)  or  thymine.  As  a  reference  compound,  isoorotic  acid  methyl  ester  was 
 
synthesized by reaction with SOCl2 in methanol. Several derivatives were obtained 
with the purpose of varying the group at N1, the type (monomeric or dimeric) of the 
amine residue and the size and rigidity of the spacer, in order to produce chemical 
diversity. Direct alkylation of isoorotic acid with reactive substrates, such as methyl or 
allyl  halides  lead  to  dialkylated  products  at  both  nitrogen  atoms;  therefore, 
regioselective mono alkylation of uracil was performed using temporary protection of 
the carboxylic and carbonyl oxygens with trimethylsilyl groups, through reaction with 
hexamethyldisilazane   (HMDS)   in   a   3:1   excess   and   in   the   presence   of 
trimethylchlorosilane (TMS Cl), as shown in Figure 3. 
Reaction of thymine with more hindered long chain primary haloalkanes lead to 
selective monoalkylation at N(1) (Figure 4), thus affording the subtrate 4 suitable for 
the synthesis of uracil derivatives with a C8 alkyl chain at N(1). Oxidation of methyl 
group   of   4   with   K2S2O8     in   the   presence   of   copper(II)   leads   to   the 
uracil 5 carboxaldehyde which was then oxidized by reaction with sodium chlorite to 
the corresponding carboxylic acid 5 bearing a C8 alkyl chain at N1 position. 
 
 
 
 
 
 
 
 
Figure  3.  Synthesis of  N1-alkylated  isoorotic  acid  derivatives (a)  via  regioselective  alkylation  of 
Isoorotic acid ((i) HMDS,TMS-Cl, reflux 4 h; (ii) CH3I or ethyl bromoacetate in excess, reflux,18 h; (iii) 
H2O/ CH3COOH, room temp, 20 min.) and (b) via oxidation of thymine derivatives ((iv) [Br-n-C8H17, 
NaH,  DMF,  80 °C,4  h];  (v) 2,6-lutidine,  K2S2O8, CuSO4,  H2O/AcCN,  80  °C,  1,5  h;  (vi)  NaClO2, 
NaH2PO4; t-BuOH/THF, r.t., 24 h) 
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Several other commercially available diamines were used as linkers for the 
reaction  with  the  carboxylic  derivatives.  Butylamine  was  used  for  generating 
reference monomeric compound 10 (Figure 4), and benzylamine was used for 
generating compound 12, both containing a uracil moiety with a carboxamide group 
at C(5) (Figure 4). The first series of derivatives, containing either a methyl or an 
ethoxycarbonylmethyl group at N1, was synthesized using reaction with thionyl 
chloride to generate the corresponding acyl chloride, followed by reaction with the 
corresponding amine in pyridine (Figure 4a). Since the yields obtained with this 
method were not optimal (25-30%), mainly because of loss of product during workup, 
a second series of derivatives was obtained by activation of the carboxylic moiety of 
5 (Figure 3) with fluoride using 2,4,6-trifluoro-1,3,5-triazine as fluorinating agent, thus 
 
providing the stable intermediate 11 which could be isolated. Subsequent reaction of 
the acyl fluoride 11 with the corresponding diamine or monoamine in acetonitrile 
gave the compounds 12-17 (Figure 4b). 
 
 
 
 
 
 
 
Figure 4. Synthesis of monomeric and dimeric uracil derivatives: (a) 12 and 13 via 
acyl chloride ((i) SOCl2, DMF, 70-80 °C, 2 h; (ii) (H2N)n-G, Py, 2 h); (b) 19-23 via 
acyl fluoride ((iii) H2N-G-NH2 or H2N-G-NH2. 2HCl, DIEA, AcCN, 80 °C, 7 h; (iv) 1 
M HCl, 0.5 h) 
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We have recently reported a novel class of C(5) linked N(1) alkylated uracil 
dimers rationally designed to potentially interact with adenine in biological systems: 
these pyrimidine derivatives have shown antiproliferative and erythroid differentiation 
activities toward human chronic myelogenous leukemia K562 cells (Accetta et al., 
2009). Results are described in the following Section 1.3. 
 
 
 
 
 
1.2 Terminal differentiation therapy of human cancer 
 
 
Cancer morbidity and mortality continue to be major problems worldwide, 
despite significant improvements and innovations in the diagnosis, prevention and 
therapy  of  specific  cancers,  delimiting  longevity  and  the  quality  of  human  life. 
Although the precise reason for the lack of greater efficacy of current therapies is not 
known, it may relate to the fact that cancer is not caused by a single genetic change, 
but instead represents the combination of common and distinct multi-step changes in 
specific neoplasms. 
Cancer is a process in which changes in regulating circuits are produced, such 
as  proliferation  control,  the  balance  between  cellular  survival  and  programmed 
cellular death (apoptosis), the communication with neighboring cells and extracellular 
matrix, angiogenesis, and, finally, migration of the tumoral cell, invasion and 
metastatic dissemination. This process implies the progressive development of a 
more malign phenotype with an increase of genetic alteration involving genes at 
several levels of expression during long periods of time. These genetic changes 
uncouple the normal balance between multiplication and cellular differentiation with 
an  increase in  the  rate  of  proliferating cells;  it  results in  the  formation of  new 
abnormal cellular products which block final differentiation of cells leading to 
accumulation of immature cells (Sell et al., 2006). Moreover, the progeny of mutated 
cell is maintained in a self-renewing tissue stem cell and its immediate progeny or 
due to cellular components that display stem cell like properties known as cancer 
stem cells (CSCs), that grow into cancer. Failure to achieve complete and safe 
eradication of cancer is due to the presence of quiescent population of CSCs (Garg, 
2009). 
 
Once cancer is diagnoses, a variety of treatment options are considered, 
mostly depending on tumor type, extent, and location of the cancer lesion. The most 
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commonly used therapeutic modalities are radiation therapy and chemotherapy. 
These therapies have proven successful for some tumors; nevertheless, even if 
classic chemotherapeutical agents have been very important, the mechanism of 
action of these drugs depends on the cytodestruction of the neoplastic cells, and their 
beneficial effect are normally accompanied by a notable morbidity, cytotoxicity and 
drug resistance (both single and multidrug) (Marchel et al., 2006). 
The knowledge of the mechanisms involved in differentiation and malignant 
transformation has allowed the search of alternative routes for anticancer therapy 
that does not imply cellular death. Example of these alternative routes of cancer 
therapy are radiation therapy, immunotherapy, differentiation therapy and 
angiogenesis inhibition therapy (Fisher et al., 1985, 1986; Rosen, 2000). 
The objective of these multiple treatment protocols is to eliminate the problems 
associated with cancer cell resistance to a particular drug or class of drugs and to 
diminish toxicity associated with high-dose chemotherapy. 
 
 
 
 
1.2.1 Cell differentiation 
 
 
Cancer begins when a normal cell, which replicates only slightly or not at all, 
suffers a somatic mutation in a gene and starts to proliferate uncontrollably. 
Everything indicates that several successive mutations are necessary to change a 
normal cell into invading carcinoma (Burnet M., 1957) and demonstrates the 
monoclonal origin of tumors (cellular clone is produced from mutated cell) in which 
each one of its components reproduces the mutations. 
Differentiation program is a complex multistep developmental process of cell 
specialization that follows the determination (set of progressive restrictions in cell 
developmental potentials) of a genetic program specific for cell lineage. Development 
of the differentiation program includes the cellular type and that distinguish the 
specialized cells, such as muscle cells, nerve and skin. Terminal differentiation is the 
end stage of this process where the cells irreversibly lose their proliferative capacity 
and which represents a form of negative control of growing. Regulating molecules 
interact to produce the correct balance between cellular multiplication and 
differentiation during embryogenesis and the normal behavior of an adult. 
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In cancer, neoplastic cells exhibits defects in their ability to differentiate, and 
the development of these defects in the process of differentiation appears to be an 
intimate part of the transformation process. Compared with normal cells, tumor cells 
are less differentiated, which is one of their important biological characteristics. This 
“undifferentiated state” of tumors is the direct consequence of the “uncontrolled cell 
proliferation  state”:  cells  are  blocked  in  a  stage  in  which  they  retain  infinite 
proliferative capably. This hallmark has suggested a novel and potentially less toxic 
form of cancer therapy involves the use of agents, alone or in combination, that 
modify the  state of  differentiation and growth of  cancer cells: the differentiation 
therapy (Fischer et al., 1985). 
 
 
 
 
1.2.2 The differentiation therapy 
 
 
Because normal terminal differentiation often results in non-proliferating cells 
that often undergo apoptosis as they complete their normal life span, it was plausible 
to develop strategies to activate normal pathways of differentiation in premalignant 
and malignant cells using physiological or pharmacological agents that can bypass 
the epigenetic and genetic abnormalities that abrogate differentiation. This approach 
is called differentiation therapy. 
Differentiation therapy is based on the concept that cancer cells are normal 
cells that have been arrested at an immature or less differentiated state, lack the 
ability to control their own growth, and so multiply at an abnormal fast rate. 
Differentiation therapy aim to force the cancer cell to resume the process of 
maturation, so as to prevent, suppress or reverse the malignant phenotype by 
inducing differentiation with the associated growth arrest, senescence and apoptosis 
(Figure 5). Although differentiation therapy does not destroy the cancer cell, it 
restrains their growth and allows the application of more conventional therapy (such 
as chemotherapy) to eradicate the malignant cells. 
Even if only partially successful, differentiation therapy can convert malignant 
tumors into benign tumors. The mechanism by which differentiation inducing agents 
cause  phenotypic  changes  in  tumor  cells  is  believed  to  involve  the  selective 
activation of defined sets of genes that negatively control cell proliferation and the 
suppression of genes facilitating expression of the cancer state (Jiang et al., 1994). 
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By defining the spectrum of genes that are modified as a consequence of induction 
or irreversible growth arrest, terminal cell differentiation and loss of tumorigenic 
potential, it should be possible to identify potentially important target genes and 
molecules for therapeutic intervention in cancer. 
The first differentiation agent found to be successful was all-trans-retinoic acid 
(ATRA) in the treatment of acute promyelocytic leukemia (APL); APL, a distinct 
subtype of acute myelogenous leukemia (AML), results from the arrest of the 
maturation of  hematopoietic progenitors at the promyelocyte stage. It has  been 
shown that APL is associated with a reciprocal chromosomal translocation, involving 
chromosomes 15 and 17, which fuses the gene encoding the retinoic acid receptor a 
(RARa) and the promyelocytic leukemia (PML) gene. The introduction of all-trans 
retinoic acid (ATRA) in 1987 changed the treatment paradigm of APL (Huang et al., 
1988). Huang and collaborators demonstrated for the first time a complete remission 
of APL following ATRA treatment. Several studies conducted during the early 1990s 
found that APL patients receiving induction therapy consisting of ATRA followed by 
chemotherapy fared  significantly better  than  patients treated  with  chemotherapy 
alone. 
 
In addition, ATRA therapy has significant and potentially fatal adverse effects, 
known as retinoic acid syndrome, which consists of elevated white blood cell (WBC) 
counts, fever, respiratory distress, interstitial pulmonary infiltration, pleural effusion, 
and weight gain. Among patients in remission following treatment with ATRA alone, 
the incidence of retinoic acid syndrome is approximately 25%, (Vahdat et al., 1994) 
whereas that in patients treated with a combination of ATRA plus chemotherapy is 
reduced to 5%.(Sanz et al., 1999). Based on the results of these studies, the 
combination of ATRA plus chemotherapy became the standard approach for treating 
newly diagnosed APL. Most APL patients are actually treated first with ATRA; this 
compound induces a complete remission in about 70% of cases. ATRA is considered 
the “prototype” of differentiation therapy agents. 
Another example of terminal differentiation induction regarding the therapy of 
melanoma. Cutaneous malignant melanoma is the fifth most common cancer in the 
United States and it is also the most frequent cause of death from malignancy in 
young Caucasian females (Meier et al., 1998). 
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Figure 5. Targets for differentiation therapy. In a normal differentiation pathway, a hypothetical stem 
cell designated A is required to undergo a series of progressive changes in gene expression and 
resultant phenotypic changes represented by the letters B, C and D before reaching the terminally 
differentiated mature cell stage designated E. Cancer development is associated with aberrant 
differentiation. This can be represented by a block in differentiation that can occur already in 
premalignant cells. The scheme shows three possible blocks at late stages of the differentiation 
pathway (stage D) and at early stages of the pathway (stage B) 
 
 
 
 
Although the focus of intense research, the molecular changes regulating melanoma 
development and progression remain to be defined, since melanomas are extremely 
heterogeneous  in   their   genetic  background.  Numerous  studies  confirm  that 
melanoma cell exhibits characteristics similar to those observed in de-differentiated 
cells. Jiang and Fisher (1993) have demonstrated that the treatment of metastatic 
human melanoma cells with a combination of human fibroblast interferon (IFN-b) and 
antileukemic compound mezerein (MEZ) results in a loss of tumorigenic potential, 
irreversible growth arrest, antigenic modulation, enhanced melanin synthesis, 
profound  changes  in  gene  expression  and  terminal  cell  differentiation.  The 
mechanism by which IFNs cause growth arrest and differentiation remains to be 
clearly define; however, many evidence suggested that the signaling pathway for 
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IFNs (Jag/STAT) may interact with other major pathways in order to elicit effect on 
tumor growth, such as MAPK, PKA and PKC pathways (Weber et al., 1998). 
In the literature is also reported, by more than three decades, the terminal 
 
differentiation effect of suberoylanilide hydroxamic acid, also named SAHA 
(Vorinostat). 
SAHA is an HDAC inhibitor and it is currently used for the treatment of cutaneous T 
cell lymphoma. But, early indications about the differentiating effect of SAHA are 
older than three decades ago, when Breslow and collaborators (1991), showed that, 
if  used  at  lower  concentrations  of  toxic,  SAHA  caused  growth  arrest  and 
differentiation in murine 
erythroleukemia MELC cells (Breslow et al., 1991). This drug is also used in clinical 
trials against both hematological and solid tumors (Marks PA., 2007). 
A variety of anticancer agents (Table 1), both natural and synthetic, have been 
found to induce terminal differentiation and/or apoptosis rather than by cytotoxic 
action in vitro in various cell lines, including murine erythroleukemia cells, human 
myeloid leukemia cells and murine and human embryonal carcinoma cells 
(Leszczyniecka et al., 2001) . 
 
 
 
 
Table 1. Differentiation-inducing agents and their suggested mechanism of action (Lotan R., 2002) 
 
Differentiation-inducing agent Mechanism of action 
 
Inhibit  histone deacetylase, thereby  enhancing gene  expression, 
Short-chain fatty acids (butyrate and derivatives 
 
 
Aromatic fatty acids (phenylbutyrate, 
phenylacetate) 
alter the methylation and phosphorylation of nuclear proteins and 
alter gene transcription 
Inhibition  of  protein  prenylation  critical  for  signal  transduction; 
activation of peroxisome proliferator-activated receptor, a 
transcription factor related to the steroid nuclear receptor 
superfamily; hypomethylation of DNA; depletion of circulating 
glutamine which is required for tumour growth 
Trichostain A, SAHA Inhibit histone deacetylase, thereby modulating gene expression 
PPAR ligands Activate nuclear receptors (PPARs) and modulate gene transcription 
Haxamethylenebisacetamide Modulate cell cycle and differentiation related genes 
Vitamin A analogues (retinoids) 
Activate nuclear receptors (RARs and RXRs) and modulate gene 
transcription 
Vitamin D3 analogues Activate nuclear receptors (VDR) and modulate gene transcription 
Cytokines (TNF-α interleukins) 
Act via cell surface receptors to induce signal transduction pathways 
resulting in alterations in gene expression 
Interferons 
Activate  transcription  factors   (Stats)   and   thereby   alter   gene 
transcription 
5-Aza-2-deoxycytidine 
Decreases DNA hypermethylation and thereby restores expression 
of silenced genes 
Staurosporin Protein kinase C inhibition 
8-Choloro-cyclic adenosine monophosphate 
(8-Cl-cAMP) 
Downregulates RI and upregulates the RIIb subunit of protein kinase 
A 
Actinomycin D DNA intercalation 
Cytosine arabinoside; cyclophosphamides; 
   aclacinomycin (at subtoxic concentrations)  
Inhibition of DNA synthesis  
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Some of these molecules, such as trichostatin A and cytosine arabinoside, 
together with other described in the following section, are classified as 
chemotherapeutic thanks to their high cytotoxic effect; but in addition, when used at 
sub-toxic concentrations, they are able to induce also the terminal erythroid 
differentiation. 
 
 
 
 
1.2.3 Antitumor agents acting through induction of erythroid terminal 
differentiation 
 
In the literature there are numerous publications concerning the study of 
anticancer agents known as inducers of terminal differentiation. In particular, we want 
to focus our attention on anticancer possessing also erythro-differentiating ability. It is 
possible to divide these molecules in  different categories, such as (a)  cytotoxic 
agents, (b) HDAC inhibitors, (c) DNA binding drugs (DBD) and (d) from natural world. 
The same rationale that has led to the successful application of combination of 
cytotoxic agents with non-overlapping toxicities and distinct mechanisms of action 
can be applied to differentiation-inducing agents. 
 
 
 
 
1.2.3.1 Cytotoxic agents 
 
 
Cytarabine, or cytosine arabinoside (AraC), is a chemotherapy agent used 
mainly in  the treatment of  cancers of  white  blood  cells  such  as acute  myeloid 
leukemia (AML) and non-Hodgkin lymphoma. AraC interferes with the synthesis of 
DNA: inhibiting both DNA and RNA polymerases, leads tumor cells unable to 
duplicate themselves. Myleran is an alkylating agents used for CML therapy and after 
bone marrow transplantation; and vinblastine, is currently used for lymphoma, 
testicular, breast and bladder cancer therapy. These molecules terminate actively 
cycling progenitors and perturb cellular growth to trigger rapid erythroid-regeneration 
kinetics and formation of mature red blood cells to contain hemoglobin (Galanello et 
al., 1988). 
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1.2.3.2 Hydroxyurea 
 
 
The Multicenter Study of Hydroxyurea was initiated in 1992 to establish the 
first  drug  treatment  for  Sickle  Cell  Disease  (SCD).  Hydroxyurea  (HU)  is  a 
ribonuclease reductase inhibitor that produces blockade of DNA synthesis and cell 
death. This compound also alters growth rates and gene expression in mammalian 
cells (Adunyah et al., 1995). One of the first studies showing a clear effect of HU on 
erythroid differentiation was published in 1993 by Fibach and his collaborators, in 
which HU was found to have multiple effects on human peripheral blood-derived 
progenitor cell: an increase in the proportion of fetal hemoglobin (HbF) produced; an 
inhibition of cell proliferation; and an increase in hemoglobin (Hb) content per cell. 
Several reports confirmed the HbF augmenting effect of HU both in vitro and in vivo 
(Wang et al., 2002; Fucharoen et al., 2004; Siriboon et al., 1996; Loukopoulos et al., 
2005; Loutradi et al., 2000; Zargari et al., 2004), as summarized in Table 2. For 
example, Yavarian et al. (Yavarian et al., 2004) reported the treatment with HU of 
133 patients with transfusion-dependent β-thalassemia. After one year of treatment 
these patients were classified into: good responders (61%) who shifted from monthly 
blood transfusion dependency to a stable transfusion-free condition; moderate 
responders (23%) who remained transfusion dependent but at longer intervals (6 
months  or  more),  and  non-responders,  who  remained  at  the  same  level  of 
transfusion dependency. 
 
 
Table 2. Clinical trials employing Hydroxyurea as In vivo inducer of HbF (from Gambari e 
Fibach, medicinal chemistry of fetal hemoglobin inducer for treatment of beta-thalassemia, 
Curr Med Chem, 2007, 14:199-212) 
 
 
References Genotype/Phenotype
(a)
 
N° of patients 
treated
(b)
 
N° of patients responding 
to the treatment
(c)
 
 
Hoppe et al., 1999 β-thalassemia intermedia 5 3 (60%) 
de Paula et al., 2003 β-thalassemia intermedia 7 3 (43%) 
de Paula et al., 2003 β-thalassemia major 4 1 (25%) 
Bradai et al., 2003 β-thalassemia intermedia 2 2 (100%) 
Bradai et al., 2003 β-thalassemia major 5 5 (100%) 
Alebouyeh et al., 
 
2004 
β-thalassemia major 36 25 (69%) 
Yavarian et al., 2004     β-thalassemia major                133                         81 (61%) 
Dixit et al., 2005            H-β-thalassemia intermedia     37                           26 (70%) 
Karimi et al., 2005         β-thalassemia intermedia        166                         83 (50%) 
Singer et al., 2005         HbE/β°-thalassemia                  42                           20 (50%) 
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1.2.3.3 Histone deacetylases Inhibitors (HDACi) 
 
 
Gene expression is controlled by alterations in chromatin structure produced 
by acetylation or deacetylation of histone tails, resulting in gene activation or 
repression,  respectively.  Histone  deacetylase  (HDAC)  enzymes  produce 
deacetylation of histone tails, causing chromatin condensation and transcriptional 
silencing. 
Several findings suggest that inhibition of the activity of histone deacetylases 
(HDACs) is associated  with an  increased expression of the  γ-globin genes. Several 
inhibitors, such as sodium butyrate, trichostatin A, adicipin, and scriptaid, used at low 
doses, are employed in colorectal cancer therapy. Moreover, they have been shown 
to induce HbF synthesis in vitro; butyrate also induced HbF in humans (Perrine et al., 
1993; McCaffrey et al., 1997; Pace et al., 2003; Cao et al., 2004; Johnson et al., 
 
2001;  Pace et al., 2005). Mechanistically, the HDAC inhibitors bind to a central zinc 
atom in HDACs to block enzymatic deacetylation of histone H3 and H4, leading to an 
hyperacetylation of ε-amino groups of lysine residues in histones. This in turn causes 
a decreased association of basic core histone proteins with the DNA, rendering 
certain genes more accessible to the transcriptional machinery (Cao et al., 2004). 
 
 
 
 
1.2.3.4 DNA-binding drugs 
 
 
The DNA-binding drugs (DBDs) are  molecules able to interact with the major 
groove of  DNA are  expected to inhibit complex formation between transcription 
factors and target DNA elements (Gambari et al., 2003). Several DBDs are or have 
been used in therapy. Chromomycin and mithramycin (MTH) were used in different 
kinds of cancer, such as ovarian, stomac, bladder, prostate cancer and hepatoma 
and they are also employed in the treatment of hypercalcemia; MTH is also used in 
CML and AML therapy. Tallimustine and tallimustine analogues are anticancer and 
antiviral agents. Many reports demonstrated that some DBDs display DNA sequence 
selectivity,  and  that  even  similar  DBDs  differ  with  respect  to  stability  of  their 
complexes with DNA. Our group has demonstrated that tallimustine (Baraldi et al., 
2000; Bianchi et al., 2001; Chiarabelli et al., 2003) and some cisplatin analogues 
(well-known alkylating agent used for testicular, ovarian, lung, breast, stomach, 
prostate cancers and also for neuroblastoma, melanoma and sarcoma) (Bianchi et 
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al., 2000) as well as the GC-rich binders chromomycin and MTH (Bianchi et al., 
 
1999) are powerful inducers of differentiation of K562 cells, suggesting that the 
expression of crucial genes involved in erythroid differentiation of these cells are 
influenced  by  DBDs.  Several  DBDs,  such  as  tallimustine,  MTH  and  cisplatin, 
increase  of  fetal  hemoglobin (HbF)  production in  erythroid  precursor  cells  from 
normal human subjects. The extent of induction was found to be higher than that of 
hydroxyurea (HU). Since, among the DBDs studied, MTH displayed the lowest 
cytotoxicity, we compared it to HU on fetal hemoglobin production by thalassemic 
erythroid precursors (Fibach et al., 2003). The results demonstrated that in cultures 
derived from 12 patients, mithramycin increased HbF production in all cases, while 
HU was not effective in two cases and was toxic in one. In the majority of cases the 
activity of mithramycin was higher than hydroxyurea. In all cases, HU strongly 
inhibited cell proliferation, while, at concentrations able to induce HbF production, 
mithramycin had minimal effect on cell growth. 
 
 
 
 
1.2.3.5 Erythro-differentiating agents from natural world 
 
 
Several reviews and papers have been published on the possible use of 
extracts from medicinal plants for biomedical purposes   including therapeutic 
strategies for the treatment of a number of diseases such as dyslipidemia (Alder et 
al., 2003) and aterosclerosis (Wang  et al., 1999), hepatitis (Luper et al., 1998), 
inflammatory diseases (Nakhai et al., 2007), osteoporosis (Xie et al., 2005), bacterial 
and virus infections (Khan et al., 2005). In the case of cancer, only few examples are 
available, as rapamycin and its analogues everolimus and resveratrol, that are briefly 
described. 
Rapamycin (Figure 6a) is a lipophilic macrolide, isolated from a strain of 
Streptomyces hygroscopicus found in a soil from Easter Island, that possesses 
immunosuppressive, antifungal and anti-tumor properties. This molecule is also 
approved by the U.S. Food and Drug Administration as an immunosuppressive agent 
for preventing rejection in patients receiving organ transplantation. The rapamycin, 
employed in combined therapy with doxorubicin, drive AKT-positive lymphomas into 
remission in mice. Our group has demonstrated that rapamycin, tested on the human 
leukemia  K562  cell  line  and  the  two-phase  liquid  culture  of  human  erythroid 
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progenitors isolated from normal donors and patients with beta-thalassemia, has the 
ability to induce terminal erythroid differentiation and induction of HbF levels. The 
interest in rapamycin as an HbF-inducer is related to the fact that its effect is not 
associated with cytotoxicity and cell growth inhibition, in contrast to other inducers. 
 
 
 
 
 
 
Figure 6. Chemical structure of Rapamycin (A) and Everolimus (B) 
 
 
 
 
 
Several rapamycin-like molecules have been described, exhibiting better 
characteristics than rapamycin. For instance, everolimus (Figure 6b) is an 
immunosuppressive macrolide bearing a stable 2-hydroxyethyl chain substitution at 
position 40 on the rapamycin structure (Dumont et al., 2004; Augustine et al., 2004). 
Clinical experience, largely limited to its use in kidney transplant patients, indicates 
that the administration of everolimus is associated with low rates of acute rejection 
and a tolerable safety profile. Everolimus is a mTOR inhibitor and it acts by the block 
of proliferation. Recent observations in heart transplant patients suggest that the anti- 
proliferative effects of this compound may prevent allograft vasculopathy. Zuccato et 
al., (Zuccato et al., 2007) have determined the effects of everolimus on the erythroid 
differentiation  of K562  cells  and  on  the  γ-globin mRNA accumulation in cultures of 
erythroid precursors isolated from β-thalassaemia patients. 
Resveratrol,  3,5,4’-trihydroxystilbene  (Figure  7),  is  a  natural  phytoalexin 
present in large quantity in red wine, preferentially in the skin of grapes (Jeandet et 
al., 1991). 
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Figure 7. Chemical structure of Resveratrol 
 
 
 
 
 
Actually, resveratrol is used in support of conventional anticancer 
chemotherapy in skin cancer, breast and prostate cancer. Rodrigue et al. (Rodrigue 
et al., 2001)   found that resveratrol possesses similar properties to HU toward 
erythroid differentiation. They firmly demonstrated that resveratrol induces 
differentiation of K562 cells and augmentation of HbF in erythroid precursor cells 
isolated from eight sickle cell patients. 
In our laboratories, when erythroid precursor cells from normal subjects were treated 
with increasing concentrations of resveratrol and analysis of accumulation of globin 
mRNA sequences was performed by quantitative RT-PCR, a clear increase in 
accumulation  of γ-globin  mRNA content was found.  Increase  in  accumulation  of α- 
globin and  β-globin mRNA was much lower. Taken together these data strongly 
indicate resveratrol as a strong inducer of HbF and a selective stimulator of the 
expression in γ-globin genes (Bianchi et al., 2009). 
The potential of agents that stimulate cell differentiation to serve for cancer 
therapy has been studied extensively in vitro and in animal models. Such agents can 
suppress growth and enhance differentiation, which may also lead to apoptosis. Only 
a few of the numerous differentiation inducing agents shown in Table 1 have been 
examined in clinical trials and even for those that have been investigated, most trials 
were phase I or II. The only definitive demonstration of the efficacy of differentiation 
therapy is the treatment of acute promyelocytic leukemia patients with ATRA. 
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1.2.4 K562 cell line as useful experimental model for erythroid differentiation 
 
 
Erythroleukemic K562 cell line was isolated and characterized by Lozzio and 
Lozzio (Lozzio et al., 1975) from a patient with chronic myelogenous leukemia in 
blast crisis. K562 cell line has been extensively employed as a very useful in vitro 
model to study the molecular mechanism(s) regulating the expression of embryonic 
and fetal human globin genes (Rutherford et al., 1981). K562 cells exhibit a low 
proportion of hemoglobin-synthesizing cells under standard cell growth conditions, 
but are able to undergo terminal erythroid differentiation when treated with a variety 
of compounds, including short fatty acids, 5-azacytidine (Gambari et al., 2007), 
mithramycin and chromomycin (Bianchi et al., 1999; Fibach et al., 2003), cisplatin 
and  cisplatin  analogs  (Bianchi  et  al.,  2000),  tallimustine  (Bianchi  et  al.,  2001; 
Gambari and Fibach, 2007), rapamycin (Fibach et al., 2006), everolimus (Zuccato et 
al., 2007), psoralens (Lampronti et al., 2003) and resveratrol (Bianchi et al., 2009). 
Following erythroid induction, increase of expression of ε and γ globin genes is 
observed, leading to accumulation of Hb Portland (ζ2γ2) and Hb Gower 1 (ζ2ε2) 
(Gambari et al., 2007). 
Several antitumor drugs were demonstrated to induce erythroid differentiation 
of K562 cells. Some of us have recently demonstrated that DNA binding drugs 
(DBDs) exhibiting antitumor activity are powerful inducers of differentiation of K562 
cells, suggesting that the expression of crucial genes involved in terminal erythroid 
differentiation of these cells is influenced by DBDs. 
Thus, this experimental cell system appears to be suitable for the screening of 
molecules able to inhibit cell growth by acting on the activation of terminal 
differentiation pathways. 
K562 cells grow in culture as single, undifferentiated, cells in suspension, with 
low production of hemoglobins. When stimulated by various agents, they respond 
within  few  days  with  a  significant  increase  in  the  production  of hemoglobins  and  γ- 
globin mRNA (Bianchi et al., 1999). 
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1.3 “New uracil dimers showing erythroid differentiation inducing activities” 
 
 
As described in section 1.1.3 and reported by Accetta et al. (2009), a series of 
uracil dimers has been synthesized starting from uracil, thymine or 5-carboxyuracil 
(isoorotic acid), and tested for antiproliferative and erythroid differentiation activity. 
 
 
 
 
1.3.1 Screening of anti-proliferative and differentiation inducing properties 
 
 
We first determined for all the synthesized molecules the effects on cell 
proliferation (Table 3). To this aim, K562 cells were cultured in the presence of 
increasing  concentrations  of  compounds  and  cell   number  per  milliliter  was 
determined after 3, 4, and 5 days. These time points were selected because between 
days 3 and 5 untreated control K562 cells are on the log phase of cell growth. 
In order to determine the effects on the erythroid differentiation, cells were 
seeded at an initial concentration of 3×104 cells/ml and the proportion of benzidine- 
positive cells was determined after 4-7 days of cell culture using a solution containing 
0.2% benzidine in 0.5M glacial acetic acid (10% H2O2) (Bianchi et al., 2001). 
Benzidine positivity indicates the presence of intracellular hemoglobin. All methods 
will be better described in “Materials and Methods” chapter. Table 3 indicates the 
antiproliferative  effects  (IC50   values)  and  the  erythroid  induction  ability  (%  of 
benzidine positive cells) of all the tested compounds. The best erythroid induction 
ability was displayed by compound 14. The data shown in Table 3 were obtained 
using concentrations of compounds approaching those giving 50% of inhibition of cell 
growth (these concentrations were chosen to better compare the potential erythroid 
inducting activity in experimental conditions leading, for most of the compounds 
tested, to similar effects on cell proliferation rate). In addition, it should be noted that 
compound 14 was able to induce erythroid differentiation of K562 cells after 6 days 
cell culture even if added at concentrations lower than that shown in Table 3 (an 
average of 52 ± 4.5 % of benzidine positive cells was obtained in four independent 
experiments with 400 μM compound 14). 
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Table 3. Antiproliferative Effects (IC50) and Percentage of Benzidine-Positive 
Cells after Treatment with uracil compounds and concentration used 
 
Compound IC50 (µM) %B+ cells concentration (µM) 
1 > 800 5 ±3.4 800 
5 247 ± 33 30 ± 5.8 300 
  9  > 800  1 ± 0.8  800   
10 536 ± 45 5 ± 2.3 800 
  12  75 ± 7.3  5 ± 3.3  100   
13 247 ± 23 40 ± 8.4 200 
14 517 ± 63 78 ± 7.3 600 
15 600 ± 85 40 ± 5.5 600 
  16  220 ± 35  50 ± 6.8  600   
17 420 ± 93 45 ± 3.3 600 
 
Results are presented as average ± SD of three independent experiments performed). The IC50 was 
calculated as the concentration of compounds necessary to decrease cell number (after 4 days 
culture period) at 50% of the values obtained in control untreated K562 cell cultures. The % of 
benzidine positive (hemoglobin containing) cells was determined after 6 days induction period at 
concentrations of the tested compounds indicated in the right column. 
 
 
 
 
1.3.2 Conclusions 
 
 
In conclusion, in this paper, we have demonstrated for the first time that this 
kind of uracil derivatives can be considered to be a new class of erythroid 
differentiation inducers, and that dimeric derivatives with suitable spacers have the 
best performing characteristics: low cytoxicity and higher differentiating ability. 
Furthermore, the best results were obtained with the compound bearing a 
naphthalene linker (compound 14), which avoids collapse of the uracil moieties, 
indicating that a possible recognition of complementary functionalities (such as 
adenine derivatives) could be implicated in the induction of biological properties. 
These findings can be the starting point for the quest for more effective and 
specific drugs for the induction of terminal erythroid differentiation, ultimately leading 
to new insights in the treatment of neoplastic diseases with molecules acting by 
inducing differentiation rather than by exerting cytotoxic effects. In addition, these 
molecules  might  be  of  interest  for  the  experimental  treatment  of  β-thalassemic 
erythroid cells for which the induction of γ-globin mRNA could be very beneficial. 
(Fibach et al., 2003). In this respect it has been demonstrated that inducers of K562 
erythroid differentiation are often able to induce fetal hemoglobin production in 
erythroid cells isolated from β-thalassemia patients (Gambari et al., 2007). 
- 23 -  
1.4 “C(5) modified uracil derivatives showing antiproliferative and erythroid 
differentiation inducing activities on human chronic myelogenous leukemia 
K562 cells” 
 
 
As just described, we have recently reported a novel class of C(5) linked N(1) 
alkylated uracil dimers rationally designed to potentially interact with adenine in 
biological systems: these pyrimidine derivatives have shown antiproliferative and 
erythroid differentiation activities toward human chronic myelogenous leukemia K562 
cells (Accetta et al., 2009). Following these results, in this thesis we would present 
some biological data obtained from a series of C(5) uracil monomers. These 
monomers were used, as previously described, as intermediates for the synthesis 
reactions. 
 
 
 
 
1.4.1 Chemical synthesis of uracil monomers 
 
 
Compounds 1, 2 and 4 were purchased from Sigma-Aldrich and tested without 
further purification. Synthesis of compounds 5, 8, 9, 10 and 11 is described in section 
1.1.3 of this thesis and reported in Accetta et al. (2009). All syntheses started from 
uracil, thymine or 5-carboxyuracil (isoorotic acid). Also full synthetic procedures and 
characterization of compounds 3, 12, 13, 14, 15, 16, 17 and 18 are reported section 
1.1.3 (Accetta et al., 2010). 
 
The C(5) position of pyrimidine nucleosides can be easily modified with a 
variety of different residues. Substitution at this position is often used for introducing 
substituents on DNA oligomers with reporter groups. In a general project, aimed at 
molecular engineering of peptide nucleic acid (PNA) derivatives (A. Accetta, PhD 
thesis, 2010), a set of N(1) and/or N(3) alkyl-C(5) modified uracil derivatives were 
prepared. Since these compounds are structurally analogs of modified nucleosides, 
they could be considered as potential drugs per se. This set of compounds was 
chosen for screening since: i) it contains compounds alkylated at N(1) and N(3) 
positions or both; ii) it contains a series of C(5) derivatives with different functional 
groups; iii) it has lipophilic groups in both the N(1), N(3), or C(5) region of uracil; iv) it 
contains derivatives with intact uracil (and thymine) hydrogen bond pattern or lacking 
of the N(3) hydrogen. 
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Briefly, modification of uracil at both N(1) and C(5) positions was obtained in several 
ways. For the more reactive uracil and isoorotic acid, and in the presence of small 
electrophiles such as methyl iodide, the regioselective alkylation at N(1) can be 
obtained by temporary protection of the N(3) with trimethylsilyl (Accetta et al., 2009) 
or benzoyl groups. 
The  latter  method  was  used  in  the  synthesis  of  7  from  6.  Azidomethyl 
derivative 3 was obtained by reaction of uracil with formaldehyde, thus introducing a 
5-hydroxymethyl derivative which could be further elaborated to azide by nucleophilic 
substitution (via a chloromethyl intermediate). Alkylation of 3 with α-bromoacetic acid 
derivatives led to compounds 15 and 16. The latter was converted to 17, bearing an 
amino group through Staudinger reduction. The amide derivative 18 was then 
obtained by reaction of the amino compounds with 2-naphthalenecarboxylic acid 
after  activation  of  the  latter  with  HBTU.  Regioselective  alkylation  at  N(1)  was 
obtained also by exploiting the higher reactivity of the N(1) position in thymine and 
iodouracil toward sterically hindered electrophiles, which allowed direct synthesis of 
compounds 9 , according to Coutouli-Argyropoulou and Zachariadou, (Coutouli- 
Argyropoulou et al., 2005)  and 13. The N(1), N(3)- doubly alkylated compound 12 
was obtained as a side product of thymine alkylation. Oxidation of thymine methyl 
group led to the N(1)- alkylated-5-carboxylic derivative 10 (Accetta et al., 2009), 
which was then converted into the carboxyamide derivative 11 via HBTU activation 
and reaction with benzylamine. Hydrolysis of 13 with TFA provided derivative 14, 
bearing a polar substituent in the N(1) position. 
- 25 -  
 
 
 
 
Figure 8. Chemical structures of uracil monomers tested. Alternative name: 1, uracil; 2, thymine (5- 
methyluracil);  3,  5-azidomethyluracil;  4,  (thymin-1-yl)acetic  acid  (1-(carboxymethyl)thymine);  5, 
methyl 5-uracilcarboxylate (methyl isoorotate); 6, 3-benzoyluracil; 7, 3-benzoyl-1-methyluracil; 8 N- 
butyl-1-methyl-5-uracilcarboxamide; 9, 1-octylthymine; 10, 1-octyl-5-uracilcarboxylic acid (1- 
octylisoorotic acid); 11, N-benzyl-1-octyl-5-uracilcarboxamide; 12, 1,3-dioctylthymine; 13, t-butyl (5- 
iodouracil-1-yl)acetate;   14,   (5-iodouracil-1-yl)acetic  acid;   15,   t-butyl   (5-azidomethyluracil-   1- 
yl)acetate; 16, ethyl (5-azidomehtyluracil-1-yl)acetate; 17, ethyl (5-aminomethyluracil-1-yl)acetate; 
18, ethyl [5-(N-(2-naphthylcarboxyl)aminomethyl)uracil-1-yl]acetate 
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1.5 Aim and thesis outlook 
 
 
Recently we have reporter a novel class of C(5) linked N(1)-alkylated uracil 
dimers rationally designed to potentially interact with adenine in biological system. 
These pyrimidine derivatives have shown antiproliferative and erythroid differentiation 
activities toward human chronic myelogenous leukemia K562 cells (Accetta et al., 
2009). In this thesis we report the screening study on a set of different modified C(5) 
uracil derivatives; many of them are reaction intermediates for the synthesis of 
modified uracil dimers. We have evaluated their antiproliferative effect in connection 
with erythroid differentiation pathways; we would like to propose this molecules as a 
new class of drugs candidates for the treatment of chronic myelogenous leukemia. 
As pointed out from the title of this thesis, we analyzed the biological activity, 
in particular on erythroid differentiation pathway, of uracil modified monomer used as 
intermediates of reaction during the synthesis of uracil dimers. These uracil dimers 
have previously showed interesting biological properties probably in connection with 
their  ability  to  cooperatively  interact  with  adenine.  Using  the  same  geometry, 
Corradini and his collaborators have synthetized the PNA monomer containing these 
novel modified dimeric uracils. This new nucleobases performed better than thymine 
for the adenine recognition on complementary DNA, conferring better selectivity and 
affinity. These “engineering” uracil were used to the specific design of anti-miR-221 
PNAs. The biological activities of these anti-miR-221 PNA were evaluated in a breast 
cancer cell model, and the results are reported in the Part 2 of this PhD thesis. 
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- MATERIALS AND METHODS - 
 
 
 
 
 
2.1 Cell culture: human erythroleukemic K562 cell line 
 
 
The human K562 cell line,  isolated from a patient with chronic myelogenous 
leukemia in blast crisis and characterized by Lozzio and Lozzio (Lozzio et al., 1975), 
were obtained from the American Type Culture Collection (Rockville, Md., USA). 
K562 were maintained in a humidified atmosphere of 5% CO2/air at 37 °C in 
suspension culture using Roswell Park Memorial Institute 1640 medium (RPMI 1640) 
(Sigma, St. Louis, MO, USA) supplemented with 10% fetal bovine serum (FBS; 
Analitical de Mori, Milan, Italy), 50 units/ml penicillin and 50 mg/ml streptomycin 
(Bianchi et al., 2001). 
 
 
 
 
2.2 C(5) modified uracil monomers 
 
 
For the experiments regarding erythroid differentiation in K562 cell line, we 
used a serie of uracil monomers and dimers synthesized by Prof. Roberto Corradini 
and his collaborators, in particular Alessandro Accetta, at University of Parma, Dept. 
of Organic and Industrial Chemistry. The methods of design and synthesis are well 
described in Accetta et al., 2009. Here, we report the chemical structure of 
compounds tested (Table 4). 
 
 
Table 4. Chemical structure of compounds tested 
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2.3 Antiproliferative activity 
 
 
We first determined for all the uracil-derived compounds the effects on cell 
proliferation. To this aim, K562 cells were seeded at an initial concentration of 3 x 104 
cells/ml and cultured in the presence of increasing concentrations of compounds. 
Non-treated cells were considered as control. Cell number/ ml was determined after 
3, 4, and 5 days, using a ZF Coulter Counter (Coulter Electronics, Hialeah, FL, USA). 
These time points were selected because between days 3 and 5 untreated control 
K562 cells are on the log phase of cell growth (Bianchi et al., 2001). The IC50 value 
(concentration of compound required to inhibit proliferation by 50%) was calculated 
on three independent experiments. 
 
 
 
 
2.4 Benzidine assay 
 
 
In order to determine the effects on the erythroid differentiation of uracil- 
derivatives monomers, K562 cells were seeded at an initial concentration of 3 x 104 
cells/ml and the proportion of benzidine- positive cells was determined after 4- 7 days 
of cell treatment with the compounds, using a solution containing 0.2% benzidine in 
0.5 M glacial acetic acid (10% H2O2) as previously described (Bianchi et al, 2001). 
The percentage of benzidine-positive cells (blue-cells) was calculated on total cells 
and indicates the presence of intracellular hemoglobin. 
 
 
 
 
2.5 Transfection of K562 cells with fluorescence protein genes under the γ- 
globin and the β-globin gene promoters 
 
K562 cells were stably transfected with the pCCL.Promβ.HcRed1. 
Promγ.EGFP, containing the green and red fluorescence protein (FP) genes under 
the control of the γ-globin and β-globin gene promoters, respectively (Guerrini et al., 
2009; Lampronti et al., 2009). In this system, increases in the green and red signals 
are consistent with γ-globin and β-globin gene promoter driven activity, respectively. 
To determine the activity of chemical compounds in inducing the expression of γ- 
globin and β-globin genes, cells were seeded at 8x103 cells/ml and treated with the 
appropriate concentration of the chemical inducer. After 5 days of culture, cells were 
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assayed for fluorescent proteins expression. First of all they were analyzed under a 
fluorescence inverted microscope, using filters suitable for both green and red FPs. 
The  fluorescence intensity  was  then  determined by  fluorescence- activated  cell 
sorting (FACS) analysis. 
 
 
 
 
2.6 RNA isolation 
 
 
The total cellular RNA was extracted by TRIZOL® Reagent (Sigma-Aldrich, 
St.Louis, Missouri, USA). All reagents and materials used were RNase-free. After 6 
days of treatment with the compounds, the cells were centrifuged at 1,200 rpm for 10 
minutes at 4°C, washed in 1X PBS, re-centrifuged and then lysed with 1 ml TRIZOL® 
Reagent. The homogenate was incubated 5 minutes at room temperature and  200 μl 
of chloroform were added; the samples were shaken vigorously for 15 second, 
incubated for 5 minutes at room temperature and finally centrifuged at 12,000 rpm for 
15 minutes at 4°C. The aqueous phase was transferred into a clean tube and 500 µl 
of isopropanol was added. The RNAs were and incubated for 10 minute at room 
temperature (25°C). After that, the samples were centrifuged at 12,000 rpm for 10 
minutes at 4°C; the isolated RNA was precipitated in 2 volumes of absolute ethanol 
and stored at -80°C, washed once with cold 75% ethanol, dried and dissolved in 10 
µl of diethylpyrocarbonate (DEPC)-treated water before use (Sambrook et al., 1989) 
 
and conserved at -80°C. 
 
 
 
 
 
2.6.1 RNA quantification 
 
 
The   concentration  of   RNA   should   be   determined  by   measuring   the 
absorbance at 260 nm (A260) in a spectrophotometer. The concentration is obtained 
by the equation: 
 
 
g/ml = ODx40xDIL 
 
 
 
where OD is the value read from the instrument, 40 is the correction coefficient for 
reading the RNA at the spectrophotometer (according to the Lambert-Beer law) and 
DIL is the dilution factor. An absorbance of 1 unit at 260 nm corresponds to 40 µg of 
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RNA per ml (A260 =1= 40 µg/ml). This relation is valid only for measurements in 
water. 
 
 
 
 
2.6.2 RNA electrophoresis on agarose gel 
 
 
The 1% agarose gel is prepared by dissolving 1 g of agarose powder in 100 ml 
of TAE 1x (obtained by dilution from 50x TAE = 2 M Tris-HCl, 0.05 M EDTA pH = 8.0 
and 5.71% acid Acetic 99.8%); EtBr 10 g/ml was added to the solution. 
 
 
 
 
2.7 Reverse transcription reaction- Random Hexamer 
 
 
Reverse transcription of 1 µg of total RNA was performed using with the 
 
TaqMan® Reverse Transcription Reagents PCR kit (Applied Biosystems). 
 
RNA was incubated with 2,5 µM Random Hexamers at 25°C for 10 minutes and then 
immediately cooled to 4°C. After that, the RT reaction solution, prepared considering 
a final volume of 50 µl, progressively adding the following reagents: 1X TaqMan RT 
Buffer (10X), 5,5 mM MgCl2 (25 mM),  deoxyNTPs Mixture, 0,4 U/µl RNase Inhibitor 
and 1,25 U/µl MultiScribeTM Reverse Transcriptase (50 U/µl) was added. To perform 
 
the reverse transcription reaction, the samples were incubated   for 30 minutes at 
 
48°C, to allow the extension, and at 95°C for 5 minute to inactivate the enzyme. After 
thermal cycling, cDNA were stored at -80°C. 
 
 
 
 
2.8 Real-Time Quantitative Polymerase Chain Reaction 
 
 
The quantitative real-time polymerase chain reaction (qPCR) assays of 
transcripts were carried out using gene-specific double fluorescently labelled probes 
(Applied Biosystems, Warrington Cheshire, UK) in a 7700 Sequence Detection 
System, version 1.6.3. To evaluate the erythroid induction of uracil derivatives in 
K562 cell line, the following primer and probe sequences were used (Table 5). The 
kit for quantitative qRT-PCR for ζ-globin mRNA and  ε-globin mRNA was from Applied 
Biosystems (ζ-globin mRNA: Hs00923579_m1; ε-globin mRNA: Hs00362216_m1). 
The fluorescent reporter and the quencher were 6-carboxyfluorescein (FAM) and 6- 
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carboxy-N,N,N′,N′-tetramethylrhodamine (TAMRA), respectively. The reference 
sequences were 18S ribosomal RNA, where the probe was fluorescently labelled 
with VIC TM (Applied Biosystems). 
 
 
Table 5. Sequences of primer and probe udes for qPCR gene expression analysis 
 
Primers & Probes Sequences 
α-globin fw 5’-TCCCCACCACCA AGACCTAC-3’ 
α-globin rev 5’-CCTTAACCTGGGCAGAGCC-3’ 
α -globin probe 5’-FAM-TCCCGCACTTCGACCTGAGCCA-TAMRA-3’ 
γ -globin fw 5’-TGGCAAGAAGGTGCTGACTTC-3’ 
γ -globin rev 5’-TCACTCAGCTGGGCAAAGG-3’ 
γ- globin probe 5’-FAM-TGGGAGATGCCATAAAGCACCTGG -TAMRA-3’ 
glycophorin A fw 5′-CGGTATTCGCCGACTGATAAA-3 ′ 
glycophorin A rev 5′-AAAGGCAGTCTGTGTCAGGT-3′ 
glycophorin A probe 5′-FAM-AAAGCCCATCTGATGTAAAACCTCTTCCCCT-TAMRA-3′ 
transferrin receptor fw 5′-TCAGAGCGTCGGGATATCG -3′ transferrin 
receptor rev 5′-TGAACTGCCACACAGAAGAAC A-3′ 
transferrin receptor probe 5′-FAM-TGGCGGCTCGGGACGGA-TAMRA-3′ 
 
 
 
 
The n-fold increase was determined as published elsewhere (Fibach et al., 
 
2003; Lampronti et al., 2003)  by comparing the ‘threshold’ cycle (CT ) value relative 
to the amplification of the cDNA to be quantified with that of the amplified reference 
18S  ribosomal  RNA (or U6 RNA) sequences (ΔCT  value). In order to quantify the 
increase in the levels of expression of a target gene in different PCR products, the 
differences between  ΔCT  values were  considered (ΔΔCT). The  ΔΔCT  represents the 
negative exponent in the equation 2 – ΔΔCT, quantifying the n-fold increase in the 
expression of the target gene in several samples, taking the levels of the 18S RNA 
(or U6 RNA) sequences as unchanged. 
 
 
 
 
2.9 High Performance Liquid Chromatography 
 
 
The hemoglobin contents in K562 cells were evaluated using High 
Performance Liquid Chromatography (HPLC). Cells were treated with the 
compounds for 6 days; after, cells were harvested, washed once with PBS, and 
the pellets were lysed in water. After incubation on ice for 15 min and spinning for 
5 min at 14,000 rpm in a microcentrifuge, the supernatant was collected and 
hemoglobin  proteins  were  separated  by  cation-exchange  HPLC,  using  a 
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Beckman Coulter instrument System Gold 126 Solvent Module-166 Detector and 
a 3.5 x 0.46 cm column packed with porous (100-nm pore size) 5-mm 
microparticulate polyaspartic acid-silica, Poly CAT A (Poly LC, Columbia MD, 
USA) (Ching-Nan et al., 1993). Samples were eluted in a solvent gradient using 
aqueous sodium chloride-BisTris-KCN buffers, and detection was performed at 
415 nm. The gradient was made up of mobile phase A (20 mM Bis Tris, 2 mM 
KCN, pH 6.98) and mobile phase B (20 mM Bis Tris, 2 mM KCN, 200 mM NaCl, 
pH 6.57), with a flow rate of 1.7 ml/min. Elution of hemoglobins was performed by 
increasing buffer B from 11% to 40% and to 100% at 8 and 12 min, respectively, 
and then decreasing to 11% buffer B for the least 8 min before application of next 
sample. The peak areas were used for quantification of individual hemoglobin 
peaks, utilizing standard controls of HbA and HbF (Analytical Control Systems, 
Fishers IN, USA) (Fibach et al., 2003). 
 
 
 
 
2.10 FACS analysis 
 
 
For   the   determination  of   fluorescence  intensity  by   FACScan  (Becton 
Dickinson, Franklin Lakes, NJ, USA), cells were harvested and washed. Then 1x104 
cells were analyzed by the CellQuest™ version 3.3 software (Becton Dickinson, 
Franklin Lakes, NJ, USA), using the fl1 channel to detect green fluorescence and fl3 
channel to detect red fluorescence. The results were expressed as median fold, i.e. 
the ratio between the median fluorescence intensity values obtained in the presence 
and absence of treatment, respectively. A graphic presentation of data was finally 
obtained  by  histograms,  showing  the  number  of  cells  versus  the  expressed 
fluorescence intensity (Salvatori et al., 2009). 
 
 
 
 
2.11 Measurement of apoptosis 
 
 
2.11.1 DeadEndTM Colorimetric TUNEL System 
 
 
Apoptotic cells were detected by the DeadEndTM Colorimetric TUNEL System 
(Promega Italia, Milan, Italy) according to the manufacturer’s instructions. The 
DeadEnd™ Colorimetric TUNEL System end-labels the fragmented DNA of apoptotic 
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cells using a modified TUNEL (TdT-mediated dUTP Nick-End Labeling) assay. 
Biotinylated nucleotide is incorporated at the 3′-OH DNA ends using the enzyme 
Terminal Deoxynucleotidyl Transferase, Recombinant (rTdT). Horseradish- 
peroxidase-labeled   streptavidin   (Streptavidin   HRP)   is   then   bound   to   these 
biotinylated  nucleotides,  which  are  detected  using  the  peroxidase  substrate, 
hydrogen peroxide, and the stable chromogen, diaminobenzidine (DAB). Using this 
procedure, apoptotic nuclei are stained dark brown. 
K562 cells were treated with the increasing concentrations of compounds; 
after 5 days, (when differentiated) the cells were rinsed twice with PBS solution 
and fixed for 25 min in 4% paraformaldehyde at room temperature. Measurement 
of apoptosis was calculated as a percentage of apoptotic nuclei (dark brown 
nuclei) versus total nuclei, evaluated in three independent experiments. A dark 
brown DAB signal indicates positive staining, while shades of blue-green to 
greenish tan indicate a non-reactive cell. The positive-control was the treatment 
with DNA-se 1 (Lampronti et al., 2009). 
 
 
 
 
2.11.2 Annexin V/PI release assay 
 
 
Apoptosis  was  also  detected  with  Annexin  V/PI  release  assay.  The 
ApoAlert Annexin V Apoptosis Kit provides a simple and effective method to 
detect one of the earliest events in apoptosis (the externalization of 
phosphatidylserine) in living cells. This assay takes advantage of the fact that 
phosphatidylserine (PS) is translocated from the inner (cytoplasmic) leaflet of the 
plasma membrane to the outer (cell surface) leaflet soon after the induction of 
apoptosis, and that the annexin V protein has a strong, specific affinity for PS. PS 
on the outer leaflet is available to bind labeled annexin V, providing the basis for a 
simple staining assay. 
Cells were treated with the compounds and, after 72 hours, cells were 
collected, centrifuged for 5 min at 1,500 rpm. Cells were rinsed with Binding 
Buffer and then Annexin V was added and the samples were incubated at room 
temperature for 15 min in the dark, according to the manufacturer’s instructions. 
For the analysis we have used FACS Calibur Becton Dickinson Immunocytometry 
System (Becton Dickinson, San Jose, CA, USA) (Viola et al., 2008). 
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2.11.3 Cell cycle analysis by FACS 
 
 
Cell cycle analysis was performed by flow cytometry of propidium iodide- 
treated cells, using the FACS Calibur Becton Dickinson Immunocytometry System 
(Becton Dickinson, San Jose, CA, USA). PI, a DNA intercalating fluorescent 
compound, can directly correlate the fluorescence with the amount of cell DNA 
content. As the DNA content of cells duplicates during the S phase of the cell cycle, 
the relative amount of cells in the G0 phase and G1 phase (before S phase), in the S 
phase, and in the G2 phase and M phase (after S phase) can be determined, as the 
fluorescence of cells in the G2/M phase will be twice as high as that of cells in the 
G0/G1 phase. 
K562 were seeded at initial concentration of 1x105 cell/ml in 12-well plate and 
 
treated with the compounds. After 72 hours, the cells were collected, washed with 
PBS and centrifuged at 1,500 rpm for 5 minutes. The supernatant was eliminated and 
the cells were stained in the dark for 30 minutes with propidium iodide (50 µg/ml), 
NP40 and RNase (10 µg/µl). After incubation, cells were washed twice with PBS, 
centrifuged at 1,500 rpm for 5 minutes and analyzed (Chui et al., 2010). 
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- RESULTS - 
 
 
 
 
 
3.1  Antiproliferative  and  erythroid  differentiating  activities  of  the  uracil 
monomers 
 
We first determined for all the synthesized molecules the effects on cell 
proliferation and on erythroid differentiation. To this aim, K562 cells were cultured in 
the presence of increasing concentrations of compounds; after 3, 4 and 5 days of 
treatment cell number/ml was determined by Coulter Counter and IC50  value 
(concentration of compound able to inhibit by 50% the cells growth) and after 5, 6 
and 7 days of treatment we evaluated, using benzidine assay, the erythroid 
differentiation (% B+ cells), as reported in “Materials and Methods” Chapter. 
 
 
Table 6. Antiproliferative activity (IC50)
a 
and induction of erythroind 
differentiation
b 
(% B+ cells) of uracil derived-compunds  on erythroleukemia 
K562 cells line. 
 
Compound IC50 % B+ cells Concentration (µM) 
1 > 400 µM 1.1 ± 0.8 400 
2 > 400 µM 1.3 ± 0.6 400 
3 120.05 ± 4.7 µM 4.1 ± 1.2 100 
4 > 400 µM 2.0 ± 0.9 400 
5 > 800 µM 7.3 ± 1.9 800 
6 350.7 ± 15.9 µM 1.1 ± 0.5 400 
7 650.6 ± 12.4 µM 1.5 ± 0.8 800 
8 488 ± 68 µM 12 ± 1.9 400 
9 29.4 ± 1.2 µM 98 ± 3.6 50 
10 268 ± 15.5 µM 25 ± 2.9 200 
11 66.54 ± 13 µM 2.2 ± 1.0 100 
12 29.7 ± 1.4 µM 2.1 ± 0.9 50 
13 > 400 µM 1.2 ± 0.2 400 
14 > 400 µM 1.6 ± 0.8 400 
15 721.3 ± 20.9 µM 2.3 ± 0.6 800 
16 764.2 ± 25.6 µM 2.1 ± 0.8 800 
17 > 800 µM 2.0 ± 0.9 800 
18 115 ± 16 µM 30 ± 4.9 200 
a 
Results are presented as average ± S.D. (three independent experiments performed). 
b 
Values 
are expressed as average ± S.D. (three independent experiments performed) after 6 days of 
treatment at concentrations close to those needed to obtain 50% inhibition of cell growth after 3 
day culture period (and reported of the far right column) 
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As shown in Table 6, it appears evident that the most active compounds with 
respect to antiproliferative effects (IC50 values lower that 150  μM) are  compounds 3, 
9, 11, 12 and 18; compound 9 being the most active molecule (IC50 = 29.4 ± 1.2 µM). 
 
However, among these molecules, only compound 9 is a very effective inducer of 
erythroid differentiation of K562 cells (Table 6). In fact, compounds 9 and 12 have 
similar IC50 (29.4 ± 1.2 µM and 29.7 ± 1.4 µM, respectively) , but when we analyze 
the proportion of benzidine- positive cells, 50 μM compound 9 display over 90% 
hemoglobin-expressing cells,  while  50  μM compound 12 shown only about 2% of 
benzidine-positive cells. As far as the other compounds, only 8, 10 and 18 are able to 
induce differentiation (12 ± 1.9,  25 ± 2.9,  30 ± 4.9 μM, respectively) but at very high 
concentrations (400 μM and  200 μM, respectively). When the same compounds were 
added at higher concentrations, no further increase in the proportion of benzidine- 
positive  cells  was  obtained  (data  not  shown).  According  with  these  results, 
compound 9 was analyzed in more detail. 
 
 
 
 
3.2 Effects of compound 9 on proliferation and erythroid differentiation of K562 
cells 
 
The analysis of the effects of compound 9 on the K562 cellular system is 
shown in Figure 9. In the experiment shown in Figure 9a, K562 cells were cultured 
for 6-7 days in the absence or in the presence of increasing concentrations (10, 30, 
50 μM) of compound  9. As it is clearly evident, a concentration-dependent inhibition 
 
of cell growth was observed. Figure 9c reports the effect on the proliferation of K562 
cells after 3 days of treatment with compound 9 at different concentrations. IC50 was 
obtained at about 30 μM. Figure 9d shows the percentages of differentiation induced 
by compound 9 at different concentrations (10, 30 and 50 μM). 
We  like  to  underline  that  more  than  60%  benzidine-positive  cells  are 
detectable after only 3 days of induction, demonstrating that the inducing effects of 
compound 9 was very high, and it can be considered among the most powerful 
inducer of K562 differentiation (see also Table 7). Despite the fact that there is no 
linear relationship between proportion of differentiated cells and cells with lower 
proliferation efficiency, the data summarized in Figure 9 c and d, demonstrate that 
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30  μM compound 9 is a concentration sufficient to (a) inhibit cell growth and (b) 
 
induce differentiation of the majority of treated K562 cells. 
 
 
 
 
 
 
 
Figure 9. Effect of compound 9 on the proliferation (A) and erythroid differentiation of K562 
cells (B). The effect on the proliferation of K562 after 3 days of treatment with compd 9 at 
different concentration (C) and % of benzidine-positive cells after 6 days of treatment (D). 
The values in treated cultures represented in C) were compared with untreated control 
cultures (taken as 100%) 
 
 
 
 
 
 
Figure 10. K562 untreated cells (A) and treated with   30 µM compound 9 (B). The 
positive-benzidine cells are blue, depending from the accumulation of hemoglobin 
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Further experiments are required to verify whether decrease of cell growth is a 
pre-requisite for differentiation or is the cause of this feature. Figure 10 shows a 
microscopic analysis of K562 cells cultured taken after 6 days of K562 cell cultured in 
the  absence or in  the  presence of 30  μM compound 9. In these assays, the blue- 
color of benzidine-stained cells is compatible with high accumulation of hemoglobin 
(Bianchi et al., 2001). 
In a second set of experiments, the biological activity of compound 9 was 
 
compared to that of 5-fluorouracil (5-FU), extensively employed as anti-tumor agent 
in leukemias (Mini et al., 1990; Schilsky et al., 1996). Interestingly, as far as the 
effects on cell proliferation, similar IC50 values were obtained when compound 9 and 
5-FU were employed. 
 
 
 
 
Table 7. Antiproliferative effects (IC50)
a  
and induction of erythroid 
differentiation
b    
(%  B+  cells)  of   uracil,  compound  9  and  5- 
fluorouracil on K562 cell line. 
 
Compound IC50 % B+ cells (30 µM) 
Uracil > 500 µM 1.2 ± 0.2 
Compound 9 17.52 ± 2.88 µM 92.3 ± 2.1 
5-Fluorouracil 17.73 ± 2.23 µM 3.1 ± 0.6 
 
a  
Results are presented as average ± S.D. (three independent experiments 
performed) of concentration needed to obtain 50% inhibition of cell growth after 3 
days culture period. 
b   
Values  are  expressed  as  average  ±  S.D.  (three  independent  experiments 
performed) after 6 days of treatment. 
 
 
 
 
On the other hand the effects of compound 9 and 5-FU on erythroid 
differentiation were found to be very different, being only compound 9 able to activate 
the full program of differentiation. As expected, uracil, in agreement with the first set 
of results depicted in Table 6, did not show any effects on K562 with respect to 
inhibition of cell proliferation and induction of erythroid differentiation (Table 7). 
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3.3 Effects of compound 9 on the transcriptional activity of the γ-globin and the 
 
β-globin gene promoters of K562 cells 
 
 
To determine the effects of compound 9 on the transcription of the globin 
genes, we used a clonal K562 cell population stably transfected with a reporter 
construct,  carrying the  genes  for  the  green  (EGFP)  and  red  (RFP)  fluorescent 
proteins  (FP)  genes, under  the  control  of the  γ-globin and the β-globin promoters, 
respectively (Guerrini et al., 2009). To compare the relative effect of compound 9 on 
the   transcriptional   activity   of  γ-globin   and   β-globin  promoters,  the  experiment 
depicted in Figure 11 was performed. Cells were treated with 30 µM compound 9, 
isolated after 5 days and employed in FACS analysis. This assay shows that 
compound 9 enhanced EGFP by 2.10 ± 0.63, whereas the increase in RFP was 1.39 
± 0.10 fold, indicating an effect of compound 9 on the transcription directed by both 
the -globin and  β-globin gene promoters. On the contrary, as recently published by 
our  research  group,  other  erythroid  differentiation  inducers  have  a  stimolatory 
selectivity for the -globin or the β-globin gene promoter. (Guerrini et al., 2009). 
 
 
 
 
 
 
Figure 11. Representative example of FACS analysis of a K562 cell clone containing the 
reporter construct pCCL.Promβ.HcRed1.Promγ.EGFP, untreated or treated with compound 9 
30  μM for  5  days. (A,B) Histogram plots obtained from untreated (solid lines) or treated 
(dotted  lines)  cells,  showing  the  relationship  between  number  of  cells  and  intensity  of 
expressed fluorescence, green (A) or red (B), respectively. (C) Dot plots obtained from 
untreated (−, upper panel) or treated (+, lower panel) cells, showing the cell population 
distribution as a function of the two different fluorescences 
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3.4  Effects  of  compound  9  on  biochemical  parameters  associated  to  the 
activation of the K562 erythroid phenotype 
 
The effects of compound 9 on the transcription of α-globin mRNA and  γ-globin 
mRNA   were   analyzed  by   qRT-PCR  amplifications.  Cells   were  treated  with 
compounds and after 6 days total RNA was extracted by TriReagent assay, reverse 
transcribed into cDNA and amplified by Real Time PCR, using gene-specific double 
fluorescence labeled probes in an ABI Prism 7700 Sequence Detection System 
version 1.7.3 (Applied Biosystem, Monza, Italy). As reported in Figure 12a , the 
treatment  with  increasing  concentration  of  compound  9  (10,  30  and  50  µM) 
stimulates  a  sharp accumulation  of  α-globin  mRNA  and  γ-globin mRNA. More in 
detail, treatment with 10 µM induce an  increase of 8,88  times and  8,90  times for α- 
globin mRNA and  γ-globin mRNA, respectively; treatment with 30 µM induce an 
accumulation  of   α- and  γ-globin mRNA of 14.22 and 16.22 greater than negative 
control (untreated cells); finally treatment with 50 µM compound 9 is able to induce 
an increase of 17.03  times and  16.45  times for α- and  γ-globin mRNA. 
We have also compared the globins accumulation of compound 9 with 100 µM 
of compounds 10 and 11 (Figure 12b), which induce erythroid differentiation on K562 
cell model to a much lower extent (Table 6). 
 
 
 
 
 
 
Figure 12. (A) Accumulation of α-globin mRNA and γ-globin in K562 cells treated for 6 days with 
30  μM compound 9. Results  are presented as fold  increase  of α-globin  and γ-globin mRNAs 
with respect to untreated cells. (B) Effect of compounds 9, 11 and 10 on accumulation of α- 
globin and γ-globin mRNA. The results of untreated cells were taken as 1. Results represent the 
average ±S.D. of three independent experiments 
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Figure 13. Comparison with chemical structures of compound 9, 10 and 11 
 
 
 
Following the preliminary results (Table 6)  compounds 10 and 11 induce only 
slight increase of accumulation of α-globin (1.24 and 3.29, respectively) and  γ-globin 
mRNAs (3.51 and 4.11, respectively). Further qRT-PCR data demonstrated that also 
the embryonic-type ζ- and  ε-globin mRNAs are induced by compound 9 (Figure 14). 
In addition, the effects of compound 9 on other genes involved in the expression of 
erythroid program. To this aim the mRNA coding glycophorin A (Watanabe et al., 
1985; Kohmura et al., 2004; Ida et al., 2009) and transferrin receptor (Gambari et al., 
 
1986; Harigae et al., 2006) were studied by qRT-PCR. 
 
 
 
 
 
 
 
Figure 14. Accumulation (fold increase in respect to control uninduced cells) of the 
α-like ζ- and α-globin mRNAs,  the β-like ε- and γ-globin mRNA, the glycophorin A 
and transferrin receptor mRNAs in K562 cells treated for 6 days with 30 μM 
compound   9.   Results   represent   the   average   ±S.D.   of   three  independent 
experiments 
 
 
The  results obtained are  shown  in  Figure 14  and  demonstrate that  both 
relative amounts of glycophorin A and transferrin receptor mRNAs increase following 
treatment with compound 9, confirms the induction of erythroid pathway by this 
compound. 
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3.5 Effect of compound 9 on hemoglobin accumulation measured by HPLC 
 
 
After  analyzing  globins  gene  expression,  we  investigated,  using  HPLC 
 
technology, the accumulation of hemoglobin in K562 cells treated with the compound 
 
9. Cells were treated for 6 days with compound 9, harvested, washed with PBS and 
lyses with water and incubation on ice for 15 minutes. After centrifugation, the 
supernatant was collected and hemoglobin proteins were separated by cation- 
exchange HPLC, using a Beckman Coulter instrument System Gold 126 Solvent 
Module-166 Detector and a 3.5 x 0.46 cm column packed with porous (100-nm pore 
size) 5-mm microparticulate polyaspartic acid-silica, Poly CAT A (Poly LC, Columbia 
MD, USA). 
Fully in agreement with HPLC analyses, showing that this molecule induces a 
sharp increase of embryonic and fetal hemoglobins (Figure 15). At the retention time 
of 0.30 minutes we find the peak of embryonic hemoglobins, Gower 1 (ζ2ε2) and 
Portland (ζ2γ2), constituting 100% of the sample composition. Treating cells with the 
compound 9, we can see a decrease to 76.19% of the embryonic hemoglobins, but 
an increases to 23.81% of fetal hemoglobin (retention time 2.208 minutes). 
 
 
 
 
Figure 15. HPLC analysis of K562 cellular lysates: chromatogram A shows the hemoglobin profile 
(Hb  Portland  and  Hb  Gower1)  in  untreated  cells,  chromatogram  B  presents  the  increased 
production of Hb Portland/Gower1 and HbF in K562 cells treated with compound 9 
 
 
 
 
3.6 The induction of erythroid differentiation of compound 9 is not associated 
with the activation of the apoptotic pathway 
 
Since several inducers of erythroid differentiation are also strong inducers of 
apoptosis of K562 cells (for instance mithramycin and psoralens) (Bianchi et al., 
2001; Lampronti et al., 2003) we performed a series of experiments to detect the 
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apoptotic induction of compound 9 in K562 cells. Cell cycle analysis was done by 
flow cytometry of propidium iodide-treated cells, using the FACS Calibur Becton 
Dickinson Immunocytometry System (Becton Dickinson, San Jose, CA, USA) (Figure 
16). FACS analysis demonstrates no major alteration of cell cycle parameters and no 
 
accumulation of sub-G1 cells (an hallmark of apoptosis). As shown in Figure 16, 
there are no significant changes in the profile of the cell cycle; in fact G0/G1 phase is 
always about 39%, both in negative control and in treatments with 30 and 50 µM 
compound 9. 
About apoptotic phase, the values change from 4.1% to 7.4%  and finally to 10.2% 
(negative control, 30 and 50 µM compound 9, respectively) of total cells; this variation 
is likely to be induced by the toxicity of the compound at used concentrations. 
 
 
 
 
 
 
Figure 16. Analysis of cell cycle using a fluorescence-activated cell sorter (FACS). A: untreated 
K562 cells; B,C: K562 cells treated with 30 µM  (B) and 50 µM (C) compound 9. Similar data 
were reproducibly obtained in three independent experiments 
 
 
 
 
Apoptosis  was  not  evident  also  when  Annexin  V–FITC  staining  was 
performed.  Cells  were  treated  with  the  compounds  for  72  hours,  collected, 
centrifuged and rinsed with Binding Buffer; then, annexin V was added and the 
samples were incubated at room temperature for 15 min in the dark, according to the 
manufacturer’s instructions. For the analysis we have used FACS Calibur Becton 
Dickinson Immunocytometry System (Becton Dickinson, San Jose, CA, USA) (Viola 
et al., 2008) (Table 8). 
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Finally, we have detected apoptosis using the colorimetric DeadEnd TUNEL 
assay (Figure 17). K562 cells were treated with the increasing concentrations of 
compounds; after 5 days, in according to the manufacturer’s instructions, K562 were 
rinse with PBS and fixed with 4% paraformaldehyde at room temperature. 
 
 
Table 8. Apoptosis of K562 cells detected by flow cytometry after annexin V–FITC staining. For this 
analysis the cells were treated with annexin V and PI, 30 µM and 50 µM compound 9. 
 
Treatment PI-positive 
(necrosis) 
PI   &   Annexin 
positive 
PI   &   Annexin 
negative 
Annexin-positive 
(apoptosis) 
NTC 0.0 0.04 99.91 0.05 
NTC + Annexin 0.0 0.07 99.58 0.35 
NTC + PI 0.39 0.04 99.53 0.03 
NTC + Annexin & PI 0.13 0.18 98.88 0.80 
Compd 9 30 µM 0.59 1.44 96.96 1.00 
Compd 9 50 µM 1.31 0.66 97.52 0.51 
 
 
 
 
 
 
Figure 17. Detection of apoptosis by DeadEnd TUNEL assay in K562 cell line (A), treated 
with DNAse I (1U/ml) (B), 30 µM compound 9 (C). Brown color reaction, visible only in the 
treatment with the DNAse I, indicates apoptotic cells. Cells were photographed at a 
magnification of 20X 
 
 
Measurement of apoptosis was calculated as a % of apoptotic nuclei (dark 
brown nuclei) versus total nuclei, evaluated in three independent experiments. As 
shown in Figure 20 the treatment with 30 µM of compound 9 not induce apoptosis. 
For positive control we have used DNAse I, a well-known apoptotic inducer. 
 
 
The results reported in Part 1 of thesis are already published in the following paper: 
 
Brognara E, Lampronti I, Breveglieri G, Accetta A, Corradini R, Manicardi A, Borgatti M, 
Canella A, Multineddu C, Marchelli R, Gambari R., 2011. C(5) modified uracil derivatives 
showing antiproliferative and erythroid differentiation inducing activities on human 
chronic myelogenous leukemia K562 cells. Eur J Pharmacol. 672(1-3):30-37 
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- DISCUSSION AND CONCLUSIONS (1) - 
 
 
 
 
 
The biological activity of the derivatives tested in this study can lead to the 
following alternative effects: (a) a strong antiproliferative effect linked to an high level 
of erythroid differentiation activity and (b) an antiproliferative effect independent from 
the activation of the erythroid program (Table 6). The highest antiproliferative effect 
and erythroid induction ability was exhibited by compound 9, a thymine derivative 
bearing a n-octyl chain on nitrogen N(1), whereas   thymine (compound 2) did not 
show any effect, suggesting the importance of the linear alkyl chain in position  N(1). 
The insertion of the alkyl chain in both N(1) and N(3) positions of thymine (compound 
12) brought   a loss of erythroid induction activity with retention of antiproliferative 
effect, suggesting the fundamental role of hydrogen in position N(3) of thymine for 
the erythroid induction activity. Appreciable, even if in some cases much lower, 
erythroid differentiation activity was shown by derivatives 8, 10 and 18. Activity of 
compound 10 can be rationalized considering its structural similarities to compound 9 
(methyl group substituted by COOH); compounds 8 and 18 show the same pattern, 
when properly oriented (Brognara et al., 2011); therefore, they can be considered as 
“C-nucleoside” equivalent (Lu et al., 2009) of compound 9 with exchange of the role 
of N(1) and C(5), which leads to N(3)-H in the same relative orientation with  respect 
to the lipophilic group as in thymine derivatives. In conclusion we found a simple 
thymine derivative, N(1)-octyl-thymine that exhibit strong antiproliferative activity, high 
ability to induce terminal erythroid differentiation without activation of the apoptotic 
pathway. To our knowledge this compound should be considered among the most 
efficient inducers of erythroid differentiation of K562 cells. 
However, this work should be considered as the starting point for the 
development  of  more  effective  and  specific  drugs  for  the  induction  of  terminal 
erythroid differentiation, with the aim of leading new insights in the treatment of 
neoplastic diseases with molecules acting by inducing differentiation rather than 
simply by exerting cytotoxic and/or antiproliferative effects. Compound 9 might be of 
some  interest  since  strongly  inhibits  cell  growth  (the  activity  is  similar  to  that 
displayed   by   5-fluorouracil),   but   at   the   same   time   does   induce   erythroid 
differentiation. In this respect, the development of new compounds against chronic 
myelogenous leukaemia cell  lines  might be of great interest, since it has been 
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already demonstrated that synergistic effects of molecules inducing differentiation 
can be useful for the efficient treatment of chronic myelogenous leukaemia 
(Rabizadeh et al., 2007, Jakubowska et al., 2008). 
In addition, and more importantly, Imatinib mesylate-resistant human chronic 
myelogenous leukemia cell lines can be treated with erythroid inducers, as recently 
demonstrated using the phytoalexin resveratrol (Puissant et al., 2008). It should be 
interesting to determine the activity of compound 9 in Imatinib-resistant cell lines, 
since the effects of resveratrol as erythroid-inducing agent are significantly different 
from those  displayed by  compound 9  in  respect to induction of  globin  mRNAs 
(Bianchi et al., 2009) and activation of apoptosis and cell-cycle alterations (Puissant 
et al., 2008). 
On the other hand, molecules similar to compound 9 might be of interest for the 
 
experimental treatment of -thalassemic erythroid cells, for which the induction of 
- globin mRNA could be very beneficial (Fibach et al., 2003; Gambari et al., 2007). 
In  this  respect  it   has  been  demonstrated  that  inducers  of  K562  erythroid 
 
differentiation are often able to induce fetal hemoglobin production in erythroid cells 
isolated from -thalassemia patients (Gambari et al., 2007). 
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- INTRODUCTION - 
 
 
 
 
 
The  double  helix  of  DNA is  Nature’s  simple  and  elegant  solution  to  the 
problem of storing, retrieving, and communicating the genetic information of a living 
organism. DNA has many important characteristics that allow it to perform these 
functions. Two of the most important properties are the specificity and the reversible 
nature of the hydrogen bonding between complementary nucleobases, properties 
which allow the strands of the double helix to be unwound and then rewound in 
exactly the same configuration. 
The field of life science realized early on the important implications of these 
traits. If specific, single strands of DNA could be synthesized, then the base 
sequences  of  genes  could  be  studied  and  manipulated  using  these  defined 
molecules. Synthetic oligonucleotides are now indispensable tools for life scientists, 
with many applications in molecular biology, genetic diagnostics, and most likely also 
soon in medicine. 
 
 
 
 
1.1 Peptide nucleic acids 
 
Peptide nucleic acid (PNA) is an artificially synthesized polymer similar to DNA 
or  RNA  invented  by  Peter  E.  Nielsen, Michael  Egholm,  Rolf  H.  Berg  and  Ole 
Buchardt (Univ. Copenhagen) in 1991 (Nielsen et al., 1991). As shown in Figure 1 
While DNA and RNA have a deoxyribose and ribose sugar backbone, respectively, 
PNA's backbone is composed of repeating N-(2-aminoethyl)-glycine units linked by 
peptide bonds. The various purine and pyrimidine bases are linked to the backbone 
by methylene carbonyl bonds (Egholm et al., 1993). 
PNA was originally designed as a ligand for the recognition of double stranded 
DNA (Nielsen et al., 1999). The concept was to mimic an oligonucleotide binding to 
double stranded DNA via Hoogsteen base pairing in the major groove.   Thus the 
nucleobases of DNA were retained, but the deoxyribose phosphodiester backbone of 
DNA  was  replaced  by  a  neutral  pseudo-peptide  backbone.  Nielsen  and  his 
colleagues could not imagine all the possible properties and applications that could 
be developed based on the neutral backbone. With many properties that set them 
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apart from traditional DNA analogs, PNAs have added a new dimension to synthetic 
 
DNA analogs and mimics in molecular biology, diagnostics, and therapeutics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. DNA and PNA chemical structures 
 
 
 
 
 
1.1.1 PNAs Structure and Properties 
 
The PNAs have been introduced by Nielsen et al. (1999); PNAs are synthetic 
DNA analogs in which the phosphodiester backbone is replaced by repetitive units of 
N-(2-aminoethyl) glycine to which the purine and pyrimidine bases are attached via a 
methyl carbonyl linker (Figure 1). The procedures for PNA synthesis are similar to 
those employed for peptide synthesis, using standard solid-phase manual or 
automated synthesis. The PNA molecules can routinely be labeled with biotin or 
fluorophores. A subsequent generation of PNAs could involve modification of the N- 
(2-aminoethyl) glycine backbone (PNA analogs) or chimeric architecture, like PNA- 
peptide chimeras or PNA-DNA chimeras developed in order to improve the solubility 
and the cellular uptake of PNAs or to exhibit new biological properties (Koch et al., 
1995). The synthetic backbone provides PNA with unique hybridization 
characteristics. Unlike DNA and RNA, the PNA backbone is not charged. 
Consequently, there is no electrostatic repulsion when PNAs hybridize to its target 
nucleic acid sequence, giving a higher stability to the PNA-DNA or PNA-RNA 
duplexes than the natural homo- or heteroduplexes. This greater stability is reflected 
by a higher thermal melting temperature (Tm), as compared to the corresponding 
DNA-DNA or DNA-RNA duplexes (Jensen et al., 1997). The unnatural backbone of 
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PNAs also means that PNAs are not degraded by nucleases or proteases. For 
instance, incubation of PNAs with S1 nuclease or DNAse I has no effect on PNA 
(Demidov et al., 1993). Owing to this resistance to the enzyme degradation, the 
lifetime of PNAs is extended both in vivo and in vitro. Also, PNAs are not recognized 
by polymerases and therefore cannot be directly used as primers or be copied. 
 
 
 
 
1.1.2 Strand invasion and PNAs applications 
 
PNAs hybridize to complementary DNA or RNA in a sequence-dependent 
manner, according to the Watson–Crick hydrogen bonding scheme. In contrast to 
DNA, PNA can bind in either parallel or antiparallel manner. However, the antiparallel 
binding is favored over the parallel one. Structural information on the PNA binding 
modes have been obtained by nuclear magnetic resonance and by X-ray 
crystallography (Rasmussen et al., 1997). 
 
 
 
 
 
 
 
Figure 2. Scheme of PNA binding modes for targeting double-stranded DNA. PNA oligomers are 
drawn in bold. (1) Standard duplex invasion complex formed with some homopurine PNAs. (2) Double- 
duplex invasion complex, very stable but only possible with PNAs containing modified nucleobases. 
(3)  Conventional  triple  helical  structure  (triplex) formed  with  cytosine-rich  homopyrimidine  PNAs 
binding to complementary homopurine DNA targets. (4) Stable triplex invasion complex, leading to the 
displacement of the second DNA strand into a 'D-loop'. 
 
 
 
 
PNA probes can bind to either single-stranded DNA or RNA, or to double- 
stranded DNA (Figure 2). Homopyrimidine PNAs with a minimum of 10-mers, as well 
as PNAs containing a high proportion of pyrimidine residues, bind to complementary 
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DNA sequences to form highly stable (PNA)2–DNA triplex helices displaying Tm over 
 
70°C. In these triplexes, one PNA strand hybridizes to DNA through standard 
Watson–Crick base pairing rules, while the other PNA strand binds to DNA through 
Hoogsteen hydrogen bonds. The resulting structure is called P-loops. The stability of 
these triple helixes is so high that homopyrimidine PNA targeted to purine tracts of 
dsDNA invades the duplex by displacing one of the DNA strands (Nielsen et al., 
1999). The efficiency of this strand invasion can be further enhanced by using two 
homopyrimidine PNA oligomers connected via a flexible linker or by the presence of 
nonstandard nucleobases in the PNA molecule. 
Finally, PNA–DNA hybridization is significantly more affected by base 
mismatches than DNA–DNA hybridization. Using a 15-mer PNA, all possible single 
mismatch combinations were tested in both PNA/DNA duplexes and corresponding 
DNA/DNA duplexes. In the PNA/DNA duplexes, the average Tm was 15°C, whereas 
it was 11°C in the corresponding DNA/DNA duplexes (Giesen et al., 1998; Nielsen et 
al., 1999). Similar results were obtained for PNA/RNA duplexes. This high level of 
discrimination at single base level indicates that short PNA probes could offer high 
specificity, and thus allow the further development of several PNA-based strategies 
for molecular investigations and diagnosis. 
 
 
 
 
1.1.3 PNAs as bioactive molecules for gene expression control 
 
A very important point suggesting PNAs as appealing molecules in the field of 
artificial regulation of gene expression, both in vitro and in vivo, is that they are 
resistant to both nucleases and proteases (Borgatti et al., 2003; Calabretta et al., 
2011). Borgatti et al. have reported that PNAs and PNA–DNA chimeras, unlike DNA 
molecules, are stable in cellular extracts and serum; in their studies, these authors 
also determined the resistance of double-stranded decoy molecules based on PNA– 
DNA chimeras to exonucleases (both 3´→5´ and  5´→3´ exonucleases), endonucle- 
ases and 5´-phosphatases (Borgatti et al., 2003). Finally, they used liposomes as 
protective agents in experimental conditions in which the DNA-based molecules were 
found to be unstable (high concentrations of enzymes, cellular extracts or serum). 
The results obtained demonstrated that PNA-based molecules are more resistant 
than DNA-based decoys to exo- and endo-nucleases, serum and cellular extracts. In 
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addition, the resistance of PNA-based molecules in the presence of high 
concentrations of serum and cellular extracts was increased after complexation to 
cationic liposomes. These studies are in agreement with other published reports 
demonstrating PNAs as very stable molecules in cell culture conditions and, more 
importantly, in biological fluids (Demidov et l., 1994; Shiraishi et al., 2008; Gambari et 
al.,  2010).  Moreover,  because  PNA  oligomers  lack  of  a  repetitively  charged 
backbone, they do not interact with polyanion-binding proteins, which may complicate 
the actions of nucleotide analogues when used as gene-targeting agents (Stein et al., 
1999). Accordingly, PNAs have been proposed as excellent candidates for in vitro 
 
and in vivo modulation of gene expression, as shown in Figure 3. 
 
 
 
 
 
 
 
Figure 3. Biological activity of PNAs derived from the most recent papers available in the literature 
 
 
 
 
 
PNAs are able to target RNA molecules mimicking the antisense approach 
firmly recognized as a very important experimental strategy to inhibit the biological 
activity of target mRNAs. For instance, Shiraishi et al. used antisense PNAs targeting 
the 5´-or 3´-splice sites in intron 2 or the 3´-splice site of intron 3 of mdm2 pre-mRNA 
in order to inhibit RNA splicing and expression of the mdm2 human cancer gene in 
choriocarcinoma (JAR) cells. Treatment of JAR cells with bioactive PNAs resulted in 
a reduction in the level of MDM2 protein and a concomitant increase in the level of 
tumor suppressor p53. In addition, a combination of this PNA with the DNA damaging 
agent camptothecin inhibited cell growth more than camptothecin alone. The 
interesting conclusion was that antisense targeting of splice junctions of mdm2 pre- 
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mRNA may be a powerful method to evaluate the cellular function of MDM2 splice 
variants as well as a promising approach for discovery of mdm2 targeted anticancer 
drugs (Shiraishi et al., 2010). PNAs were found to be very effective in targeting 
promoters (by triple-helix formation or following strand invasion). In this specific case, 
they  act  as  inhibitors  of  transcription,  but  also  as  transcriptional  activators 
(Mollegaard et al., 1994; Tonelli et al., 2005). Finally, despite the fact that PNA–PNA 
and PNA–DNA hybrids exhibit low binding efficiency to transcription factors (TFs) 
and therefore cannot be proposed as efficient TFs decoy molecules (Mischiati et al., 
1999). PNA–DNA chimeras have been described as reagents of great interest in 
gene therapy, as they are able to stably interact with TFs inhibiting TF-dependent 
effects (Borgatti et al., 2003; Gambari et al., 2004; Borgatti et al., 2004). This was 
studied by our research group and was demonstrated for NF-kB and Sp1, for which 
we designed bioactive double stranded PNA–DNA–PNA chimeras. However, as for 
many large macromolecules, therapeutic applications of unmodified PNAs remain 
limited by their low cellular uptake and poor ability to reach their intracellular target. 
In this respect, PNAs can be modified in order to achieve better performances in 
terms of cellular permeation, higher affinity, and specificity for the target DNA and 
RNA sequences (Wojciechiwski et al., 2007; Manicardi et al., 2010; Zhou et al., 2006; 
Shiraishi et al., 2011) In any case, their affinity for RNAs make these reagents of 
great interest in all the experimental approaches involving RNA targeting. 
 
 
 
 
1.1.4 Modified PNAs and PNAs delivery 
 
It’s important to understand the effect of PNAs on intact cells and problems 
related to its delivery into the cell. The cellular uptake of this unique nucleic acid 
analogs is very low in eukaryotic cells (Rasmussen et al., 2006): this is the major limit 
in the use of PNAs for the alteration of gene expression and, for this reason, it is still 
considered to be the major challenge that must be overcome before it can be used 
as therapeutic drug (Arghya et al., 2000).  In order to remove this drawback, several 
approaches have been considered, for example, cellular microinjection and delivery 
of unmodified PNAs. Moreover, the use of cationic liposomes and/or microspheres is 
not  indicates,  in  consideration  of  the  low  binding  efficiency  of  PNAs  to  these 
structures (Fabbri et al., 2011). 
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In this respect, we have proposed to use PNA-DNA hybrids or PNA-DNA 
chimeras to dock the PNAs to cationic liposomes (Nastruzzi et al., 2000; Borgatti et 
al., 2002; Cortesi et al., 2004). However, the use of cationic liposomes and 
microspheres might be toxic to target cells, especially if for the experiments primary 
cells were employed. Another possible strategy consists to link PNAs to polylysine 
(K) or a polyarginine (R) tails, based on the observation that this cell-membrane 
penetrating oligopeptides are able to facilitate uptake of conjugated molecules (Abes 
et al., 2008). Since this discovery, many other modifications of the original PNA 
backbones have been proposed in order to improve performances in term of affinity 
and specificity. Modification of the PNA backbone with positively charged groups 
(Figure 4) has also been demonstrated to enhance cellular uptake and consequently 
PNA efficiency (Zhou et al., 2003, 2006; Corradini et al., 2007). 
 
 
 
 
 
 
Figure 4. Structure of backbone modified PNA 
 
 
 
 
 
Although the steric requirements for binding RNA have not been extensively 
studied  so  far,  the  availability  of  different  chemical  strategies  to  design  and 
synthesize PNA analogues is the basis for the development of new peptide nucleic 
acids (PNAs) specifically aimed at targeting RNA, to be used for miR targeting 
(Section 1.2.6). 
In the last few years several research groups have been involved in the 
synthesis  and  in  the  studies  of  the  binding  properties  of  PNAs  with  a  chiral 
constrained backbone obtained by insertion of stereogenic centers either at the C2 
(alpha) or C5 (gamma) position of the monomer. The insertion of one chiral 
monomeric unit in a PNA strand has resulted in increased DNA binding affinity, when 
the side chain was positively charged (e.g. lysine or arginine). Therefore, the affinity 
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of chiral PNAs for complementary DNA emerged to be a contribution of different 
factors: electrostatic interactions, steric hindrance and, most interestingly, 
enantioselectivity with a preference for the D-configuration at the 2 position of the 
monomer forms (Menchise et al., 2003). The 2D-lysine "chiral box" PNA showed also 
increased sequence selectivity, both in terms of direction control and of recognition of 
a single base mismatch (Sforza et al., 2000). In fact, this type of structures was found 
ideal for targeting point mutations in genes of diagnostic interest as published by our 
collaborators Corradini et al., 2004, and  Tedeschi et al., 2005. Recently, Ly and co- 
workers reported the  synthesis  and  uptake properties  of γGPNA,  in  which  the  PNA 
backbone had a homo-arginine side chain at the 5-position  (or γ position)  (Sahu et 
al., 2009), showing an excellent cellular uptake. More recently, chiral PNAs with L- or 
D-stereocenters either at the 2- or the 5-positions of the monomer or with both 
stereocenters simultaneously present have also been synthesized (Sforza et al., 
2007, Manicardi et al., 2010); the biological activities of these modified PNAs are 
describe in Results section of Part 2. 
Substitution at both C(2) and C(5) carbons of the PNA backbone with amino 
acid side chains leads to ambivalent structures having properties of DNA or RNA 
mimic on one side and peptide mimics on the other side, thus allowing recognition by 
specific receptors, as shown very recently by a short PNA mimicking the function of a 
nuclear localization peptide (NLS) (Sforza et al., 2010). Thus, and to obtain PNAs 
with both peptide properties and RNA binding ability. This strategy can be used to 
further improve the efficiency of PNAs for miR targeting. In fact, the use of peptides 
as carriers represents a “Achille’s heel” of the potential PNA-based drug candidates, 
since the peptide part might be subjected to enzymatic degradation, whereas the 
incorporation of the peptide signal into the PNA backbone does not lead to enzymatic 
degradation, even in the presence of highly active proteases. 
PNAs bearing modified nucleobases able to induce additional interactions 
providing high improvement in RNA and DNA binding affinities have also been 
described (Wojciechowski et al., 2009). Combination of modified nucleobases and 
backbone modification with C(2) or C(5) modified residues was found to be the best 
approach in order to achieve strand invasion into mixed DNA sequences (Ishizuka et 
al., 2009, Chenna et al., 2008), a strategy which could also be very fruitful in 
challenging double-stranded miRs. 
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1.1.5 Synthesis of Modified peptide nucleic acids monomers 
 
The peptide nucleic acids (PNAs) used in our experiments were synthesized 
by Prof. Roberto Corradini and his groups (University of Parma, Dept. of Organic and 
Industrial Chemistry) (Manicardi et al., 2010). They first designed the synthesis of 
new class of dimers by substitution of amide linker on C(5) with more flexible methyl 
amino linker, shows in Figure 5; this modification should depress part of self- 
aggregation of dimmers in favor of solubility since secondary amine is protonate in 
physiological conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figura 5. 5-Carboxiamido-Uracil and 5-methylamido Uracil structures 
 
 
 
Synthesis of these dimers was well described in section 1.1.3 of Part 1; briefly, 
it was designed by reaction of 5 formyl uracils with different diamine linker through 
reductive amination reaction. The synthesis of 5 formyl uracils was carried out by 
oxidation of N(1) alkylated thymine or by formylation under Vielsmeyer Haack 
conditions     of     N(1) alkylated N(3) benzoylated     uracil.     The     synthesis     of 
5 methylazidouracil PNA monomers is described below in two phases: synthesis of 
5 methylazidouracil (Figure 6) and its incorporation into Boc-amino-ethyl-glycine 
backbone (Figure 7). The synthesis of 5 methylazidouracil started from the 
regioselective hydroxymethylation of C(5) of uracil to afford 5 hydroxymethyluracil 20, 
that was transformed to the alkyl chloride 21 using concentrated HCl. Nucleophilic 
 
substitution of 21 with sodium azide gives the desired product 22. This last reaction 
was carried out at low temperature (0°C) in order to avoid self-reaction of 21 on its 
N(1)  or  N(3),  which  would  form polymeric compounds, thus  lowering the  yield. 
5 methyluracil was then regioselectively alkylated on N(1) by bromoacetic acid esters 
to give 23 and 24, leading to only 49% yield due to formation of the bis alkylated side 
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product.  Ester  deprotection  of  23  and  24  using  appropriate  conditions  (basic 
hydrolysis for 24 and acid cleavage for 23) leads to compound 25. 
5 methylazidouracil acetic acid 25 was activated with DCC/DhBtOH and linked to the 
Boc aeg OEt backbone to afford the ethyl ester PNA monomer 26. The hydrolysis of 
ethyl ester of 26 afforded the desired PNA monomer ready to use for the solid phase 
 
synthesis of oligomers (Accetta A., 2010). 
 
 
 
 
 
 
 
Figure 6. Synthesis of 5 azidomethyluracil. (i) [CH2O, Et3N, water, 60°C, overnigth]. (ii) [HCl 37%, 4H, 
rt]. (iii) [NaN3, DMF, 0°C, 1h] 
 
 
 
 
 
 
 
 
Figure 7. Synthesis of 5 methylazidouracil  Boc PNA monomer. (i) [BrCH2COOR, K2CO3, DMF, rt, 
overnight ]. (ii) [(a) TFA/DCM; (b) NaOH, water/MeOH for 24h]. (iii) [DCC, DhBtOH, DIEA, DMF]. (iv) 
[NaOH, water/MeOH] 
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1.1.6 Synthesis of PNAs oligomers based on engineered uracil derivatives 
 
Chemical modification of Peptide Nucleic Acids (PNA) is being studied 
extensively as an approach for the development of improved probes for nucleic acids 
recognition and for therapy based on gene regulation (Tonelli et al., 2005). The 
synthesis of modified PNA oligomers often requires optimization and slightly 
modification of the standard procedures in order to ensure better yields and purity 
and  was  performed  using  different  strategies:  the  synthesis  of  PNA  oligomers 
containing Mod 1  and Mod 2  was performed by hybrid Boc/Fmoc chemistry, while 
modified monomers (Mod-3) were Fmoc protected at the aminoethyl nitrose (Figure 
 
8). The PNA oligomer containing Mod 2  showed interesting recognition properties 
towards complementary DNA. The amide group directly linked to the C(5) position of 
 
uracil (Figure 9a) was tolerated and did not lead to a dramatic drops in stability of the 
 
PNA:DNA duplex. 
 
 
 
 
 
 
 
Figure 8. Modification incorporate into PNA oligomers employed 
 
 
 
 
 
However, we explored the possibility to use derivatives with a substituent 
showing electronic effects more similar to those of thymine by simply reversing the 
amide (Mod 4) on the C(5) position of uracil (Figure 9b). PNA oligomers containing 
Mod 4 were synthesized using an innovative strategy by means of an azide modified 
precursor  monomer  of  uracil  which  could  be  further  modified  by  solid  phase 
synthesis. This strategy can allow faster and simpler synthesis of oligomers, since it 
avoids the necessity to synthesize PNA monomers containing hindered and complex 
modified bases. 
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Furthermore, the modification of the base on solid phase could avoid problems 
of steric hindrance in coupling steps, since the modified base is built step by step. 
The 5 (azidomethyl)uracil PNA monomer  (Figure 10) was chosen as the common 
precursor monomer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. (a) Carboxamido derivatives; 
(b) Reversed Amide, methylamido derivatives 
 
 
 
 
The azide group was chosen because it is easily transformed into an amino 
group under mild conditions, such as those used in Staudinger’s reduction, which can 
be performed also on solid phase; the amino group thus obtained can be used in 
reactions with activated carboxylic acids to form a new amide bond on the C(5) 
position of uracil. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. 5 (azidomethyl) PNA 
monomer.   The azide group was 
chosen   as   hidden   and   protected 
amino group 
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In  conclusion, these  findings are  not  only  important  for  improving of  the 
stability and selectivity of PNA oligomers, but it is important since these engineered 
PNAs were specifically designed in order to precisely interact with specific sites on 
complementary DNA or RNA. Inversion of the amide group of Mod 1  to Mod 4 
resulted to be detrimental for stability, but not for selectivity; however, in this case the 
 
different fluorescence response of naphthalene in PNA PR AAUN3 with full match 
and mismatched DNA opens the possibility to develop fluorescent probes for DNA 
 
recognition. 
 
 
 
 
 
1.2 Targeting microRNAs involved in human diseases 
 
 
 
1.2.1 The microRNA 
 
The identification of all epigenetic modifications involved in gene expression is 
one of the major steps forward for understanding human biology in both normal and 
pathological conditions. This field is referred to as epigenomics, and it is defined as 
epigenetic changes (i.e. DNA methylation, histone modification and expression of 
noncoding RNAs such as microRNAs) on a genomic scale (Costa F., 2010). In this 
context, microRNAs play a pivotal role. 
MicroRNAs (miRNAs, miRs) are a family of small (19–25 nucleotides in length) 
noncoding RNAs that regulate gene expression by sequence-selective targeting of 
mRNAs, leading to a translational repression or mRNA degradation, depending on 
the degree of complementarity between miRNAs and the target mRNA sequences 
(He et al., 2010; Krol et al., 2010). Since their discovery and first characterization on 
1993 by Ambros V., Lee R. and Feinbaum R., the number of microRNA sequences 
deposited in the miRBase databases is continuously growing (Kozomara et al., 2010) 
and the microRNAs are proving to have an important role in the cellular regulatory 
pathways. 
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1.2.2  MicroRNA  biological  relevance:  involvement  in  the  gene  expression 
control 
 
Considering that a single miRNA can target several mRNAs and a single 
mRNA might contain in the 3’-UTR sequence several signals for miRNA recognition, 
it is calculated that at least 10-40% of human mRNAs are a target for microRNAs 
(Tsai et al., 2010). In fact, a single miRNA might bind to as many as 200 gene targets 
and that these targets can be diverse in their function; they include transcription 
factors, secreted factors, receptor and transporters. So, miRs potentially control the 
expression of about one-third of human mRNAs (Kerscher et al., 2006). 
Therefore, a great interest is concentrated on the identification of validated 
targets of microRNAs. This specific field of microRNA research has confirmed that 
the complex networks constituted by miRNAs and RNA targets coding for structural 
and regulatory proteins lead to the control of highly regulated biological functions, 
such as differentiation (Masaki et al., 2007), cell cycle (Wang et al., 2009) and 
apoptosis (Subramanian et al., 2010). 
Since a single 3’UTR of a given mRNA contains signal sequences for several 
microRNAs, which microRNA should be targeted in order to achieve alteration of the 
expression of the gene should be experimentally evaluated. With respect to the 
possible effects of the expression of other mRNA targets, it should be clearly stated 
that alteration of a single microRNA might retain multiple effects. 
On the other hand, miRNAs usually bind to their targets with incomplete 
complementarity; for this reason, the identification of gene targets with only a simple 
BLAST search is impossible. However, current bioinformatics approaches have taken 
advantage of the fact that miRNAs within families have highest homology at the 5’ 
end of the mature miRNA, which is crucial for the stability and proper loading of the 
miRNA into the miRISC complex (Schwartz et al., 2003). 
 
 
 
 
1.2.3 Biogenesis of microRNAs 
 
Some miRNAs are encoded by unique genes (intergenic miRNAs) (Berezikov 
et al., 2007) and others are embedded into the intronic regions of protein-coding 
genes (intragenic miRNAs) (Hinske et al., 2010). The transcription by RNA 
polymerase II of these miR genes gives rise to long primary miRNAs (pri-miRNAs) 
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with typical stem-loop structures. These are rapidly processed by the nuclear RNase 
endonuclease-III Drosha, which, removing the branches, gives rise to precursor 
miRNAs (pre-miRNA) of around 60-100 nucleotides in length (Figure 11). In both 
cases of intergenic miRNAs and intragenic miRNAs, the pre-miRNAs are transported 
from the nucleus to the cytoplasm by exportin-5. In the cytoplasm, pre-miRNAs are 
further processed by another RNase endonuclease-III (Dicer) to generate mature 
miRNAs around 22-nt long, which generate the RNA-induced silencing complex 
RISC. 
 
 
 
 
1.2.4 MicroRNA and gene regulation 
 
Structurally,  miRNAs  are  small  non-coding  regulatory  RNAs;  these  small 
RNAs post-transcriptionally repress gene expression by recognizing complementary 
target sites most often in the 3’ untranslated region (UTR) of target messenger RNAs 
(mRNAs) (Bagga et al., 2005). However, animal miRNAs may also target 5’UTR and 
coding regions of mRNAs, as documented by experiments involving both artificial 
and natural mRNAs and also by bioinformatic predictions (Orom et al., 2008). 
MicroRNAs silence the expression of the target mRNAs, either by mRNA cleavage or 
by translation repression. Nevertheless, it has been described that miRNAs can also 
increase  the  expression  of  a  target  mRNA  (Vasudevan  et  al.,  2007).  Perfect 
miRNA:mRNA complementarity leads to cleavage of the mRNA by AGO2; this is the 
small interfering RNA (siRNA) pathway, which while important experimentally, is not 
thought to occur with endogenous mammalian miRs. Instead, the imperfect pairing 
with mRNA causes a down-regulation of translation, even if the mechanism by which 
this occurs is still not clear. Whatever the precise nature of the mechanism, affected 
mRNAs accumulate in granular cytoplasmic “P-bodies” along with RISC proteins 
(Pillai  et  al.,  2005).  Generally,  mRNA  abundance  is  ultimately  also  reduced 
(Hendrickson et al., 2009). This is important, as it means that the impact of miR 
activity can be assessed (at least to some extent) by measures of mRNA abundance 
such as expression profiling. 
The basic mechanism leading to alteration of gene expression is based on the 
recruitment of  mature miRNA at  the  level  of  the  RISC silencing complex. This 
process occurs in the cytoplasm, where the pre-miRNA hairpin is cleaved by the 
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RNase III enzyme Dicer, which interacts with the 3’ end of the hairpin and cuts away 
the loop joining the 3’ and 5’ arms, yielding an imperfect miRNA/ miRNA duplex. 
One of the strands is incorporated into the RISC, where it binds to target mRNA 
 
sequence. Perfect or near perfect base pairing with the target RNA promotes 
cleavage of the RNA (Choe et al., 2011). It is proposed that in the case of partially 
complementary microRNAs, in order to recognize their targets, nucleotides 2-7 of the 
miRNA (the ‘seed sequence’) are important (Cuccato et al., 2011). 
 
 
 
 
 
 
 
 
Figure  11.  Biogenesis  and  action  of  miRNAs.  (Step  1)  miRNAs  are  transcribed  mainly  by 
polymerase II. miRNA transcribed from genes (step 2a), polycistronic clusters (step 2b), or the 
intronic region (step 2c), called pri-miRNAs, and in the first two cases are then processed by the 
type III RNase Drosha. (Step 3) The newly formed stem–loop structure, pre-miRNA, is recognized 
by the XPO5, Ran-GTP complex, and is transported to the cytoplasm through the NPC. Dicer 
cleaves the loop (step 4), leaving a double-strand fragment, the miRNA:miRNA* duplex (step 5). 
The blue stand is the future mature miRNA, while the red strand is its antisense miRNA*. The 
duplex is then unwound and loaded into the miRISC complex (step 6) where it recognizes and 
anneals to its mRNA target 3′ UTR (step 7). The messenger RNA:miRISC complex mediates 
translational repression (step 8a) and mRNA decay (step 8b). From Araldi E., Schipani E., Genes 
Dev, 2010; 24:1075-1080 
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This is the key process permitting mature miRNAs to exert their effects in gene 
regulation. The final effect of miRNAs activity is the inhibition of the synthesis of the 
protein(s) encoded by the target mRNA(s). This has of course important biological 
implications depending on the role of the protein in the cellular network. Since a 
single 3’UTR of a given mRNA contains signal sequences for several microRNAs, 
applied biological studies are needed to determine which microRNA should be 
targeted to achieve alteration of gene expression. Possible effects on the expression 
of other mRNA targets should be considered. An alteration of a single microRNA may 
exhibit multiple effects, possibly in combination with the targeting activity of other 
miRNAs, enabling the achievement of strong biological effect (Hemida et al., 2010; 
Bader et al., 2010). 
 
 
 
 
1.2.5 MicroRNA and cancer 
 
 
Like transcription factors, miRNAs regulate diverse cellular pathway and are 
widely believed to regulate most biological processes. Genetic (deletion, amplification 
or translocation) or epigenetic (DNA methylation, histone modification and expression 
of non-coding microRNAs) alterations had been demonstrated to be associated with 
human pathologies. A recent study showed that about 50% of annotated human 
microRNAs are located in areas of the genome, known as “fragile sites”, that are 
associated with cancer; for this reason, miRNAs play a pivotal role in cancer 
development and progression (Calin et al., 2004). 
As well as guided alterations of miRNAs have been suggested as a novel 
approach  to  develop  innovative  therapeutic  protocols.  MicroRNA  therapeutics 
appears as a novel field in which miRNA activity is the major target of the intervention 
(Hemida et al., 2010; Sibley et al., 2010). Interestingly, microRNAs play a double role 
in cancer, behaving both as oncogenes or tumor suppressor genes (Figure 12). 
In   general,  miRs   promoting  cancer  targets  mRNA  coding  for   tumor- 
suppression proteins, while microRNAs exhibiting tumor-suppression properties 
usually target mRNAs coding oncoproteins (Table 2). MicroRNAs which have been 
demonstrated to play a crucial role in the initiation and progression of human cancer 
are defined as oncogenic miRNAs (oncomiRs). The oncomiR expression profiling of 
human  malignancies has  also  identified a  number of  diagnostic and  prognostic 
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cancer signals; table 1 show representative examples of oncomiRs (Cho et al., 2007; 
Lowery et al., 2008). Mir-15a and miR-16 are severely down-regulated in 70% of 
patients with chronic lymphocytic leukemia (CLL) and induce apoptosis by targeting 
antiapoptotic gene B cell lymphoma 2 (BCL2) mRNA (Cimmino et al., 2005), which is 
a key player in many types of human cancers including leukemias, lymphomas, and 
carcinomas (Sanchez et al., 2003). 
Emerging evidences suggests that miR let-7 family may play a critical role in 
lung cancer development. Takamizawa et al. (2004) observed that the expression 
levels of let-7 were frequently reduced in both in vitro and in vivo lung cancer studies. 
Also Johnson et al. (2005) showed that lung tumor tissues display significantly 
reduced levels of let-7 and significantly increased levels of RAS protein relative to 
normal lung tissue, suggesting let-7 regulation of RAS as a mechanism for lung 
oncogenesis. MiR-let7 is not down-regulated in lung cancer, but also in  breast, 
gastric, ovary and colon cancer, while it is overexpressed in AML disease. Colorectal 
neoplasia is also characterized by alterations in miRNAs expression. MiR-145 and 
miR-143 are frequently reduced at the adenomatous and cancer stages of colorectal 
neoplasia. However, it was also described that the levels of pre-miR-143 and pre- 
miR-145 are not altered in precancerous and neoplastic colorectal tissue, suggesting 
that post-transcriptional control is the cause for the reduced mature miRNA levels 
(Michael et al., 2003). 
The role of miR-26a in carcinogenesis appears to be a complicated one, in the 
sense that both oncogenic and tumor suppressive effects were reported in cancers 
such as glioblastoma and hepatocellular carcinoma, respectively. A reduced 
expression of miR-26a is observed in hepatocellular carcinoma (HCC) cells; in a 
recent study published by Chen et al. (2011), tumors had reduced levels of miR-26 
expression, as compared with paired non-cancerous tissues, which indicated that the 
level of miR-26 expression was also associated with hepatocellular carcinoma. The 
same miR is, instead, overexpressed in breast cancer and glioblastoma (Huse et al., 
2009). 
 
An opposite effect on tumor development is displayed by other miRNAs; miR- 
 
200 family is deeply involved in EMT process and is deregulated in breast cancer 
(Korpal et al., 2008). miR-10b is highly expressed in metastatic breast cancer cells 
and positively regulates cell migration and invasion (Ma et al., 2007). 
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Figure 12. MicroRNAs can function as tumor suppressors and oncogenes. 
(a)  In  normal  tissues,  proper  miRNA  transcription,  processing  and  binding  to  complementary 
sequences on the target mRNA results in the repression of target-gene expression through a block in 
protein translation or altered mRNA stability (not shown). The overall result is normal rates of cellular 
growth, proliferation, differentiation and cell death. (b) The reduction or deletion of a miRNA that 
functions as a tumor suppressor leads to tumor formation. A reduction in or elimination of mature 
miRNA levels can occur because of defects at any stage of miRNA biogenesis (indicated by question 
marks) and ultimately leads to the inappropriate expression of the miRNA-target oncoprotein (purple 
squares). The overall outcome might involve increased proliferation, invasiveness or angiogenesis, 
decreased levels of apoptosis, or undifferentiated or de-differentiated tissue, ultimately leading to 
tumor formation. (c) The amplification or overexpression of a miRNA that has an oncogenic role 
would also result in tumor formation. In this situation, increased amounts of a miRNA, which might be 
produced at inappropriate times or in the wrong tissues, would eliminate the expression of a miRNA- 
target tumor-suppressor gene (pink) and lead to cancer progression. Increased levels of mature 
miRNA might occur because of amplification of the miRNA gene, a constitutively active promoter, 
increased efficiency in miRNA processing or increased stability of the miRNA (indicated by question 
marks). ORF, open reading frame. 
From Kerscher E., Oncomirs-microRNAs with a role in cancer, 2006, nature reviews, 6:259-269 
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Table 1. MiRNAs exhibiting oncogene function in cancer (oncomiRs). (Gambari et al., 2011) 
 
 
 
Abbreviations: MITF, microphthalmia-associated transcription factor-M; FOXO3, forkhead box O3; p27Kip1, cyclin- 
dependent kinase inhibitor 1B; PUMA, BCL2 binding component 3; PTEN, PDCD4, phosphatase and tensin homolog; 
TPM1, tropomyosin 1; P53, tumor protein p53; TGF-B, transforming growth factor, beta 1; CCNG1, cyclin G1; Rb1, 
retinoblastoma tumor suppressor; JAK2; PDK1, 30-phosphoinositide dependent protein kinase-1; E2F1, E2F transcription 
factor 1; Bim, BCL2-like 11 (apoptosis facilitator); CDH1, cadherin 1, type 1, E-cadherin (epithelial); POX, proline oxidase; 
FOXF2, forkhead box F2; BBC3, BCL2 binding component 3; RB, retinoblastoma 1; HGS, hepatocyte growth factor- 
regulated tyrosine kinase substrate; KLF4, Kruppel-like factor 4; Sufu, suppressor of fused homolog (Drosophila); Fus-1, 
tumor suppressor candidate 2; and LATS2, large tumor suppressor, homolog 2 (Drosophila) 
 
 
 
 
In human testicular germ cell tumors two miRNAs were reported to be 
oncogenic, miR-372 and miR-373; they down-regulate p53-mediated CDK inhibition 
through direct inhibition of the Large Tumor Suppressor Homolog 2 (LATS2), and 
permitted the proliferation and tumorigenesis of primary human cells which have both 
oncogenic RAS and active wild-type p53 (Voorhoeve et al., 2006). In several types of 
lymphomas, including Burkitt’s lymphoma, the expression of miR-155 is increased 
compared to normal cells. Mir-155 is located in the conserved region of the BIC gene 
and expression of BIC/miR-155 is elevated in Hodgkin and Burkitt lymphoma (Eis et 
al., 2005). 
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Table 2 MiRNAs exhibiting tumor suppressor functions (Gambari et al., 2011) 
 
 
Abbreviations: HGF, hepatocyte growth factor (hepapoietin A; scatter factor); c-MET, met proto-oncogene (hepatocyte growth 
factor receptor); GMNN, geminin, DNA replication inhibitor; CCNE2, cyclin E2; SIRT1, sirtuin 1; Mcl-1, myeloid cell leukemia 
sequence 1 (BCL2-related); BCL2, B-cell CLL/lymphoma 2; AKR1C1, aldo–keto reductase family 1, member C1 (dihydrodiol 
dehydrogenase 1; 20-alpha (3-alpha)-hydroxysteroid dehydrogenase); AKR1C2, aldo–keto reductase family 1, member C2 
(dihydrodiol dehydrogenase 2; bile acid binding protein; 3-alpha hydroxysteroid dehydrogenase, type III); YW HAZ, tyrosine 3- 
monooxygenase/tryptophan 5-monooxygenase activation protein, zeta polypeptide; ROBO1, Robo1 receptor; EGFL7, EGF-like- 
domain, multiple 7; FSCN1, fascin homolog 1, actin-bundling protein (Strongylocentrotus purpuratus); TAGLN2, transgelin 2; 
CHN1, chimerin (chimaerin) 1; ErbB3, v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian); E2F1, E2F 
transcription factor 1; E2F5, E2F transcription factor 5, p130-binding; ZEB2, zinc finger E-box binding homeobox 2; PRKCE, 
protein kinase C, epsilon; MYCN, v-myc myelocytomatosis viral related oncogene, neuroblastoma derived (avian); EZH2, 
enhancer of zeste homolog 2; PRC2, polycomb repressive complex 2; and TrkB, neurotrophic tyrosine kinase, receptor, type 2 
 
 
 
 
Finally, also miR-17-92 cluster was found overexpressed in lung cancer 
(Hayashita et al., 2005). In conclusion, miRNAs are deeply involved in tumor onset 
and progression so that therapeutic strategies involving miRNA silencing have been 
proposed. Since miRNAs can behave as tumor suppressor genes, miRNA 
replacement therapy has been also proposed as a possible therapy of cancer (Bader 
et al., 2010). However, it remained unclear if the reduced miRNA expression was the 
cause or the consequence of malignant transformation. 
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1.2.5.1 MicroRNA in breast cancer 
 
 
Over the past few years, miRNA profiling studies have led to the identification 
of miRNAs that are aberrantly expressed in human breast cancer. The function of 
only a handful of these miRNAs in breast cancer has been investigated. As in other 
cancers, some miRNAs can function as tumor suppressors and other miRNAs as 
oncogenes. Thus, tumor formation may arise from a reduction or deletion of a tumor 
suppressor miRNA and/or amplification or overexpression of an oncogenic miRNA. In 
addition,   tumor   metastasis   may   be   promoted   by   enhanced   expression   of 
prometastatic and/or down regulation of antimetastatic miRNAs. The functions of 
these miRNAs in breast tumor progression and metastasis are discussed below. 
 
 
 
 
1.2.5.2 Tumor suppressor miRNA in breast cancer 
 
 
Among all, recent findings have focused attention especially on some miRs 
that inhibit the breast cancer formation and/or metastases. MiR-206 is up-regulated 
in estrogen receptor (ER) α-negative breast cancer; it was recently shown to inhibit 
the expression of ESR1 mRNA through two binding site in the ESR1 3’-UTR (Adams 
et al., 2007). Another study showed that miR-206 expression decreased in ERα- 
positive  human  breast  cancer  tissues  and  that  miR-206  suppresses  ESR1 
expression and inhibits growth of MCF-7 breast cancer cells (Leivonen et al., 2009). 
The tumor suppressive role for miR-206 in breast cancer was further substantiated 
by the recent demonstration that miR-206, miR-335 and miR-126 are potently down- 
regulated in metastatic breast cancer cells compared to parental cells. Importantly, 
restoring the expression of these three miRNAs reduced their invasive capacity 
(Tavazoie et al., 2008). 
MiR-125a and miR-125b are down-regulated in HER2-amplified and HER2- 
overexpressing breast cancers. These two miRNAs are potential tumor suppressors 
and their overexpression in SKBR3 cells (a HER2-dependent human breast cancer 
cell line) suppresses HER2 and HER3 mRNA and protein levels, leading to a 
reduction in anchorage-dependent growth, cell motility, and invasiveness (Scott et 
al., 2007). 
Invasion and metastasis are the hallmarks of malignant tumor progression. 
Increasing evidence indicates that activation of the embryonic program “epithelial- 
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mesenchymal transition” (EMT) promotes these processes by allowing detachment of 
cells from each other, thereby increasing tumor cell mobility and dissemination. In 
recent years, it has become evident that aberrant activation of EMT is responsible for 
the malignant transformation of many human cancers. EMT is activated by EMT- 
inducing transcriptional repressor, including ZFH family transcription factors. 
Recently, ZEB1, a ZFH-family member, was shown to be a crucial EMT activator in 
human cancers, including breast cancer (Aigner et al., 2007). The miR-200 family of 
miRNAs  has  been  shown  to  be  crucial  inducers  of  an  epithelial  phenotype by 
suppressing the expression of the EMT inducers ZEB1and ZEB2: over expression of 
miR-200 family members in mesenchymal cells initiated mesenchymal-to-epithelial 
transition and, by additional analysis, decrease in miRNA-200 family miRNAs was 
associated with highly aggressive, metaplastic breast tumors (Gregory et al., 2008), 
indicating that miR-200 family was strongly associated with the epithelial phenotype. 
MiR-34a is one of several miRNAs that are down regulated in multiple cancers and 
has been shown to be transcriptionally regulated by p53. In the context of breast 
cancer, only one study has shown that miR-34a levels were lower in triple negative 
and mesenchymal breast cancer cell lines compared with normal epithelial lines and 
HER-2+ lines (Kato et al., 2009). 
MiR-31  was  recently  shown  to  prevent  metastasis  at  multiple  steps  by 
inhibiting the expression of prometastatic genes. MiR-31 is expressed in normal 
breast cells and its abundance was shown to be dependent on the metastatic state of 
the tumor. It is moderately decreased in non-metastatic breast cancer cell lines and 
is almost undetectable in metastatic mouse and human breast cancer cell lines. 
Importantly, the authors demonstrated that introducing miR-31 in metastatic breast 
cancer cells suppressed metastasis-related functions (motility and invasion) in vitro 
and metastasis in vivo (Valastyan et al., 2009). 
 
 
 
 
1.2.5.3 Oncogenic miRNA in breast cancer 
 
 
MiR-21 was one of the first oncogenic miRs to be characterized, being up- 
regulated in numerous tumors, a finding initially made in glioblastoma (Chan et al., 
2005) and soon afterward in breast cancer (Iorio et al., 2005). Si et al. (2007) found 
that antagonizing miR-21 caused apoptosis in MCF-7 cells, which was associated 
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with lower expression of Bcl-2 protein in the anti-miR-21-transfected MCF-7 cells and 
also in tumors derived from these cells, suggesting that Bcl-2 may be an indirect 
target of miR-21. 
MiR-155 is over-expressed in a number of human malignancies, including 
breast cancer. A recent study has shown that miR-155 is up-regulated in normal 
mouse mammary gland epithelial cells (NMuMG cells) by the TGF-β/Smad4 pathway 
and mediates TGF-β-  induced EMT and cell invasion (Kong et al., 2008). They 
further demonstrated that miR-155 is associated with cancer invasiveness in human 
primary breast carcinoma by showing that miR-155 is highly expressed in invasive 
tumors but not in noninvasive cancer tissues. These results implicate miR-155 in 
EMT and invasion as observed in NMuMG cells and suggest that miR-155 may play 
a critical role in breast cancer metastasis. 
The miR-10 family consists of miR-10a and miR-10b. They are up-regulated in 
numerous tumors, including brain, colon and liver cancer (Volinia et al., 2006; Gaur 
et  al.,  2007; Varnholt et al.,  2008). MiR-10a binds  to  several  mRNAs via  their 
5’UTRs, inducing up-regulation and overexpression aids RAS-driven formation in cell 
culture (Orom et al., 2008). Unlike miR-155, miR-10b was highly expressed only in 
metastatic cancer cells; in fact, miR-10b overexpression initiates invasion and 
metastasis in a murine model of breast cancer (Ma et al., 2007); the same study 
reports  an  association  between  miR-10b  expression  and  metastasis  in  human 
tumors. 
MiRNAs of the miR-373/520c family were identified as prometastatic using a 
forward genetic screen involving overexpression of almost 450 miRNAs in a non- 
metastatic human MCF-7 breast cancer cell line (Kato et al., 2009). 
 
 
 
 
1.2.6 Antisense strategy and miR targeting 
 
 
The most widely used approach to alter processing or targeting functions of 
microRNA is the antisense strategies, which have been reported in several papers in 
which microRNAs have been targeted by anti-miR molecules. This antisense strategy 
appears to be more specific in respect to targeting of transcription factors or miRNA 
promoters, since it affects single microRNAs or microRNA families, while targeting 
transcription factors or transcription factors binding sites is expected to have deep 
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effects on the whole transcriptome, due to the fact that a single transcription factor is 
able to bind and regulate several genes. In addition, recent reports suggest that 
miRNAs can be packaged in exosome fractions, followed by release of exosome/ 
miRNAs from producing cells into body fluids. This last feature has important 
diagnostic/prognostic implications. 
Given the role of miRNAs in epigenetic regulation of gene expression, miRNAs 
have been proposed as possible candidates for drug targeting with the objective of 
interfering with biological functions, altering the expression of the mRNAs specifically 
regulated by the targeted miRNAs (Kota et al., 2010). The number of known 
microRNAs which regulate gene expression is continuously growing, with 1,527 
sequences present to date in the miRbase for humans (as available on January 30th, 
2012  at  www.mirbase.org).  An  increasing  number  of  reports  have  shown  that 
targeting of microRNA biogenesis has a deep impact on specific phenotypes and 
even on pathological conditions. It has been demonstrated that miRNAs can be 
antagonized in vivo by oligonucleotides composed of highly affine nucleotide mimics 
(Elmen et al., 2008). Up to now synthetic oligonucleotides have been used for 
targeting microRNAs, although with several problems, including delivery and stability. 
Only one of the two strands of miR (termed guiding strand) is incorporated into the 
miRISC complex, and is therefore the ideal target for oligonucleotides designed to 
inhibit miR functions. Though long mRNA containing multiple target sites could serve 
as scavenger for miR (called RNA sponge), RNA molecules are not very effective as 
anti-miR, since they would recreate a dsRNA similar to the miR precursor. 
Therefore, several modified oligonucleotide analogs have been designed in 
order to bind to the guiding strand by Watson–Crick base pairing and prevent further 
processing. In principle, all derivatives which were proved to be effective in the so 
called antisense strategy can  also  be used  to  target miR.  High  stability of the 
complex formed by the anti-miR agent and the target miRNA is therefore one of the 
major points. Stability of anti- miR under physiological condition is another important 
issue; good cellular delivery is also necessary in order to achieve miR inhibition. 
RNAs are sensitive to both chemical and enzymatic degradation, due to the presence 
of the 2’-OH group, which can be converted to an internal nucleophile and thus 
represents RNA ‘‘Achille’s heel’’; therefore, alkylation of the 2’-oxygen in RNA has 
the effect of producing more stable derivatives with good affinity for complementary 
miR. Commercially available antago-miRs mainly belong to this class, in particular 
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with methyl and methoxyethyl as alkyl groups; 2’-deoxy-2’-fluoro derivatives have 
also been used. Locked nucleic acids (LNAs) are RNA analogs in which a methylene 
bridge  has  been  introduced  between  the  2’-oxygen  and  the  C(4)-carbon,  thus 
creating a further ring which strongly constrain the furanoside in a C3’-endo-like (i.e. 
RNA-like) conformation, more effective for RNA recognition. Usually, oligomers 
containing LNA used in antisense studies have alternated LNA–DNA monomers, 
whereas those used as anti-miRs are partially made of LNA monomers inserted in a 
strand composed of 2’-O-methyl RNA units. For example, Elmen et al. (2008) had 
demonstrated that antagonism on microRNA-122 in mice, treated with LNA-anti-miR, 
leads to up-regulation of a large set of predicted target mRNA in the liver. More 
drastic change in the backbone of oligonucleotides derivatives are represented by 
peptide nucleic acid (PNAs). 
 
 
 
 
1.2.6.1 MiR targeting by PNAs 
 
 
PNAs are very promising tools for RNA recognition, since they have a higher 
affinity for RNA than for DNA (Nielsen et al., 2004), are more specific and are 
resistant  to  DNAses  and  proteases  (Demidov  et  al.,  1994).  Despite  the  PNAs 
possess many advantages for their application as an anti-miR strategy, the literature 
are reporter only few jobs. One of the reasons is the lack of cellular permeation by 
simple unmodified PNA, or segregation in lysosomes of some PNA-peptide 
conjugates, which can prevent the access to the target miRNA. As described in 
Section 1.1.4 of Part 2, some changes have been tested to bypass these limits. The 
first example of targeting microRNAs using PNA-based molecules is provided by 
miR-122. Fabani and his collaborators demonstrated, using PNAs and PNA-peptide 
conjugates, that these oligonucleotide analogs, in particular K-PNA-K3, evaluated for 
the first time in microRNA inhibition, are more effective than standard 2'-O-methyl 
oligonucleotides in binding and inhibiting microRNA action (Fabani et al., 2009). In a 
parallel work, Oh et al. (2009) described the effectiveness of miR targeting by PNA- 
peptide conjugates, using a series of cell penetrating peptides (CPP) as carriers, 
including R6 pen, Tat, a four Lys sequence, and transportan ( Oh, et al., 2009). PNAs 
were  found  to  be  more  effective  than  LNAs  and  2’-OMe  oligonucleotides. 
Furthermore PNAs were found to be more resistant to degradation than LNAs, even 
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if stored at room temperature, suggesting better performances of the former class as 
candidate drugs. More recently, a PNA targeted against miR-155 has been used in 
cellular systems and in mice (Fabani et al., 2010). In this study, the induction of miR- 
155 by bacterial lipopolysaccharide (LPS) was reduced by using a PNA matching the 
miR target and linked to four lysine residues. 
 
 
In a recent study we have evaluated the activity of a PNA targeting miR-210, 
which is associated to hypoxia, and is modulated during erythroid differentiation, in 
leukemic K562 cells (Fabbri et al., 2010). The major conclusions of our study were 
that a PNA against miR-210 conjugated with a polyarginine peptide (R-pep-PNA- 
a210): (a) is efficiently internalized within the target cells; (b) strongly inhibits miR- 
210 activity; (c) deeply alters the expression of raptor and γ-globin genes. Unlike 
commercially available antagomiRs, which need continuous administrations, a single 
administration of R-pep-PNA-a210 was sufficient to obtain the biological effects. 
 
 
Following the results obtained from inhibition of miR-210, we have synthesized 
a R8-PNA-anti-miR-221; the microRNA-221 is of great interest because it has been 
found to be associated with cancer, since it is able to target the 3’UTR of onco- 
suppressor mRNA p27kip1, as below described. 
 
 
 
 
1.3 Cell cycle deregulation in human breast cancer 
 
 
 
1.3.1 The cell cycle 
 
 
As “cell cycle” we define the process by which a cell correctly divides into two 
daughter cells and is central to the understanding of all life (Nurse, 2000). It is in fact 
largely accepted that is essential for their survival that the two daughter cells receive 
a  full  complement  of  all  the  organelles  and  a  copy  of  the  genome  correctly 
duplicated. A typical eukaryotic cell cycle is illustrated by human cells in culture, 
which divide approximately every 24 hours. The cell cycle comprises a series of 
tightly controlled events that drive the replication of DNA and cell division. It is divided 
into several phases: preparation for (G1 phase), and execution of, DNA synthesis (S 
phase),  a  second  gap  phase  (G2),  and  mitosis  (M).  Quiescence  (G0)  is  a 
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biochemically distinct state from which cells can re-enter the cell cycle and go on to 
DNA replication and mitosis. To ensure that DNA faithfully replicates and that the 
replicated chromosomes correctly segregates into the two newly divided cells, in all 
eukaryotic cells, cell cycle progression is stringently controlled (Heichman et al., 
1994; Wuarin et al., 1996). In particular several mechanisms ensure that S phase is 
completed before mitosis begins and that M phase started only if the DNA has been 
faithfully replicated. This is possible since two Gap phases (the G1 separating the M 
and S phases, and the G2 between the S and M phases) are present in somatic cells 
and dictate the timing of cell division during which the control mechanisms principally 
act. However, in embryonic cells, that need to fast replicate, the two Gap phases 
seem to be absent. In living organisms the cells are usually in a state of quiescence 
called G0 and can re-enter into the cell cycle after stimuli derived from the local 
microenvironment (for example growth factors stimulation). This process was been 
reproduced in in vitro experiments, about 35 years ago, by Arthur Pardee (1974), that 
was able to demonstrate that, in a normal cell, growth factors are necessary to 
initiate and maintain the transition from early to late G1 phase since to the so called 
“restriction point” or G1 phase checkpoint experiments. The beginning of the G1 
phase is the only part of the cell cycle that seems to be dependent on growth factors 
stimulation. When cells are stimulated by growth factors to enter the cycle from G0, 
they generally require continuous mitogen stimulation to be driven to the restriction 
point, after which mitogens can be withdrawn and cells will enter S phase and 
complete the cycle in their absence. Once the restriction point has been passed, and 
cell is irreversibly committed to complete cell division, the cell enter S phase during 
which the DNA is duplicated. At this point, in the G2 phase, before the Mitosis (M 
phase) could start, the cell control that DNA has been faithful duplicated checks the 
internal signaling events necessary for a successful division. As cells exit mitosis, the 
cell cycle is reset, allowing the establishment of a new, competent replication state in 
G0 or G1 phases. 
 
 
 
 
1.3.2 Cyclins and CDKs 
 
 
The transitions between these phases of the cell cycle are orderly regulated by 
 
Cyclin-Dependent Kinases (CDK) activity (Figure 13). CDKs are serine and threonine 
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kinases,  and  their  actions  are  dependent  on  associations  with  their  activating 
subunits, cyclins (Hunt, 1991; Sherr, 1994). Cyclin abundance is regulated by protein 
synthesis and degradation; the activity of CDKs is therefore regulated to a large 
degree by the presence of different cyclins. Cyclin specificity can be achieved in 
various ways: cyclins are expressed or are present at stable levels at different times; 
they are differentially sensitive to cell-cycle-regulated inhibitors; they are differentially 
restricted to specific subcellular locations; or they bind specifically to only some 
phosphorylation targets. Cyclins are regulated at the level of protein degradation by 
ubiquitin-mediated proteolysis. Proteins that are tagged with a chain of ubiquitin 
molecules are degraded by the 26S proteasome. The sensitivity of different cyclins to 
different ubiquitin ligases constitutes an important mechanism for cyclin specificity in 
controlling the cell-cycle engine. 
Restriction point control is mediated by two families of enzymes, the cyclin D- 
and E- dependent kinases. The D-type cyclins (D1, D2, and D3) (Matsushime et al.; 
Xiong et al.; Motokura et al., 1991) interact combinatorially with two distinct catalytic 
partners: CDK4 and CDK6 (Meyerson et al., 1994). Whereas CDK4 and CDK6 are 
relatively long-lived proteins, the D-type cyclins are unstable, and their induction, 
synthesis, and assembly with their catalytic partners all depend upon persistent 
mitogenic signaling. D-type cyclins are usually absent from cell cycles that proceed 
independently of extrinsic mitogenic signals. Conversely, constitutive activation of the 
cyclin pathway can reduce or overcome certain requirements for cell proliferation and 
thereby contribute to oncogenic transformation (Sherr et al., 1996). 
The mitogen-dependent accumulation of the cyclin D-dependent kinases 
triggers the phosphorylation of the Retinoblastoma protein (Rb), thereby helping to 
cancel its growth-repressive functions (Ewen et al., 1993). Rb represses the 
transcription of genes whose products are required for DNA synthesis by binding 
transcription factors such as the E2Fs. Apart from a battery of genes that regulate 
DNA transcription, E2Fs induce the cyclin E and A genes. Cyclin E enters into a 
complex with its catalytic partner CDK2 (Koff et al., 1991; Lew et al., 1991) and 
collaborates with the cyclin D-dependent kinases to complete Rb phosphorylation 
(Lundberg et al., 1998). This shift in Rb phosphorylation from mitogen-dependent 
cyclin D-CDK4/6 complexes to mitogen-independent cyclin E-CDK2 accounts in part 
for the loss of dependency on extracellular growth factors at the restriction point. The 
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activity of the cyclin E-CDK2 complex peaks at the G1-S transition, after which cyclin 
 
E is degraded and replaced by cyclin A. 
 
Other levels of CDKs regulation are represented by phosphorylation and 
dephosphorylation of CDKs catalytic activity. The cyclin-CDK complexes can be kept 
in an inactive state by phosphorylation on one, or sometimes two, residues in the 
ATP-binding site of the CDK. CDK proteins generally remain at constant levels 
throughout the cell cycle, while cyclins and post-translational modifiers (including 
kinases and phosphatases) undergo periodic fluctuation to regulate DNA syntheses 
and cell  division (Caldon et al., 2006). The sequential accumulation of different 
cyclins allows the formation of specific cyclin-CDK complexes that target substrates 
involved in transitions between the cell-cycle phases. During G1 phase the 
predominant  cyclin-CDK  complexes  are  cyclin  D-CDK4/6  and  cyclin  E-CDK2, 
followed by cyclin A-CDK2 during S phase, then cyclin A-CDK1 and cyclin B-CDK1 
during G2 and mitosis. Although control of the G2/M transition is implicated in events 
in cancer resulting in chromosomal aberrations, the G1/S transition encompasses 
many of the important cell-cycle events that may be specifically altered in breast 
cancer, including the actions of the oncogenes/ tumor suppressors cyclin E, cyclin 
D1, and p27kip1. 
 
 
 
 
 
1.3.2.1 Cyclin D1-CDK4/6 
 
 
Cyclin D1 is a critical modulator of the G1/S transition through Rb 
phosphorylation  and  p21/  p27  titration.  Its  levels  and  activity  are  regulated  to 
integrate extracellular signaling with the cell-cycle machinery. During G1, cyclin D1 is 
controlled by a number of mitogenic factors, acting on its transcription and translation 
as well as the stability, localization and CDK complex association of the cyclin D1 
protein. Cyclin D1 is excluded from the nucleus during S phase and the protein is 
rapidly degraded, through phosphorylation by GSK-3b (Sherr et al., 1999). 
CDK4 and CDK6 display much more restricted substrate preferences than the 
other CDKs; their principal known substrates are the product of the retinoblastoma 
gene, pRb, and other members of the pocket protein family, which, in their non- 
phosphorylated forms, inhibit the E2F-mediated transcription of genes essential for 
DNA synthesis. The importance of pRb as a CDK4/6 substrate is illustrated by the 
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observation that cyclin D1 is not required for G1 phase progression in cells lacking 
pRb. In breast cancer, a non-functional Rb pathway, characterized by loss of Rb or 
lack of concordance between Rb phosphorylation and cell proliferation, is associated 
with tamoxifen- resistance (Lehn et al., 2011). Furthermore, cyclin D1 expression is 
required for tamoxifen-induced cell cycle progression, suggesting a role for CDK4/6 
activity. 
 
 
1.3.2.2 Cyclin E-CDK2 
 
 
The two E-type cyclins, cyclins E1 and E2 (collectively referred to as cyclin E), 
are closely related and often co-expressed. During G1 phase, CDK2 is activated 
through binding cyclin E, and then, via phosphorylation of target proteins, facilitates 
the first steps of S phase. One critical target for cyclin E-CDK2 is pRb, but in addition 
to promoting S phase entry through pRb phosphorylation, cyclin E-CDK2 also 
phosphorylates a number of proteins with a more direct role in DNA replication, 
including NPAT, which facilitates histone synthesis, and components of the pre- 
replication complex (Hwang et al., 2005). The activity of cyclin E-CDK2 is finely 
regulated through protein-protein interactions, phosphorylation events and 
degradation, but a primary level of control is through the periodic expression of cyclin 
E. Cyclin E1 is a well-known E2F target gene and cyclin E2 is also likely to be E2F- 
regulated. During G1 phase, pRb phosphorylation by cyclin D1- CDK4/6 allows the 
release of E2F, which in turn drives cyclin E expression to reach a maximum near the 
G1/S phase boundary (Sherr et al., 2005; Hwang et al., 2005). As the cyclin E-CDK2 
complex is activated, it phosphorylates pRb, providing a positive feedback loop for 
cyclin E transcription. 
A secondary level of control of cyclin E-CDK2 is through the CDK inhibitors 
p21 and p27. These proteins bind to cyclin E-CDK2, profoundly inhibiting kinase 
activity and hence stabilizing cyclin E. The availability of p21 and p27 to inhibit cyclin 
E-CDK2 can be modulated not only through alterations in their overall abundance but 
also through their sequestration by cyclin D1-CDK4/6 and by cytoplasmic 
relocalisation (Sherr et al., 1999; Coqueret et al., 2002). The cyclin E-CDK2 complex 
also  positively  regulates its  own  activity  by  phosphorylating p27,  which  is  then 
targeted for degradation. 
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Figure 13. Schematic representation of cell cycle regulation. Mitogenic stimuli promote cell cycle 
progression from G0 to G1 inducing the expression of D type cyclins and lowering the expression of 
p27. Sequential activation of cyclin E-CDK2, cyclin ACDK2, cyclin A-CDK1 and cyclin B-CDK1 allow 
the cells to pass through the restriction point (R) and to complete the mitotic division. The passage 
through the R point is due to the inactivation of the pRb protein by CDKs-dependent phosphorylation 
 
 
 
 
1.3.3 Cyclin Kinase Inhibitors 
 
 
The CKIs, also called CDK inhibitors, can be divided into 2 families on the 
basis of sequence: the INK4 (CDK4 inhibitor) family and the Kip/Cip (kinase inhibitor 
protein) family (Hunter et al., 1994; Sherr et al., 1995; Harper et al., 1996). 
The INK4 proteins are almost entirely composed of ankyrin repeats (Serrano 
et al., 1993), a putative protein-protein interaction motif. This family comprises four 
members: p15INK4b, p16INK4a, p18INK4c and p19INK4d. In humans, INK4a and INK4b are 
closely linked on the short arm of chromosome 9, whereas INK4c maps to 
chromosome 1 and INK4d maps to chromosome 19. These inhibitors are specific for 
the CDK4 and CDK6 kinases (Hirai et al., 1995) that bind the D-type cyclins 
(Matsushime et al., 1992). These kinase complexes have been most closely linked to 
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the control of G1 phase, especially with regard to the decision to proliferate or not 
according to the presence of growth factors, and to cell size control. The INK4 
proteins are also able to inhibit CDK4/6 in a complex with cyclin D, and it will be 
interesting to see whether this bears any relation to the inhibitory mechanisms 
employed by the Kip/Cip family. 
The  Kip/Cip  family  comprises  three  proteins;  p21Cip1/W af1/Sdi1,  p27Kip1   and 
 
p57Kip2.  These  inhibitors  show  tissue  specific  distribution  patterns;  for  example, 
p27kip1  and  p57Kip2  has  been  detected in  some  specialized tissue, as  neurons, 
skeletal muscle and lung during their development, while these inhibitors are not 
expressed in proliferating cell. Their expression regulation is also differently regulated 
following specific stimuli. Indeed p57Kip2  is imprinted (Matsuoka et al., 1996), and 
 
have been implicated in cell differentiation (Elledge et al., 1996), and in the response 
to stress. p21 transcription is up-regulated in response to DNA damage by wild type 
but not mutant p53, and p27kip1  was initially identified as the factor responsible for 
inhibiting  proliferation in  contact-inhibited  and   TGFβ-treated  cells.  Until  now  the 
Kip/Cip family had been thought specific for the cyclin-CDK complexes (for the G1 
and S phase kinases). However, there is a report showing that p21, a DNA-damage- 
inducible cell-cycle inhibitor, acts also as an inhibitor of the SAPK (kinases stress- 
activated protein), group of mammalian MAP, such as JNK, suggested that p21 may 
participate in regulating signaling cascades that are activated by cellular stresses 
such as DNA damage. The first one requires that p21 bind both the CDK and the 
cyclin. In the second type of interaction, p21 bind only the cyclin or the CDK. 
 
 
 
 
1.3.4 Cyclin Kinase Inhibitor p27kip1 
 
 
Protein p27kip1 was first identified as a CDK2-inhibitory activity detected in 
contact inhibited or TGF-beta treated cells (Koff et al., 1993; Polyak et al., 1994). In 
fact p27kip1 has a crucial role in the G1-S transition, by interacting with and inhibiting 
cyclin E-CDK2 and cyclin A-CDK2 activity, thus blocking cell cycle progression.  In 
early G1 p27kip1  promotes cyclin D-CDK4/6 complex assembly and nuclear import, 
increasing cyclin D stability, all without inhibiting CDK4 kinase activity. In proliferating 
cells, p27
kip1  
is primarily associated with cyclin D-CDK4/6 complexes, but these 
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complexes are catalytically active, whereas in G1 arrested cells p27kip1 preferentially 
binds and inhibits Cyclin E-CDK2. 
 
 
 
 
 
Figure 14. p27
kip1 
pathway during eukaryotic cell cycle 
 
 
 
 
 
The sequestration of p27kip1  by cyclin D-CDK4/6 complexes effectively frees 
CDK2 from inhibition and allows both CDK4/6 and CDK2 to remain active. In this way 
mitogen induction of cyclin D expression determines cell cycle progression both by 
activating CDK4 and by sequestering p27kip1 thus favoring cyclin E-CDK2 activation. 
Activation of cyclin E by E2F, after hyper-phosphorylation of pRb, enables the 
formation of the active cyclin E-CDK2 complex. This is accelerated by the continued 
sequestration of Cip/Kip proteins into complexes with assembling cyclin D-CDK 
complexes. Cyclin E-CDK2 completes the phosphorylation of Rb, further enabling 
activation of E2F responsive genes, including cyclin A. Once cyclin E-CDK2 is 
activated, p27kip1 is rapidly degraded, contributing to the irreversibility of passage 
through the restriction point. If cells are persistently stimulated with mitogens, cyclin 
D-dependent kinase activity remains high in the subsequent cell cycles, p27kip1 levels 
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stay low, and virtually all of the p27kip1 can be found in complexes with the cyclin D- 
CDK4/6. When mitogens are withdrawn, cyclin D is rapidly degraded, and the pool of 
previously sequestered Cip/Kip proteins are mobilized to inhibit cyclin E-CDK2, 
thereby arresting progression usually within a single cycle. Multiple extracellular 
stimuli regulate p27kip1 abundance, which functions as a sensor of external signals to 
cell cycle regulation. In normal cells p27kip1 is expressed at high levels in quiescence 
phase, whereas it decreases rapidly after mitogen triggering and cell cycle re-entry. 
 
 
 
 
1.3.4.1 Regulation of p27kip1 
 
 
In normal cells, the amount of p27kip1 protein is high during G0 phase but 
decrease rapidly on re-entry of cells into G1 phase (Nourse et al., 1994). This rapid 
removal of p27kip1 at the G0/G1 transition is required for effective progression of the 
cell cycle to S phase. The abundance of p27kip1 is thought to be controlled by multiple 
mechanisms that operate at the level of its synthesis (transcription, translation), 
degradation and localization (Millard et al., 2000; Connor et al., 2003). In particular, a 
change in the subcellular localization of p27kip1 induced by the exposure of quiescent 
 
cells to growth stimuli is crucial for the down-regulation of this protein at the G0/G1 
transition. In G0 phase, p27kip1  accumulates in the nucleus, where it inhibits the 
cyclin-CDK complexes. However, p27kip1 undergoes rapid translocation from the 
nucleus into the cytoplasm by yet unspecified mechanism that seems to involve 
phosphorylation; the translocation of p27kip1  from the nucleus to the cytoplasm is 
follow by its degradation by ubiquitin-proteasome pathway (Kamura et al., 2004). 
Beside modulation of its  expression levels, subcellular localization also  plays  a 
pivotal role in governing p27kip1 function; it is widely accepted that to act as cell cycle 
inhibitor   p27kip1    must   be   located   in   the   nucleus,   whereas   its   cytoplasmic 
sequestration allows cell cycle progression (Belletti et al., 2005). In fact, to inhibit 
Cyclin  E-CDK2,  p27kip1   needs  to  be  imported  into  the  nucleus.  Nuclear  import 
depends on the presence of a nuclear localization signal (NLS) localized at the C- 
terminus of the protein (Zeng et al., 2000). 
As cells progress along the cell cycle, p27kip1  shuttles between nucleus and 
 
cytoplasm. The cytoplasmic redistribution of p27kip1 induced by mitogenic stimulation 
is dependent on the phosphorylation of a specific serine residue (S10) (Rodier et al., 
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2001),  that  promotes  its  nuclear  export  to  the  cytoplasm and  overcomes  p27- 
induced growth arrest. Other phosphorylation sites of p27kip1, such as Thr 157 and 
Thr 198 in the human protein, have been implicated in the cytoplasmic translocation 
and localization of p27kip1; this residue is located in the nuclear localization signal 
(NLS) of p27kip1, and its phosphorylation prevents the nuclear localization of p27kip1. 
Also the Thr 198 is phosphorylated, but it’s largely restricted to the cytoplasm in cell 
exposed to growth stimuli, and the nuclear export of p27kip1 during G1 phase is 
delayed by mutation of this residue to Ala (Kossatz et al., 2006). Phosphorylation of 
p27kip1 on Thr 198 thus appears to be required for the timely exit of p27kip1 from the 
nucleus after mitogenic stimulation and seems to be determinant of p27kip1 stability, 
preventing ubiquitylation and proteasomal turnover.   As described for p27kip1 
cytoplasmic localization, also p27kip1 sequestration into higher order complexes with 
cyclin D-CDK4 is important for regulating p27kip1 functions. Various growth signaling 
pathways stimulate the assembly of these heterotrimeric complexes, containing p27 
with cyclin Ds and CDK4/6. Indeed, the MEK/ERK pathway which induces cyclin D 
transcription, favors the assembly of the cycling D-CDK4 , and sequesters p27kip1 in 
inactive cytoplasmic complexes (Cheng et al., 1998). Also the proto-oncogene c-Myc, 
by increasing the expression levels of cyclin D and cyclin E, is responsible for p27kip1 
sequestration (Bouchard et al., 1999), and this molecular event appears essential for 
Myc-induced cell cycle progression. More importantly, p27kip1 sequestration seems to 
be one of the relevant mechanisms to human cancerogenesis; in fact, many of the 
molecules important for the proliferation, differentiation, survival and migration, 
commonly classified as oncogenes, including Bcr-Abl, Ras, PI3K and STAT, have the 
ability to modulate and/or down-regulate p27kip1, so that its expression may be a 
powerful prognostic marker since it may represent the readout of multiple different 
signals transduction pathways known to be involved in the onset and/or the 
development of human tumors. 
 
 
 
 
1.3.4.2 p27kip1 deregulation in breast cancer 
 
 
As previously described, p27kip1  is a key regulator of G1-to-S phase 
progression of cell cycle; it acts as cell cycle inhibitor and prevents premature 
activation of cyclin E-CDK2 in G1 and promotes the assembly and activation of D- 
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type cyclin-CDKs. While the p27kip1 gene is rarely mutated in human breast cancers, 
the action of p27kip1 is impaired in breast and other human cancers through 
accelerated p27kip1 proteolysis, sequestration by cyclin D-CDKs, and by p27kip1 
mislocalization in tumor cell cytoplasm. P27kip1 mRNA levels are constant throughout 
the cell cycle (Hengst et al., 1996). P27kip1 level and activity increase in response to 
many  stimuli, as differentiation signals (Chen et al., 1996), loss of adhesion to 
extracellular matrix (Watanabe et al., 1996) and signaling by growth-inhibitory factors 
(Koff et al., 1993). On exit from quiescence, p27kip1 protein level fall rapidly thanks to 
a dramatic decrease in p27kip1  translation and activation of ubiquitin-mediated p27kip1 
proteolysis. p27kip1 proteolysis is excessively activated in many human cancer, in 
particular in breast cancer. This is mediated by oncogenic activation of multiple 
receptor tyrosine kinase and signal transduction pathways.   Ras may play an 
important role in modulation of p27kip1 loss. Transfection of dominant negative Ras 
allele increased p27kip1 accumulation, and caused G1 arrest, suggesting that Ras is 
required for p27kip1 degradation at G1 to S phase entrance (Takuwa N et al., 1997). 
On the contrary, overexpression of mitogen-activated protein kinase (MAPK) 
in fibroblasts increased p27kip1  degradation; in fact, p27kip1  contains several MAPK 
consensus sites, and MAPK can phosphorylate p27kip1, leading to a reduction of its 
ability to bind CDK2. (Kawada et al., 1997). The regulation of p27kip1  degradation 
appears to be linked to phosphorylation of p27kip1 by cyclin E/CDK2 (Montagnoli et 
al., 1999) and its export from the nucleus (Tomoda et al., 1999). Reduced levels of 
p27kip1 protein, caused by an accelerated proteolysis, have been observed in up to 
60% of human carcinomas, including lung, prostate, breast, colon, and ovarian 
carcinoma and in melanoma, glioma, and certain lymphomas; moreover, p27kip1 loss 
is usually associated with high grade tumor. p27kip1  also plays an important role in 
cellular differentiation and development. Moeller et al., (2003) have demonstrated 
that p27kip1 knockout mice manifest altered differentiation and multiorgan hyperplasia, 
suggesting a key role for p27kip1 in terminal differentiation and a strong relation 
between reduce p27kip1 levels and tumor grade in many human cancers (Moeller et 
al., 2003). Malignant cells often show anchorage-independence, property key in 
invasive and metastatic. It has long demonstrated that the abrogation of p27kip1 
expression by antisense constructs in mammary carcinoma cells not only increased 
the proliferative fraction of tumor spheroids, rendering them more susceptible to 
cytotoxic drugs, but also reduced intercellular adhesion. Thus, loss of p27kip1  in 
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human cancers may promote tumorigenesis by abrogating the cell cycle arrest 
induced by loss of cell–cell contact or loss of contact with the tissue substratum, 
facilitating the acquisition of tumor cell motility and metastasis (Croix et al., 1996). 
Loss of p27kip1  is also an indicator of poor patient outcome in a majority of breast 
cancer studies. 
Some  research  groups  have  reported  p27kip1   studies  in  primary  breast 
 
cancers, identified p27kip1  as an independent prognostic indicator (Alkarain et al., 
 
2004). Although p27kip1 is localized exclusively into the nucleus of normal breast 
epithelial cells, tumors that retain abundant p27kip1 often show protein mislocalization 
in the cytoplasm away from nuclear cyclin-CDK targets. Cytoplasmic localization 
would prevent p27kip1  from binding and inhibiting nuclear cyclin-CDK targets. This 
mislocalization of p27kip1 has been seen in up to 40% of primary human breast 
cancers. For each level of nuclear p27kip1  staining (high or low), when p27kip1  was 
present in cytoplasm rather than in the nucleus alone, patient survival was worse. 
These  observations  raise  the  possibility  that  consideration  of  the  presence  or 
absence of cytoplasmic p27kip1  may add to the prognostic significance of p27kip1 
levels in human breast cancers. 
In addition to the well-known mechanisms of degradation, phosphorylation and 
cellular localization of p27kip1, in recent years has been investigating the possible role 
of miRNAs in the deregulation that occurs in cancer development. In was found that 
several miRNAs are directly involved in human cancers, including lung, brain, liver 
and breast. 
 
 
 
 
1.3.5 Regulation of cell cycle factors by microRNAs in human cancer 
 
 
Cell cycle regulators frequently act as oncogenes or tumor suppressors. One 
of the major cell cycle pathways, regulated by retinoblastoma (pRb) protein, is altered 
in almost every human cancer (Malumbres et al., 2001). pRb itself is abnormally 
down-regulated by the overexpression of the miR-106a in different human cancers 
(Volinia et al., 2006). 
Also P130/RBL2, another member of pRb family, is controlled by miR-290 
cluster and by miR-17-92 cluster. The cyclins and CDKs are also targeted by 
microRNA. In particular, CDK6 mRNA is down-regulated by miR-34a, miR-124 and 
- 93 -  
miR-127 (He et al., 2007). Some other oncogenic miRNAs may exert their function 
through the inhibition of cell cycle inhibitors such as members of the INK4 or Cip/Kip 
families. For example, p16INK4a is controlled by miR-24, a miRNA that is down- 
regulated during replicative senescence. 
p21Cip1 is a direct target of miR-106b, which is overexpressed in multiple tumor 
 
types and plays a critical role in cell proliferation by regulating the G1-to-S cell cycle 
transition (Ivanovska et al., 2008). 
The p27
Kip1 
protein, with a relevant role as tumor suppressor in human cancer, 
 
is mostly controlled at the post-transcriptional level. When some alterations occur, 
they predispose cells to tumorigenesis upon exposure to carcinogenesis. MiR-221 
and miR-222 can function as oncogenes in human tumors by binding to target sites 
in the 3’UTR of p27Kip1  (Figure 16) inhibiting its translation (Le Sage et al., 2007) 
mRNA transcript is directly target by miR-221 in glioblastoma (Gillies et al., 2007) 
and prostate cancer cells (Galardi et al., 2007). The physiological up-regulation of 
miR-221 and miR-222 coordinates competency for initiation of S phase with growth 
factor signaling pathways that stimulate cell proliferation. Therefore, disruption of 
miRNAs expression that target cell cycle proteins, could ultimately lead to the 
progression of the malignant phenotype in human tumors (Figure 15). 
Despite the fact that in this PhD Thesis we focused our attention on breast 
cancer cellular model systems, we like to underline that p27Kip1/miR-221 are deeply 
involved in other tumors for which PNA-based treatments are expected to be very 
appealing, as just described, glioblastoma and prostate cancer. 
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Figure 15. PNAs interference against miR-221 strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Structure of pre-miR-221 (A), schematic representation of 
RISC complex with miR-221 and 3’UTR of p27
kip1  
(B) and putative 
miR-221 sites of interaction with 3’UTR of human p27
kip1 
mRNA (C) 
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1.4 Human breast cancer MDA-MB-231 and MCF-7 as experimental model to 
 
study the miR-221 modulation after treatment with PNAs 
 
 
The  human  breast  cancer  cell  lines  (MCF-7  and  MDA-MB-231)  were 
purchased from ATCC and grown in Dulbecco's Modified Eagle Medium (D-MEM, 
Gibco), containing 10% fetal bovine serum (FBS, Celbio, Milano, Italy) and 2 mM L- 
Glutamine (Sigma-Aldrich) and maintained at 37°C in humidified atmosphere of 5% 
CO2/air. 
MDA-MB-231 (Figure 17a) was obtained from a patient in 1973 (Cailleau et 
 
al., 1974) at M. D. Anderson Cancer Center. With epithelial-like morphology, the 
MDA-MB-231 breast cancer cells appear phenotypically as spindle shaped cells. In 
vitro, the MDA-MB-231 cell line has an invasive phenotype. It has abundant activity in 
both the Boyden chamber chemoinvasion and chemotaxis assay. The MDA-MB-231 
cell line is also able to grow on agarose, an indicator of transformation and 
tumorigenicity, and displays a relatively high colony forming efficiency. 
 
 
 
 
 
 
Figure 17. Pictures of (A) human breast cancer cell lines MDA-MB-231 (Phenotype: Basal 
Breast Carcinoma; triple negative: HER2-, Estrogen Receptor-, Progesterone Receptor -) 
and (B) MCF-7 (Phenotype: Luminal Breast Carcinoma; Estrogen Receptor +,  HER2-), 
taken with optical microscope 
 
 
 
 
MCF-7 (Figure 17b) is a human breast cancer cell line that was first isolated in 
 
1970 (Soule et al., 1973) from the malignant adenocarcinoma breast tissue of a 69- 
year old woman. MCF-7 is the acronym of Michigan Cancer Foundation- 7, referring 
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to the institute in Detroit where the cell line was established. MCF-7 cells are useful 
for in vitro breast cancer studies because the cell line has retained several ideal 
characteristics particular to the mammary epithelium. These include the ability for 
MCF-7 cells to process estrogen via estrogen receptors. MCF-7 cells are also 
sensitive to cytokeratin. When grown in vitro, the cell line is capable of forming 
domes and the epithelial like cells grow in monolayers. Growth can also be inhibited 
using tumor necrosis factor alpha (TNF alpha). 
These two cell lines are widely used as an experimental model for the study of 
breast cancer. Estrogen is involved in several physiological and pathological effects 
through estrogen receptor (ER)-mediated transcriptional gene regulation. Several 
lines  of evidence  have   suggested that  estrogen  receptor α  (ERα)-negative  breast 
tumor is highly aggressive and unresponsive to hormonal therapy. MDA-MB-231 are 
ERα-negative human breast cancer cell lines, that shows high level of miR-221/miR- 
222; the over-expression of miR-221/222, in fact, suppress the expression on ERα at 
the post-transcriptional level, conferring estrogen-independent growth; moreover, it 
also suppresses the expression of different tumor suppressor, such as CDKN1B 
(p27kip1), PTEN, TIMP3, FOXO3, promoting high proliferation (Di Leva et al., 2010). 
In a recent work, le Sage et al., (2007) have examined several breast and 
glioblastoma cancer cell lines for miR-221&222 expression. To explore the effect of 
miR-221&222 antagomiRs on cellular proliferation they have selected two cell lines 
that showed endogenous expression of miR-221&222 (U87 and MDA-MB-231), and 
two negative cell lines (MCF-7 and HeLa). Interestingly, treatment of U87 and MDA- 
MB-231 with both antagomiR-221&222 resulted in a clear proliferation arrest 
phenotype, which was accompanied by a significant reduction in detectable miRNA 
levels. However, no significant effect on proliferation was observed in treated MCF-7 
and   HeLa   cell   lines.  Interestingly,  when   p27Kip1    levels   were   examined   by 
 
immunostaining, only the cells containing miR-221&222 (U87 and MDA-MB-231) 
showed increased levels of the cell cycle inhibitor p27Kip1 after administration of the 
antagomiRs. These results demonstrate the high expression of miR-221 is directly 
related to the uncontrolled proliferation and indirectly related to the down-regulation 
of tumor-suppressor p27kip1, suggesting the importance of their genetic interaction in 
the development and tumor progression (le Sage, 2007). More recently, Lee et al., 
(2011) have identified one such estrogen down-regulated microRNA, miR-34b, as an 
onco-suppressor that targets cyclin D1 and JAG-1 in a ER-positive/wild-type p53 
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breast cancer cell line (MCF-7) as well as in ovarian and endometrial cells, but not in 
ER-negative or mutant p53 breast cancer cell lines (T47D, MBA-MB-361 and MDA- 
MB-435). 
 
 
In according with our purpose, namely to determine the biological activity of 
PNAs against miR-221 and the consequent effect on p27kip1, we decided to use 
these two cell lines, in particular the MDA-MB-231, in which miR-221 is up-regulated 
and p27kip1 down-regulated. 
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- MATERIALS AND METHODS - 
 
 
 
 
 
2.1 Human breast cancer cell lines 
 
 
The  human  breast  cancer  cell  lines  (MCF-7  and  MDA-MB-231)  were 
purchased from ATCC and grown in Dulbecco's Modified Eagle Medium (D-MEM, 
Life Technologies Italia, Monza, MB),  containing 10% fetal  bovine serum (FBS, 
Celbio, Milano, Italy) and 2 mM L-Glutamine (Sigma-Aldrich) and maintained at 37°C 
in humidified atmosphere of 5% CO2/air. 
 
 
 
 
2.2 Anti-miR-221 Peptide Nucleic Acids 
 
 
The peptide nucleic acids (PNAs)  used in our experiments were synthesized 
by Prof. Roberto Corradini and his collaborators  (University of Parma, Dept. of 
Organic and Industrial Chemistry) with standard manual Boc-based chemistry using 
commercially available monomers (ASM, Hannover, Germany) with HBTU/DIPEA 
coupling as described elsewhere (Manicardi et al., 2010). All the PNAs (Table 3) 
were  synthesized  using  MBHA  resin  loaded  with  Boc-PNA-G(Z)-OH  as  first 
monomer. The R8 tail of Rpep-PNA-a221 was introduced after the 2-(2- (Fmoc 
amino) ethoxy) acetic acid; AEEA, spacer (Applied Biosystems, Foster City, CA, 
USA) was introduced using the same coupling procedures. 5(6)-carboxyfluorescein 
(Sigma-Aldrich)  was  introduced  using  DIC/DhBtOH  coupling.    The  synthesis  of 
peptide Fl-Rpep was performed using standard manual Fmoc based chemistry with 
HBTU/DIPEA coupling on a Rink amide resin loaded with Fmoc-Arg(Pmc)-OH as first 
monomer. 
 
 
 
 
Table 3. Properties of PNA-a221 and Rpep-PNA-a221 
 
Name Sequence Molecular Weight 
PNA-a221 H-AAACCCAGCAGACAATGT-NH2 4881 Da 
Fl-PNA-a221 Fl-AEEA- AAACCCAGCAGACAATGT-NH2 5368 Da 
Rpep-PNA-a221 H-RRRRRRRR- AAACCCAGCAGACAATGT-NH2 6129 Da 
Fl-Rpep-PNA-a221 Fl-AEEA-RRRRRRRR- AAACCCAGCAGACAATGT-NH2 6635 Da 
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2.3 PNAs antiproliferative activity on MDA-MB-231 and MCF-7 cell lines 
 
 
Cells (2x104 cells/ml) were seeded in 24-well plate. After 24 hours, media was 
changed and replaced with experimental media containing different concentration of 
PNAs-a221. Untreated cells were taken as growth control. Cells were growth for 72 
hours in a humidified incubator in 5% CO2 at 37°C. After this incubation, medium was 
removed, cell wash with PBS (Phosphate Buffered Saline), trypsinized for 5 minute at 
37°C and counted by a ZF Coulter Counter. The IC50 value is means ± SD from three 
independent experiments. 
 
 
 
 
2.4 Cellular Uptake of PNAs 
 
 
The first step necessary for obtaining anti-miR221 activity in cells is the 
effective cellular uptake of PNAs. For this reason, we have performed a series of 
experiments using both MDA-MB-231 and MCF-7 cell lines. 
 
 
 
 
2.4.1 Fluorescence activated cell sorting 
 
 
Since different PNA structures could be affected by proteases present in 
serum, leading to different cellular uptake, the first experiments have been conducted 
in the presence or in the absence of serum. Presence of DNAse and proteinase 
activity in serum has been reported and this can lead to partial degradation of the 
carrier polyarginine peptide, whereas the PNA unnatural backbone was reported to 
be very stable to degradation in human serum (Demidov et al., 1994). 
MDA-MB-231 and MCF-7 cells were seeded, respectively, at 1,5 x 105 and 2 x 
 
105 cell/ml in 6-well plate. When cells were adherent, we treated them with different 
concentration of fluorescein-labeled PNAs. After 24 hours of incubation, cells were 
washed once with PBS, trypsinized and analyzed by fluorescence-activated cell 
sorting analysis (FACS). 
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2.4.2 BioStation IM technology 
 
 
The Nikon BioStation IM (Figure 18) is a cell incubator (providing consistent 
environmental  control   of   temperature,  humidity   and   gas   concentration)  and 
monitoring system that allows to conduct live cell imaging. The BioStation IM 
incorporates a motorized inverted microscope, an incubation chamber, and a high- 
sensitivity cooled CCD camera into a single package. Being an all-in-one, complete 
solution   from  one   vendor,   IM   overcomes  stability   and   compatibility  issues 
experienced in multi-vendor systems. 
 
 
 
 
 
 
Figure  18.  Biostation  IM  technology  (A)  and  total  integrated  system  (B);  The  BioStation  IM 
incorporates a motorized inverted microscope, an incubation chamber, and a high-sensitivity cooled 
CCD camera into a single package 
 
 
 
 
Cells are easily maintained at the appropriate temperature, humidity and CO2 
(or O2) levels with BioStation IM. 5% CO2 (or O2), either from a premixed tank or the 
optional CO2 (or O2) mixer is humidified by bubbling through a bottle of water located 
at the front of the instrument. Sensors located throughout the instruments keep the 
temperature of the sample at 37°C. 
Cells were seeded at 2x105 cell/ml, 300 µl in each well in a μ–Dish Hi–Q4 and 
 
monitored for 24 hours. The images were taken every 30 minutes of incubation. 
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2.5 RNA isolation 
 
 
MDA-MB-231 and MCF-7 cells were seeded at initial concentration of 3x104 or 
 
2x104  cell/ml in a 12-well plate; when cells were adherents, treated for 48 and 96 
hours with PNAs. After the incubation, cells were washed with PBS 1x and 
trypsinized. The total cellular RNA was isolated   by TRIZOL® Reagent (Sigma- 
Aldrich, St.Louis, Missouri, USA), as well described in Chapter “Materials and 
Methods” of Part 1 of this PhD Thesis, quantified by measuring the absorbance at 
260 nm (A260) in a spectrophotometer, and quality controlled by electrophoresis on 
 
1% agarose gel. 
 
 
 
 
 
2.6 Reverse transcription reaction (RT-PCR) 
 
 
2.6.1 RT with Random Primer 
 
 
Reverse transcription of 1 µg of total RNA was performed using with the 
TaqMan® Reverse Transcription Reagents PCR kit (Applied Biosystems). RNA was 
incubated with 2,5 µM Random Hexamers at 25°C for 10 minutes and then 
immediately cooled to 4°C. After that, the RT reaction solution, prepared considering 
a final volume of 50 µl, progressively adding the following reagents: 1X TaqMan RT 
Buffer (10X), 5,5 mM MgCl2 (25 mM), deoxyNTPs Mixture, 0,4 U/µl RNase Inhibitor 
and 1,25 U/µl MultiScribeTM Reverse Transcriptase (50 U/µl) was added. To perform 
 
the reverse transcription reaction, the samples were incubated for 30 minutes at 
 
48°C, to allow the extension, and at 95°C for 5 minute to inactivate the enzyme. After 
thermal cycling, cDNA were stored at -80°C. 
 
 
 
 
2.6.2 RT for microRNA 
 
 
Reverse transcription of 1µg of total RNA was performed using with the 
TaqMan® MicroRNA Assay (Applied Biosystems).  For each RNA samples, miR-221 
and U6 RT Primers were added. The RT Master Mix reaction solution was prepared 
adding the following reagents: Reverse Transcription Buffer (10X), 1mM dNTPs 
(100mM), 0,25 U/µl RNase Inhibitor (20 U/µl), 3,33 U/ µl MultiScribeTM Reverse 
Transcriptase (50 U/µl). To perform the reverse transcription reaction, the samples 
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were incubated for 30 minutes at 16°C, 30 minutes at 42°C to allow the extension, 
and at 85°C for 5 minute to inactivate the enzyme. After thermal cycling, cDNA were 
stored at -80°C. 
 
 
 
 
2.7 Real-Time PCR 
 
 
The quantitative real-time polymerase chain reaction (qPCR) assays of 
transcripts were carried out using gene-specific double fluorescently labeled probes 
(Applied Biosystems, Warrington Cheshire, UK) in a 7700 Sequence Detection 
System, version 1.6.3. The primer and probe used to assay p27kip1 (Assay ID Details 
Hs00153277_m1) were purchased from Applied Biosystems (Applied Biosystems, 
Foster City, CA, USA). Relative expression was calculated using the comparative 
cycle threshold method and as reference genes the endogenous control human 18S 
rRNA. To perform the qPCR, the samples were firstly incubated for 2 min at 50°C 
 
and for 10 min at 95°C. The amplification consists by 40 cycles of 15 seconds at 
 
95°C and 1 min at 60°C. 
 
For has-miR-221 (Assay ID: 000524), hsa-let-7c (Assay ID: 000379) and has- 
miR-200c (Assay ID: 002300) quantification using real-time qPCR reagents, the 
primers and probes were obtained from Applied Biosystems, and reactions were 
performed in duplicate according to manufacturer’s protocols in a 7700 Sequence 
Detection System version 1.7 (Applied Biosystems, Foster City, CA, USA). Relative 
expression was calculated the comparative cycle threshold method and as reference 
genes the endogenous control human U6 RNA. To perform the qPCR reactions the 
samples were firstly incubated at 95°C for 10 minutes; the amplification was 
performed for 40 cycles of 15 seconds at 95°C and 1 min at 60°C. 
 
 
 
 
2.8 Nuclear and cytoplasmic proteins extraction 
 
 
MDA-231 cells were plated in T-75 flask cell-cultured and treated with PNA- 
a221 and Rpep-PNA-a221 2 µM for 96 and 120 hours. After incubation, cells were 
washed with PBS 1x and collected by centrifugation at 2,000 rpm for 5 minutes. To 
obtain nuclear and cytoplasmic extracts we used the Margilene Nuclear Extraction Kit 
(G-Biosciences, St Louis, MO, USA). To each cellular pellet, resuspended in 1ml 
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PBS  1X,  were  add  500  µl  of  Complete  Hypotonic  Lysis  Buffer.  Samples  were 
incubated 10 minutes on ice. After incubation, 50 µl of Detergent Solution was added, 
samples vortexed and centrifuged 5 minutes at 3,000 rpm at 4°C. The supernatant 
was removed from nuclear pellet. This supernatant contains the cytoplasmic extracts 
that were stored at -80°C until quantification. We add to nuclear pellet, 500 µl of 
Complete Wash Solution, and centrifuge samples for 5 minutes at 3,000 rpm at 4°C. 
After  removing  supernatant,  Extraction  Buffer  1  (one-half  pellet  volume)  and 
Extraction  Buffer  2  (one-half  pellet  volume)  were  added  to  the  samples,  then 
vortexed  and  incubated  on  ice  for  30  minutes.  Each  sample  was  vortexed 
momentarily at high speed every 10 minutes. Finally, nuclear pellets were centrifuged 
30 minutes at 12,000 rpm at 4°C. The supernatants, containing nuclear extracts, 
were collected and stored at -80°C until quantification. 
 
 
 
 
2.8.1 Protein extracts quantification- Bradford Assay 
 
 
The Bradford Reagent (Bio-Rad Laboratories, MI, Italy) was used to determine 
the concentration of proteins in  nuclear and cytoplasm extracted, obtained from 
MDA-231 cells treated with PNA anti-miR-221. To 1 ml of Bradford Reagent were 
added 3 µl of each samples, mixed and analyzed at spectrophotometer to determine 
the absorption at 595 nm. To normalize the quantification, a standard curve was 
prepared using BSA (bovine serum albumin) as standard protein. 
 
 
 
 
2.9 Western Blot Assay 
 
 
Twenty g of nuclear and cytoplasmic extracts were denatured for 5 min at 
 
98°C in 1X SDS sample buffer (62,5 mM Tris-HCl pH 6.8, 2% SDS, 50 mM 
Dithiotreithol (DTT), 0.01% bromophenol blue, 10% glicerol) and loaded on 12,5% 
SDS-PAGE gel in Tris-glycine Buffer (25 mM Tris, 192 mM glycine, 0.1% SDS). A 
biotinylated protein ladder  (size range of  9-200  kDa)  (Cell  Signaling, Euroclone 
S.p.A., Pero, Milano, Italy) was used as standard to determine molecular weight. The 
electrotransfer to 20 microns nitrocellulose membrane (Pierce, Euroclone S.p.A., 
Pero, Milano, Italy) was performed over-night at 360 mA and 4°C in electrotransfer 
buffer (25 mM Tris, 192 mM Glycine, 5% methanol). The membrane were prestained 
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in Ponceau S Solution (Sigma, St.Louis, MO, USA) to verify the transfer, washed with 
 
25 ml TBS (10 mM Tris-HCl pH 7.4, 150 mM NaCl) for 10 min at room temperature 
and  incubated  in  25  ml  of  blocking  buffer  for  2  h  at  room  temperature.  The 
membranes were washed three times for 5 min each with 25 ml of TBS/T (TBS, 0.1% 
Tween-20) and incubated with primary rabbit monoclonal antibody (1:1000) (Cell 
Signaling, Euroclone S.p.A., Pero, Milan, Italy) in 15 ml primary antibody dilution 
buffer with gentle agitation over-night at 4°C. The day after, the membrane were 
washed three times for 5 min each with 20 ml of TBS/T and incubated in 15 ml of 
blocking buffer, in gentle agitation for 2 h at room temperature, with an appropriate 
HRP-conjugated secondary antibody (1:2000) and an HRP-conjugated anti-biotin 
antibody (1:1000) used to detect biotinylated protein marker. Finally, after three 
washes each with 20 ml of TBS/T for 5 min, the membranes were incubated with 10 
ml LumiGLO® (0.5 ml 20X LumiGLO®, 0.5 ml 20X Peroxide and 9.0 ml Milli-Q water) 
 
(Cell Signaling, Euroclone S.p.A., Pero, Milan, Italy) in gentle agitation for 5 min at 
room temperature and exposed to x-ray film (Pierce, Euroclone S.p.A., Pero, Milan, 
Italy). As necessary, after stripping procedure using the Restore™ Western Blot 
Stripping Buffer (Pierce, Euroclone S.p.A., Pero, Milan, Italy) membranes were 
reprobed with primary and secondary antibodies. X-ray films for chemiluminescent 
blots were analysed by Gel Doc 2000 (Bio-Rad Laboratoires, Milan, Italy) using 
Quantity One program to elaborate the intensity data of our specific protein targets. 
Ponceau S staining was used as normalization control, but others marker proteins 
were taken as reference too and specifically reported. p27kip1 and  β-actin Rabbit mAb 
and were purchase from Cell Signaling (Euroclone, MI, Italy). 
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- RESULTS- 
 
 
 
 
 
3.1 Uptake and biostability of PNAs in breast cancer cell lines 
 
 
The first step necessary for obtaining anti-miR activity in cells is the effective 
cellular uptake. We have recently demonstrated that Rpep-PNA-a210 was efficiently 
internalized within leukemic K562 cells, unlike PNA-a210, and this was accompanied 
by a pronounced anti-miR activity of the former and no activity for the latter (Fabbri et 
al., 2011). 
 
 
 
 
3.1.1 Treatment with trypsin 
 
 
Trypsin is an enzyme belonging to the class of hydrolase, which catalyzes the 
cleavage with specificity for arginine and lysine.  Possessing Rpep-PNA-a221 a tag 
of  8  arginine,  as  a  preliminary experiment, we  checked  if  the  PNAs  could  be 
degraded by treatment with trypsin. We have pre-incubated 2 µM PNA-a221 and 
Rpep-PNA-a221 for 10 minutes, at room temperature, in the dark with 2 µl and 4 µl of 
0,05%Trypsin-EDTA. After incubation, PNAs were added to cells and after 24 hours 
of incubation, cells were washed once with PBS, trypsinized and analyzed by 
fluorescence-activated cell sorting analysis (FACS). 
 
 
 
 
 
 
Figure 19. FACS analysis showing the uptake of Fl-PNA-a221 and Fl- 
Rpep-PNA-a221 pre-incubated with different volumes (2 µl and 4 µl) of 
trypsin-EDTA 
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As shown in Figure 19, the treatment with 2 µl or 4 µl of trypsin does not cause 
any variation in the cellular uptake, neither  for Fl-PNA-a221 nor for Fl-Rpep-PNA- 
a221; in fact,   the Fl-PNA-a221 remains not internalized by the cells (comparable 
with untreated cells with FL-1 value from 100 to 101), while the Fl-Rpep-PNA-a221 is 
effectively absorbed (FL-1 value > 102). 
 
 
 
 
3.1.2 Culture and treatment w/ or w/o FBS 
 
 
Since different PNA structures could be affected by proteases present in 
serum, leading to different cellular uptake, these experiments have been conducted 
in the presence or in the absence of serum. Cells were cultured in a complete 
medium (D-MEM + FBS 10%) or only with D-MEM, and treated with Fl-PNAa221 and 
Fl-Rpep-PNA-a221 (1µM and 2 µM). Figure 20 reports the results obtained from 
FACS analysis. The Fl-PNA-a221, both in presence or absence of serum (Figure 19a 
and 19c) shows low internalization; these results are in agreement with previous 
results obtained with PNA-a210 (Manicardi et al., 2010). On the contrary the R8- 
conjugated Fl-PNA-a221 (Figure 20b and 20d) is efficiently internalized, better in 
presence of serum (Figure 20d). 
For this experiment we used K562 cell line, since it was a useful and simple in- 
vitro experimental cellular model.   Cells were seeded at concentration of 2x105 
cell/ml in 12-well plate, treated with increasing concentrations PNAs and cultured for 
12 hours in the presence or absence of FBS.  We can conclude that the serum does 
not  interfere  with  the  cellular  uptake,  indeed,  is  able  to  improve  cell  viability. 
Following these preliminary data, we set up uptake a series of experiments to 
investigate the uptake of PNAs in our cellular models, MDA-MB-231 and MCF-7 cells 
line. 
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Figure 20. Cellular uptake analysis (FACS) showing cellular uptake of (A) PNA-a221 and (B) 
Rpep-PNA-a221 cultured without FBS, (C) PNA-a221 and (D) Rpep-PNA-a221 cultured in the 
presence of FBS 
 
 
 
 
 
3.1.3 Cellular uptake in MDA-MB-231 and MCF-7 
 
Following our preliminary results regarding the cellular uptake, MDA-MB-231 
and MCF-7 were incubated for 24 hours with Fl-PNA-a221 and Fl-Rpep-PNA-a221 at 
1 µM, 2 µM and 4 µM concentrations. After incubation, cells were washed with PBS, 
trypsinized and analyzed by fluorescence-activated cell sorting analysis (FACS), 
obtaining the results shown in Figure 21. 
Analyzing these results, in both our cellular models, MDA-MB-231 and MCF-7, 
the PNAs with R8-peptide is better internalized by cells then other. We can also 
observe that MDA-MB-231 and MCF-7 respond in a different way to the treatment 
with Fl-Rpep-PNA-a221: although the proportion of positive cells (area under the 
curve, M1 value) is comparable for both cell lines, the two samples are differently 
distributed. In Table 4 are reported the statistic values of the analysis. 
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Fl-Rpep-PNA-a221 MDA-MB-231 MCF-7 
 M1 M2 M1 M2 
1 µM 99.88% 34.12% 98.01% 0.66% 
2 µM 99.97% 67.56% 98.56% 9.14% 
4 µM 99.99% 64.39% 99.44% 26.60% 
 
 
 
Figure 21. FACS analysis showing the cellular delivery of Fl-PNA-a221 and Rpep-PNA-a221 
in MDA-MB-231 (A,B) and MCF-7 (C,D) after 24 hours incubation at different concentration 
 
 
 
 
Table 4. Statistical analysis of Rpep-PNA-a221 uptake in MDA-MB-231 and MCF-7 by FACS 
 
 
 
 
 
 
 
M1: value (%) of fluorescent cells (>10
1
) calculated on total cell analyzed (cells Gated) 
M2: value (%) of fluorescent cells (>10
3
) calculated on total cell analyzed (cells Gated) 
 
 
 
 
It can be observed that, in both cell lines, the M1 value, which represents the 
percentage of cells with fluorescence > 101, shows no major changes; in fact, the 
values remain around 98-99%; this means that all cells analyzed have internalized 
the Fl-Rpep-PNA-a221. On the contrary, the M2 value, which is referred to strongly 
fluorescent cells, that is indicative of a higher uptake, is very different between the 
two cell lines, with values that reach approximately to 67% in MDA-MB-231 cells, 
while, in MCF-7 cells, only with 4 µM PNA, arrive to 26.60%. This analysis could 
indicate a different cellular response to this specific treatment with the PNA anti- 
miR221, considering also the different phenotype that these cells present. 
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3.1.4 Cellular uptake by BioStation IM 
 
 
We have also performed a series of experiments using the Biostation IM 
technology. Cells were seeded at 2 x 105 cell/ml, 300 µl in each well in a μ–Dish Hi– 
Q4 and monitored for 24 hours. The images were taken every 30 minutes of 
incubation, as well described in Chapter “Materials and Methods”. 
In Figure 22, there are report pictures of untreated MDA-MB-231, treated with 
 
2 µM Fl-PNA-a221 and 2 µM Fl-Rpep-PNA-a221 taken after 24 hours of incubation. As  
shown, while the Fl-PNA-a221 remains largely outside the cells (white arrows, 
Figure 22b), Fl-Rpep-PNA-a221 is absorbed by cells (yellow arrows, Figure 22c). 
Further investigations, using fluorescence microscopy, are needed to discriminate 
whether the accumulation in the cytoplasm or nucleus. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure  22.  Visible  and  fluorescent  20X  magnification  photographs  of 
MDA-MB-231 cells untreated (A), treated with Fl-PNA-a221 (B) and Fl- 
PNA-a221-Rpep (C) 
- 110 -  
3.2 Antiproliferative activity of PNA-a221 and Rpep-PNA-a221 
 
 
Having demonstrated that the Rpep-PNA-a221 is better internalized into cells 
if compared to the PNA-a221, and in order to determine the concentrations of PNAs 
to be employed for in vitro studies on MDA-MB-231 cells, we determined the IC50 
value. For this reason, MDA-MB-231 and MCF-7 cells (2x104 cells/ml) were seeded 
 
in 24-well plate; after 24 hours the media was changed and replaced with 
experimental media containing different concentration of PNAs. Cells were growth for 
72 hours and after this incubation, medium was removed, cell wash with PBS and 
 
trypsinized for 5 minute at 37°C and counted by a ZF Coulter Counter. As reported in 
Figure 23,  the treatment with PNAs anti-miR-221 do not affect the MDA-MB-231 and 
MCF-7 cell proliferation; in fact the IC50 is > 10 µM; interesting, the concentrations 
used for the next experiments (2 µM), do not affect  cells growth. Results represent 
the average ± S.D. of three independent experiments. 
 
 
 
 
 
 
Figure 23. Effect of PNA-a221 and Rpep-PNA-a221 on MDA-MB-231 (A) and MCF-7 (B) proliferation. 
Cells were treated with different concentrations of PNAs and Counted with Coulter Counter. Results 
represent the average ± S.D. of three independent experiments 
 
 
 
 
We have recently published (Fabbri et al., 2011) the antiproliferative activity of 
R-pep, composed by 8 arginine. The IC50 value, calculated on K562 cells treatment, 
was > 10 µM, suggesting, also for R8, no cytotoxic activity at the used concentrations. 
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3.3 Rpep-PNA inhibitory effects on miR-221 analyzed by qPCR assay 
 
 
We initially evaluated the accumulation of miR-221 in standard condition, 
without any treatment. The cells were cultured for 48 and 96 hours and total RNA 
was isolated. The over-expression of miR-221 in estrogen receptor (ER)-negative 
breast cancer (MDA-MB-231) is well known in literature, and it has been recently 
reported by Zhao et al., (2008); we already confirmed that miR-221 is about 4 times 
more expressed in MDA-MB-231 cells (invasive phenotype) than in MCF-7, 
suggesting a possible correlation with expression of miR-221 and cancer grade. 
(Figure 24). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 24. Accumulation of miR-221 in MCF- 
7  and  MDA-MB-231  cell  lines  in  normal 
culture conditions 
 
 
 
 
Following these results, we decided to proceed with the analysis of inhibition 
of mir-221 only in MDA-MB-231cell line, which expresses miR-221 at higher levels. 
Considering the  data  obtained by  FACS analysis regarding the  cellular uptake, 
preliminary  experiments  were  prepared  by  treating  the  cells  with  increasing 
concentrations (0.5, 1 and 2 M) of PNAs to identify the best concentration that 
express  an  anti-miR-221  activity;  the  inhibitory  activity  on  miR-221  is  dose- 
dependent. In addition, the concentration of 2 µM of Rpep-PNA-a221 prominently 
inhibits the accumulation of miR-221, both after 48 hours and 96 hours (Figure 25). 
Anti-miR-221 activity was evaluated by RT-PCR analysis. MDA-MB-231 cells were 
treated with 2 µM PNAs; after 48 and 96 hours of incubation the total RNA was 
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isolated. As shown in Figure 25, the expression of miR-221 is significantly inhibited 
by treatment with Rpep-PNA; in particular, the Ct value (cycle threshold) change from 
20.03 to 24.56 at 48 hours and from 20.29 to 23.46 at 96 hours. 
 
 
 
 
 
 
 
Figure 25.  Accumulation of miR-221, miR-let-7c and miR-200c in MDA-MB-231 cells treated for 
48 (A) and 96 (B) hours with 2 µM PNA-a221 and Rpep-PNA-a221. qRT-PCR amplifications 
were performed on RNA from untreated or treated cells using primers amplifying U6 RNA as 
reference gene. Results are presented as fold increase of miR-221, miR-let-7c and miR-200c 
mRNAs with respect to untreated cells. The results of untreated cells were taken as 1. Results 
represent the average  S.D. of three independent experiments 
 
 
 
 
Increasing of Ct value indicates a decrease in the accumulation of miR-221, 
indicating an efficient inhibition activity of Rpep-PNA-a221. It’s can also note that the 
activities of the Rpep-PNA is specific for miR-221; in fact, Figure 23 shows that this 
effects are restricted to miR-221, since, despite the fact that some alteration of miR 
content occurs, no suppression of accumulation of miR-let-7c and miR-200c has 
been obtained. These data demonstrate the specificity on the PNAs synthetized. 
 
 
 
 
3.4 Modulation of p27kip1 by treatment with anti-miR-221 PNAs 
 
 
It’ s well known in the literature, as more completely described in the chapter 
"Introduction" of this PhD Thesis, that in the 3'UTR region of p27kip1 mRNA are 
presents at least two sites recognized by miR-221(Galardi et al., 2007) Since 
microRNA-221 is able to target the onco-suppressor p27kip1  mRNA, involved in cell 
cycle control, we have prepared a series of experiments to understand whether the 
inhibition activity of miR-221 induced by PNAs could influence the expression of 
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p27kip1. Firstly, we have investigated the basal expression of p27kip1 by RT-qPCR in 
untreated cells. As shown in Figure 26, MCF-7 cells present higher level of 
accumulation of p27kip1 mRNA than MDA-MB-231 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Expression of p27
kip1 
mRNA in 
MCF-7 and MDA-MB-231 cell lines in normal 
culture conditions 
 
 
 
 
3.4.1 Accumulation of p27kip1 mRNA 
 
 
To analyze the p27kip1 mRNA accumulation, MDA-MB-231 cells were treated 
with 2 µM PNAs for 48 and 96 hours; after incubation, total RNA was isolated by 
Trizol® Reagent, following manufacture’s instruction. We perform qPCR using 
CDKN1B probe and primers (Applied Biosystems, Foster City, CA, USA). Relative 
expression was calculated using the comparative cycle threshold method and as 
reference genes the endogenous control human 18S rRNA. 
Results shown in Figure 27 indicate that no change of p27
kip1 
mRNA content 
 
occurs in MDA-MB-231 cells treated with PNA-a221, whereas significant increase of 
presence of p27kip1  mRNA is observed with the Rpep-PNA-a221, better after 96 
hours than 48 hours. This result is strongly in agreement with that obtained using the 
commercially available anti-miR against miR-221. These results about the expression 
of mRNA, have suggested us to investigate whether this variation in mRNA level 
could have a visible effect on the p27kip1 protein content. For this aim, we performed 
a series of Western Blot assay, using antibodies against p27kip1 and β-actin (Figure 
28a). 
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Figure 27. p27
kip1  
mRNA content in MDA-MB-231 cell treated with 2 µM PNA-a221 and 
Rpep-PNA-a221 for 48 hours (A) and 96 hours (B). qRT-PCR amplifications were performed 
on RNA from untreated or treated cells using primer amplifying 18S rRNA as reference gene 
 
 
 
 
3.4.2 Western Blot analysis of p27kip1 
 
 
Cytoplasmic protein extracts were obtained from MDA-MB-231 cells after 96 
hours of PNAs treatment. It’s possible to notice a visible increase in the intensity of 
the spot of p27kip1  with the Rpep-PNA-a221 treatment, if compared with untreated 
cells. Figure 27b shows the relative intensity of the p27kip1 spots, obtained from 
densitometric analysis of the films. The treatment with PNA-a221 is able to increase 
the accumulation of p27kip1  from 0.44% to 1.20%, while the relative intensity of the 
accumulation of p27kip1  increases up to 1.87% with the treatment with Rpep-PNA- 
 
a221. All the values are  normalized on β-actin protein expression, taken as reference 
protein. 
 
 
 
 
Figure 28. (A) Western Blot analysis performed on MDA-MB-231 cells treated 
with 2 µM PNAs for 96 hours. (B) Graph generated by densitometric analysis of 
the films and the normalized intensity values represent mean and standard 
deviation from three independent experiments. Ponceau S staining was used as 
normalization control 
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- DISCUSSION AND CONCLUSIONS (2) - 
 
 
 
 
 
MicroRNA-221 is deeply involved in cancer, and it was found up-regulated in 
glioma, hepatocellular carcinoma, pancreatic adenocarcinoma, melanoma, chronic 
lymphocytic leukemia, thyroid papillary carcinoma. In breast cancer, miR-221 was 
found to be up-regulated in breast cancer cell lines and primary tumor cell cultures 
exhibiting high metastatic potential. Taken together, miR-221 should be considered 
as an oncomiR and, for this reason, a strong candidate for miRNA-therapeutics 
based on antagomiR molecules. As far as possible target molecules of miR-221, 
many of them have been firmly established, such as DVL2, PUMA, PTEN, p27Kip1. In 
 
the context of breast tumors, of great interest is the study published by Farace et al., 
identifying p27Kip1 mRNA as a possible target of miR-221. This finding is very 
intriguing, since p27Kip1  has been proposed as a tumor suppressor gene, which is 
down-regulated in several types of tumors. These data support the concept that 
targeting miR-221 with antagomiR molecules might lead to an increased expression 
of  the  tumor-suppressor  p27Kip1,  bringing  novel  treatment  options  in  cancer 
treatment. 
The major conclusions of this study is that a PNA against miR-221 is efficiently 
internalized within target cells only if linked to an arginine-rich peptide, strongly 
inhibits miR-221 activity and deeply alters the expression of p27Kip1 gene. Unlike 
commercially available anti-miR, which needs continuous administrations, a single 
administration of Rpep-PNA-a221 is sufficient to obtain the biological effects without 
the  need  for  transfection  reagents.  Interestingly,  modifications  allowing  efficient 
uptake by target cells (Results, Figure 20 B and D) are necessary to obtain the 
biological activity, since PNA-a221, despite being able to hybridize to the target 
nucleotide sequence (Results, Figure 24) is not internalized (Results, Figure 20 A 
and C) and displays a very low activity on p27kip1 (Results, Figure 26 and 27). 
Therefore, efficient delivery strategies are necessary and, in this respect, we would 
like to underline that the delivery of Rpep-PNA-a221 needs no transfection reagents 
(such as lipofectin, lipofectamine and similar reagents) which, on the contrary, are 
required when RNA or DNA-based analogues are used. 
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From a theoretical point of view, these studies fully support the concept that 
p27Kip1 mRNA might be considered among possible targets of miR-221. In fact, in the 
presence of Rpep-PNA-a221 we observed effects MDA-MB-231 cells compatible 
with a decrease of miR-221 (it should be underlined that the effects of Rpep-PNA- 
a221 might be based on binding to mature miR-221, but also to pre-miR sequences), 
an increase of p27Kip1. 
From a general point of view, our results allow to propose PNA-based 
molecules as very promising reagents to modulate the biological activity of 
microRNAs. These data should encourage further research on PNA analogues to 
increase efficiency of delivery, stability and change of intracellular distribution in view 
of the selected miR targets, such as mature miR, pre-miR or primary miRNA (pri- 
miR) sequences. Despite the fact that in this paper we focused our attention on 
breast cancer cellular model systems, we like to underline that p27Kip1/miR-221 are 
 
deeply involved in other tumors for which PNA-based treatments are expected to be 
very appealing. One example in glioblastoma, which expresses high levels of miR- 
221  and  down  regulated  p27
Kip1   
that  should  be  considered  the  major  onco- 
 
suppressor protein in this type of tumors. Lu and Zhang (2009) have first 
demonstrated that miR221/222 promote malignant progression of glioblastoma 
through  activation  of  the  Akt  pathway  and  inhibition  of  p27Kip1;  in  a  second 
manuscript, the same group reported that co-suppression of miR-221/222 cluster 
suppresses human glioma cell growth by targeting p27Kip1 in vitro and in vivo (Zhang 
et al., 2009). Interestingly, modified PNAs can be easily delivered to brain tissues 
originating glioblastoma, as demonstrated by Pession et al., using PNA-based 
molecules targeting the NMYC mRNA (Pession et al., 2005). Our data strongly 
suggest  that  PNAs  targeting  miR-221  and  restoring  p27Kip1   levels  might  be 
considered for experimental therapy of gliomas. 
Based on these findings, future research activity should be focused on the 
development of more effective PNA-based anti-microRNA molecules. In this respect, 
because the use of peptides as carriers might represent a problem for potential PNA- 
based drug candidates (as the peptide portion might be subject to enzymatic 
degradation), the incorporation of positively charged peptides with the PNA backbone 
(and not at the end) would protect the molecule from proteolysis, allowing highly 
efficient uptake, and thus persevering activity against targeted microRNAs. 
- 117 -  
- REFERENCES - 
 
 
 
 
Abes R., Arzumanov A., Moulton H., Abes S., Ivanova G., Gait M.J., Iversen P., Lebleu B., 2008. 
Arginine- rich cell penetrating peptides: design, structure-activity, and applications to alter pre- 
mRNA splicing by steric-block oligonucleotides. Journal of Peptide Science, (14) 4:455-460 
 
Adams B.D., Furneaux H., White B.A., 2007. The micro-ribonucleic acid (miRNA) miR-206 targets the 
human estrogen receptor-alpha (ERalpha) and represses ERalpha messenger RNA and protein 
expression in breast cancer cell lines. Mol. Endocrinol. 21:1132-1147 
 
Aigner K., Dampier B., Descovich L., Mikula M., Sultan A., Schreiber M., 2007. The transcription factor 
ZEB1 (deltaEF1) promotes tumour cell dediff erentiation by repressing master regulators of 
epithelial polarity. Oncogene. 26:6979-6988 
 
Arghya R., Bengt N., 2000. Peptide nucleic acid (PNA): its medical and biotechnical applications and 
promise for the future, Med. Biotec. Applic. 14:1041-1060 
 
Bader AG, Brown D, Winkler M. 2010. The promise of microRNA replacement therapy. Cancer Res. 
70:7027–7030 
 
Bagga  S.,  Bracht  J.,  Hunter  S.,  Massirer  K.,  Holtz  J.,  Eachus  R.  and  Pasquinelli  A.E.,  2005. 
Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell. 122: 553–563 
 
Bartkova J., Lukas J., Bartek J., 1997. Aberrations of the G1- and G1/S-regulating genes in human 
cancer. Prog. Cell. Cycle Res. 3:211-220 
 
Belletti B., Nicoloso M.S., Schiappacassi M., Chimienti E., Berton S., Lovat F., Colombatti A., 
Baldassarre G., 2005. p27(kip1) functional regulation in human cancer: a potential target for 
therapeutic designs. Curr. Med. Chem. 12(14): 1589-1605 
 
Berezikov E., Chung W.J., Willis J., Cuppen E., Lai E.C., 2007. Mammalian mirtron genes. Mol. Cell. 
28: 328–336 
 
Borgatti M., Breda L., Cortesi R., Nastruzzi C., Romanelli A., Saviano M., Bianchi N., Mischiati C., 
Pedone C., Gambari R., 2002. Cationic liposomes as delivery systems for double-stranded 
PNA-DNA chimeras exhibiting decoy activity against NF-kappaB transcription factors. 
Biochemical Pharmacology. 64(4): 609-616 
 
Borgatti M., Finotti A., Romanelli A., Saviano M., Bianchi N., Lampronti I., Lambertini E., Penolazzi L., 
Nastruzzi C., Mischiati C., Piva R., Pedone C., Gambari R., 2004. Peptide nucleic acids (PNA)– 
DNA chimeras targeting transcription factors as a tool to modify gene expression. Curr. Drug 
Targets. 5(8): 735–744 
 
Borgatti M., Lampronti I., Romanelli A., Pedone C., Saviano M., Bianchi N., Mischiati C., Gambari R., 
2003.  Transcription  factor  decoy  molecules  based  on  a  peptide  nucleic  acid  (PNA)–DNA 
chimera mimicking Sp1 binding sites. J. Biol. Chem. 278(9): 7500–7509 
 
Borgatti M., Romanelli A., Saviano M., 2003. Resistance of decoy PNA–DNA chimeras to enzymatic 
degradation in cellular extracts and serum. Oncol. Res. 13(5): 279–287 
 
Cailleau R., Mackay B., Young K., 1974. Tissue Culture Studies on Pleural Effusions from Breast 
Carcinoma Patients. Cancer Res. 34: 801-809 
 
Calabretta  A.,  Tedeschi  T.,  Corradini  R.,  Marchelli R.,  Sforza  S.,  2011.  DNA  and  RNA  binding 
properties of an arginine-based ‘extended chiral box’ peptide nucleic acid. Tetrahedron Lett. 52: 
300–304 
 
Calin G.A., Sevignani C., Dumitru C.D., Hyslop T., Noch E., Yendamuri S., Shimizu M., Rattan S., 
Bullrich F., Negrini M., Croce C.M., 2004. Human microRNA genes are frequently located at 
- 118 -  
fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. USA. 101(9):2999- 
3004 
 
Chan J.A., Krichevsky A.M., Kosik K.S., 2005. MicroRNA-21 is an antiapoptotic factor in human 
glioblastoma cells. Cancer. Res. 65: 6029-6033 
 
Chen L., Zheng J., Zhang Y., Yang L., Wang J., Ni J., Cui D., Yu C., Cai Z., 2011. Tumor-specific 
expression of microRNA-26a suppresses human hepatocellular carcinoma growth via cyclin- 
dependent and -independent pathways. Mol. Ther. 19(8):1521-1528 
 
Chen Y., Robles A.I., Martinez L.A., Liu F., Gimenez-Conti I.B., Conti C.J., 1996. Expression of G1 
cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors in androgen-induced 
prostate proliferation in castrated rats. Cell Growth Differ. 7:1571–1578 
 
Chenna V., Rapireddy S., Sahu B., Ausin C., Pedroso E., 2008. A simple cytosine to G-clamp 
nucleobase substitution enables chiral gamma-PNAs to invade mixed-sequence double-helical 
B-form DNA. Chembiochem.  9(15):2388-2391 
 
Cho W.C.S.,  2007.  OncomiRs:  the discovery and progress of  microRNAs in cancers. Molecular 
Cancer, Vol. 6, Art. No 60. 
 
Choe J., Cho H., Lee H.C., Kim Y.K., 2010. MicroRNA/Argonaute 2 regulates nonsensemediated 
messenger RNA decay. EMBO Rep. 11:380-386 
 
Cimmino A., 2005. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. 
USA 102, 13944–13949 
 
Connor M.K., Kotchetkov R., Cariou S., Resch A., Lupetti R., Beniston R.G., Melchior F., Hengst L., 
Slingerland J.M., 2003. CRM1/Ran-mediated nuclear export of p27(Kip1) involves a nuclear 
export signal and links p27 export and proteolysis. Mol. Biol. Cell. (1):201-213 
 
Coqueret O., 2002. New roles for p21 and p27 cell-cycle inhibitors: A function for each cell 
compartment? Trends Cell. Biol .13:65-70 
 
Corradini R., Feriotto G., Sforza S., Marchelli R., Gambari R., 2004. Enhanced recognition of cystic 
fibrosis W1282X DNA point mutation by chiral peptide nucleic acid probes by a surface plasmon 
resonance biosensor. Journal of Molecular Recognition. 17(1): 76-84 
 
Corradini R., Sforza S., Tedeschi T., Totsingan F., Marchelli R., 2007. Peptide Nucleic Acids with a 
Structurally Biased Backbone: Effects of Conformational Constraints and Stereochemistry. 
Current Topics in Medicinal Chemistry. 7(7): 681-694 
 
Cortesi R., Mischiati C., Borgatti M., Breda L., Romanelli A., Saviano M., Pedone C., Gambari R., 
Nastruzzi C., 2004. Formulations for natural and peptide nucleic acids based on cationic 
polymeric submicron particles. AAPS Pharmsci 6(1): 10-21 
 
Costa F.F., 2010. Epigenomics in cancer management. Cancer Manag. Res. 2: 255–265 
 
Croix B., Florenes V., Rak A., Flanagan J.W., Bhattacharya N., Slingerland J.M., Kerbel R.S., 1996. 
Impact of the cyclin dependent kinase inhibitor p27Kip1 on adhesion-dependent resistance of 
tumor cells to anticancer agents. Nat. Med. 2: 1204-1210 
 
Cuccato G., Polynikis A., Siciliano V., Graziano M., di Bernardo M., di Bernardo D., 2011. Modeling 
RNA interference in mammalian cells. BMC Syst. Biol. 5:19-24 
 
Demidov  V.,  Frank-Kamenetskii  M.D.,  Egholm  M.,  Buchard  O.,  Nielsen  P.E.,  1993.  Sequence 
selective double strand DNA cleavage by peptide nucleic acid (PNA) targeting using nuclease 
S1. Nucl. Acids Res .21: 2103–2107 
 
Demidov V.V., Potaman V.N., Frank- Kamenetskii M.D., 1994. Stability of peptide nucleic acids in 
human serum and cellular extracts. Biochem. Pharmacol. 48(6): 1310–1313 
- 119 -  
Egholm M., Buchardt O., Christensen L., Behrens C., Freier S.M., Driver D.A., Berg R.H., Kim S.K., 
Nordén B., Nielsen P.E., 1993. PNA Hybridizes to Complementary Oligonucleotides Obeying 
the Watson-Crick Hydrogen Bonding Rules. Nature 365 (6446): 566-8 
 
Eis  P.S.,  Tam  W.,  Sun  L.,  Chadburn  A.,  Li  Z.,  Gomez  M.F.,  Lund  E.,  Dahlberg  J.E.,  2005. 
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc. Natl. Acad. Sci. USA 
102: 3627-3632 
 
Elledge S.J., Winston J., Harper J.W., 1996. A question of balance: the role of cyclinkinase inhibitors 
in development and tumorigenesis. Trends Cell. Biol. 6(10): 388-392 
 
Elme´n J., Lindow M., Silahtaroglu A., Bak M., Christensen M., Lind-Thomsen A., 2008. Antagonism of 
microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a 
large set of predicted target mRNAs in the liver. Nucleic Acids Res. 36: 1153-1162 
 
Ewen M.E., Sluss H.K., Sherr C.J., Matsushime H., Kato J., Livingston D.M., 1993. Functional 
interactions of the retinoblastoma protein with mammalian D-type cyclins. Cell. 73(3): 487-497 
 
Fabani M.M., Abreu-Goodger C., Williams D., Lyons P.A., Torres A.G., Smith K.G.C., Enright A.J., 
Gait M.J., Vigorito E., 2010. Efficient inhibition of miR-155 function in vivo by peptide nucleic 
acids. Nucleic Acids Research. 38(13): 4466-4475 
 
Fabani  M.M.,  Gait  M.J.,  2008.  miR-122  targeting  with  LNA/2'-O-methyl  oligonucleotide mixmers, 
peptide nucleic acids (PNA), and PNA-peptide conjugates. RNA. 14(2): 336-346 
 
Fabbri E., Bianchi N., Brognara E., Finotti A., Breveglieri G., Borgatti M., Manicardi A., Corradini R., 
Marchelli R., Gambari R., 2010. Inhibition of micro RNA 210 biological activity with an anti-miR- 
210 peptide nucleic acid. International Journal of Molecular Medicine. 26(1): S61-S61 
 
Fabbri E., Manicardi A., Tedeschi T., Sforza S., Bianchi N., Brognara E., Finotti A., Breveglieri G., 
Borgatti M., Corradini R., Marchelli R., Gambari R., 2011. Modulation of the Biological Activity of 
microRNA-210 with Peptide Nucleic Acids (PNAs). Chem. Med. Chem. 6(12):2192-2202 
 
Galardi S., Mercatelli N., Giorda E., Massalini S., Frajese G.V., Ciafre S.A., Farace M.G., 2007. MiR- 
221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell 
lines by targeting p27Kip1. J. Biol. Chem. 282: 23716-23724 
 
Gambari R., 2004. Biological activity and delivery of peptide nucleic acids (PNA)–DNA chimeras for 
transcription factor decoy (TFD) pharmacotherapy. Curr. Med. Chem. 11(10): 1253-1263 
 
Gambari R., Borgatti M., Bezzerri V., Nicolis E., Lampronti I., Dechecchi M.C., Mancini I., Tamanini A., 
Cabrini G., 2010. Decoy oligodeoxyribonucleotides and peptide nucleic acids-DNA chimeras 
targeting nuclear factor kB: inhibition of IL 8 gene expression in cystic fibrosis cells infected with 
Pseudomonas aeruginosa. Biochem. Pharmacol. 80(12): 1887-1894 
 
Gaur A., Jewell D.A., Liang Y., Ridzon D., Moore J.H., Chen C., Ambros V.R., Israel M.A., 2007. 
Characterization of microRNA expression levels and their biological correlates in human cancer 
cell lines. Cancer Res. 67: 2456-2468 
 
Giesen U., Kleider W., Berding C., Geiger A., Orum H., Nielsen P.E., 1998. A formula for thermal 
stability (Tm) prediction of PNA/DNA duplexes. Nucl. Acids Res. 26: 5004-5006 
 
Gillies J.K., Lorimer I.A., 2007. Regulation of p27Kip1 by miRNA 221/222 in glioblastoma. Cell Cycle 
6: 2005-2009 
 
Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall 
Y., Goodall G.J., 2008. The miR-200 family and miR-205 regulate epithelial to mesenchymal 
transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 10: 593-601 
 
Harper J.W., Elledge S.J., 1996. Cdk inhibitors in development and cancer. Curr. Opin. Genet. Dev. 
6(1):56-64 
- 120 -  
Hayashita Y., 2005. A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung 
cancers and enhances cell proliferation. Cancer Res. 65: 9628-9632 
 
He L., Hannon G.J., 2010. MicroRNAs: small RNAs with a big role in gene regulation. Nat. Rev. 
Genet. 5: 522-531 
 
He L., He X., Lowe S.W., Hannon G.J., 2007. MicroRNAs join the p53 network- another piece in the 
tumour-suppression puzzle. Nat. Rev. Cancer 7: 819-822 
 
Heichman K.A., Roberts J.M., 1994. Rules to replicate by. Cell. 79(4): 557-562 
 
Hemida M.G., Ye X., Thair S., Yang D., 2010. Exploiting the therapeutic potential of microRNAs in 
viral diseases: expectations and limitations. Mol. Diagn. Ther. 14: 271-282 
 
Hendrickson D.G., Hogan D.J., McCullough H.L., Myers J.W., Herschlag D., Ferrell J.E., Brown P.O., 
2009. Concordant regulation of translation and mRNA abundance for hundreds of targets of a 
human microRNA. PLoS Biol. 7: e1000238 
 
Hengst  L.,  Reed S.I., 1996.  Translational control  of  p27Kip1 accumulation during the cell cycle. 
Science. 271:1861-1864 
 
Hinske L.C., Galante P.A., Kuo W.P., Ohno-Machado L., 2010. A potential role for intragenic miRNAs 
on their hosts’ interactome. BMC Genomics. 11: 533-541 
 
Hirai H., Roussel M.F., Kato J.Y., Ashmun R.A., Sherr C.J., 1995. Novel INK4 proteins, p19 and p18, 
are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15: 
2672–2681 
 
Hunt T., 1991. Cell biology. Cell cycle gets more cyclins. Nature. 350(6318): 462-463 
 
Hunter T., Pines J., 1994. Cyclins and cancer II: Cyclin D and Cdk inhibitors come of age. Cell. 79(4): 
573-82 
 
Huntzinger E., Izaurralde E., 2011. Gene silencing by microRNAs: contributions of translational 
repression and mRNA decay. Nat. Rev. Genet.12:99-110 
 
Huse J.T., 2009. The PTEN-regulating microRNA miR-26a is amplified in high-grade glioma and 
facilitates gliomagenesis in vivo. Genes Dev. 23: 1327-1337 
 
Hwang H.C., Clurman B.E., 2005. Cyclin E in normal and neoplastic cell cycles. Oncogene. 24: 2776- 
2786 
 
Iorio M.V., Casalini P., Piovan C., Di Leva G., Merlo A., Triulzi T., Me´nard S., Croce C.M., Tagliabue 
E., 2009. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res. 69: 2195-2200 
 
Ishizuka T., Tedeschi T., Corradini R., Komiyama M., Sforza S., Marchelli R., 2009. SSB Assisted 
Duplex Invasion of Preorganized PNA into Double-Stranded DNA. Chem. Bio. Chem. 10(16): 
2607-2612 
 
Ivanovska I., 2008. MicroRNAs in the miR-106b family regulate p21/ CDKN1A and promote cell cycle 
progression. Mol. Cell Biol. 28: 2167-2174 
 
Jensen K.K., Orum H., Nielsen P.E., Norden B., 1997. Hybridization kinetics of peptide nucleic acids 
(PNA) with DNA and RNA studied with BIAcore technique. Biochemistry. 36: 5072–5077 
 
Johnson S.M., 2005. RAS is regulated by the let-7 microRNA family. Cell 120: 635-647 
 
Kamura T., Hara T., Matsumoto M., Ishida N., Okumura F., Hatakeyama S., Yoshida M., Nakayama 
K., Nakayama K.I., 2004. Cytoplasmic ubiquitin ligase KPC regulates proteolysis of p27(Kip1) at 
G1 phase. Nat Cell Biol. 6(12): 1229-1235 
 
Kato M., Paranjape T., Müller R.U., Ullrich R., Nallur S., Gillespie E., Keane K., Esquela-Kerscher A., 
Weidhaas J.B.,  Slack F.J.,  2009.  The mir-34 microRNA  is required for the  DNA damage 
- 121 -  
response in vivo in C. elegans and in vitro in human breast cancer cells. Oncogene. 28: 2419- 
2424 
 
Kawada M., Yamagoe S., Murakami Y., Suzuki K., Mizuno S., Uehara Y., 1997. Induction of p27Kip1 
degradation and anchorage independence by Ras through the MAP kinase signaling pathway. 
Oncogene.15: 629–637 
 
Kerscher A.E., Slacj F.J., 2006. Oncomirs- microRNNAs with a role in cancer. Nature Reviews. 6: 259- 
269 
 
Koch T., Naesby M., Wittung P., 1995. PNA-peptide chimera. Tetrahedron Lett. 36: 6933-6936 
 
Koff A., Cross F., Fisher A., Schumacher J., Leguellec K., Philippe M., Roberts J.M., 1991. Human 
cyclin E, a new cyclin that interacts with two members of the CDC2 gene family. Cell. 66(6): 
1217-1228 
 
Koff A., Ohtsuki M., Polyak K., Roberts J.M., Massague J., 1993. Negative regulation of G1 in 
mammalian cells: inhibition of cyclin E-dependent kinase by TGF-b. Science. 260: 536–539 
 
Kong W., Yang H., He L., Zhao J., Coppola D., Dalton W.S., Cheng J.Q., 2008. MicroRNA-155 is 
regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell 
plasticity by targeting RhoA. Mol. Cell. Biol. 28: 6773-6784 
 
Korpal M., Lee E.S., Hu G., Kang Y., 2008. The miR-200 family inhibits epithelial-mesenchymal 
transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors 
ZEB1 and ZEB2. J. Biol. Chem. 283: 14910-14914 
 
Kossatz U., Vervoorts J., Nickeleit I., Sundberg H.A., Arthur J.S., Manns M.P., Malek N.P., 2006. C- 
terminal phosphorylation controls the stability and function of p27kip1. EMBO J. 25(21): 5159- 
5170 
 
Kota  S.K.,  Balasubramanian  S.,  2010.  Cancer  therapy  via  modulation  of  micro  RNA  levels:  a 
promising future. Drug Discov. Today. 15: 733-740 
 
Kozomara A., Griffiths-Jones S., 2010. miRBase: integrating microRNA annotation and deep- 
sequencing data. Nucleic Acids Research. 39: D152-D157 
 
Krol J., Loedige I., Filipowicz W., 2010. The widespread regulation of microRNA biogenesis, function 
and decay. Nat. Rev. Genet. 11: 597-610 
 
le Sage C., 2007. Regulation of the p27(Kip1) tumor suppressor by miR- 221 and miR-222 promotes 
cancer cell proliferation. EMBO. J. 26: 3699-3708 
 
Lee Y.M., Lee J.Y., Ho C.C., Hong Q.S., Yu S.L., Tzeng C.R., Yang P.C., Chen H.W., 2011. 
MicroRNA 34b as a tumor suppressor in estrogen-dependent growth of breast cancer cells. 
Breast Cancer Res. 13(6): R116 
 
Leivonen S.K., Mäkelä R., Ostling P., Kohonen P., Haapa-Paananen S., Kleivi K., Enerly E., Aakula 
A., Hellström K., Sahlberg N., Kristensen V.N., Børresen-Dale A.L., Saviranta P., Perälä M., 
Kallioniemi  O.,  2009.  Protein  lysate  microarray  analysis  to  identify  microRNAs  regulating 
estrogen receptor signaling in breast cancer cell lines. Oncogene. 28: 3926-3936 
 
Lew D.J., Dulić V., Reed S.I., 1991. Isolation of three novel human cyclins by rescue of G1 cyclin (Cln) 
function in yeast. Cell. 66(6): 1197-1206 
 
Lowery A.J., Miller N., McNeill R.E., Kerin M.J., 2008. MicroRNAs as prognostic indicators and 
therapeutic targets: potential effect on breast cancer management. Clinical Cancer Research. 
14(2): 360-365 
 
Lu X., Zhao P., Zhang C., Fu Z., Chen Y., Lu A., Liu N., You Y., Pu P., Kang C., 2009. Analysis of 
miR-221 and p27 expression in human gliomas. Mol Med Report. 2(4):651-656 
- 122 -  
Lundberg A.S., Weinberg R.A., 1998. Functional inactivation of the retinoblastoma protein requires 
sequential modification by at least two distinct cyclin-cdk complexes. Mol. Cell. Biol. 18(2): 753- 
761 
 
Ma L., Teruya-Feldstein J., Weinberg R.A., 2007. Tumour invasion and metastasis initiated by 
microRNA-10b in breast cancer. Nature 449: 682-688 
 
Malumbres M., Barbacid M., 2001. To cycle or not to cycle: a critical decision in cancer. Nat. Rev. 
Cancer 1: 222-231 
 
Manicardi A., Calabretta A., Bencivenni M., Tedeschi T., Sforza S., Corradini R., Marchelli R., 2010. 
Affinity and selectivity of C2 and C5 substituted ‘chiral-box’ PNA in solution and on microarrays. 
Chirality: E161–E172 
 
Masaki S., Ohtsuka R., Abe Y., Muta K., Umemura T., 2007. Expression patterns of microRNAs 155 
and 451 during normal human erythropoiesis. Biochemical and Biophysical Research 
Communication. 364(3):  509-514 
 
Matsuoka S., Thompson J.S., Edwards M.C., Bartletta J.M., Grundy P., Kalikin L.M., Harper J.W., 
Elledge S.J., Feinberg A.P., 1996. Imprinting of the gene encoding a human cyclindependent 
kinase inhibitor, p57KIP2, on chromosome 11p15. Proc. Natl. Acad. Sci. USA. 93(7): 3026-3030 
 
Matsushime H., Ewen M.E., Strom D.K., Kato J.Y., Hanks S.K., Roussel M.F., Sherr C.J., 1992. 
Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D 
type G1 cyclins. Cell. 71(2): 323-334 
 
Matsushime H., Roussel M.F., Ashmun R.A., Sherr C.J., 1991. Colony-stimulating factor 1 regulates 
novel cyclins during the G1 phase of the cell cycle. Cell. 65(4): 701-713 
 
Menchise V., De Simone G., Tedeschi T., Corradini R., Sforza S., Marchelli R., Capasso D., Saviano 
M., Pedone C., 2003. Insights into peptide nucleic acid (PNA) structural features: The crystal 
structure of a D-lysine-based chiral PNA–DNA duplex. Proceedings of the National Academy of 
Sciences U.S.A., 100(21): 12021-12026 
 
Meyerson M., Harlow E., 1994. Identification of G1 kinase activity for cdk6, a novel cyclin D partner. 
Mol. Cell. Biol.14(3): 2077-2086 
 
Michael M.Z., SM O.C., van Holst Pellekaan N.G., Young G.P., James R.J., 2003. Reduced 
accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1: 882-891 
 
Millard S.S., Vidal A., Markus M., Koff A., 2000. A U-rich element in the 5' untranslated region is 
necessary for the translation of p27 mRNA. Mol .Cell. Biol. 20(16): 5947-5959 
 
Mischiati C., Borgatti M., Bianchi N., Rutigliano C., Tomassetti M., Feriotto G., Gambari R., 1999. 
Interaction of the human NF-kappaB p52 transcription factor with DNA-PNA hybrids mimicking 
the NF-kappaB binding sites of the human immunodeficiency virus type 1 promoter. J. Biol. 
Chem. 274(46): 33114-33122 
 
Moeller S.J., Head E.D., Sheaff R.J., 2003. p27Kip1 inhibition of GRB2-SOS formation can regulate 
Ras activation. Mol. Cell Biol. 23: 3735–3752 
 
Møllegaard N.E., Buchardt O., Egholm M., Nielsen P.E., 1994. Peptide nucleic acid.DNA strand 
displacement loops as artificial transcription promoters. Proc. Natl Acad. Sci. USA 91(9): 3892- 
3895 
 
Montagnoli  A.,  Fiore  F.,  Eytan  E.,  Carrano  A.C.,  Draetta  G.F.,  Hershko  A.,  Pagano  M.,  1999. 
Ubiquitination of  p27 is regulated by Cdk-dependent  phosphorylation and trimeric complex 
formation. Genes Dev. 13: 1181-1189 
 
Motokura T., Bloom T., Kim H.G., Jüppner H., Ruderman J.V., Kronenberg H.M., Arnold A., 1991. A 
novel cyclin encoded by a bcl1-linked candidate oncogene. Nature. 350(6318): 512-515 
- 123 -  
Nastruzzi C., Cortesi R., Esposito E., Gambari R., Borgatti M., Bianchi N., Feriotto G., Mischiati C., 
2000. Liposomes as carriers for DNA-PNA hybrids. Journal of Controlled Release. 68(2): 237- 
249 
 
Nielsen P.E., Egholm M., 1999. An introduction to peptide nucleic acid. Curr. Issues Mol. Biol. 1: 89- 
104 
 
Nielsen P.E., Egholm M., 1999. Peptide Nucleic Acids: Protocols and Applications. Horizon Scientific 
Press, Wymondham, U.K. 
 
Nielsen P.E., Egholm M., Berg R.H., Buchardt O., 1991. Sequence-selective recognition of DNA by 
strand displacement with a thymine-substituted polyamide. Science 254 (5037): 1497-1500 
 
Nourse J., Firpo E., Flanagan W.M., Coats S., Polyak K., Lee M.H, Massague J., Crabtree G.R., 
Roberts J.M., 1994. Interleukin-2-mediated elimination of the p27Kip1 cyclindependent kinase 
inhibitor prevented by rapamycin. Nature. 372(6506): 570-573 
 
Nurse P., 2000. A long twentieth century of the cell cycle and beyond. Cell. 100(1): 71-78 
 
Oh S.Y., Ju Y.S., Park H., 2009. A Highly effective and long-lasting inhibition of miRNA with PNA- 
based antisense oligonucleotides. Molecules and Cells. 28(4): 341-345 
 
Orom U.A., Nielsen F.C., Lund A.H., 2008. MicroRNA-10a binds the 5’UTR of ribosomal protein 
mRNAs and enhances their translation. Mol. Cell. 30: 460-471 
 
Pillai R.S., Bhattacharyya S.N., Artus C.G., Zoller T., Cougot N., Basyuk E., Bertrand E., Filipowicz W., 
2005. Inhibition of translational initiation by let-7 microRNA in human cells. Science 309: 1573- 
1576 
 
Rasmussen  F.W.,  Bendifallah  N.,  Zachar  V.,  Shiraishi  T.,  Fink  T.,  Ebbesen  P.,  Nielsen  P.E., 
Koppelhus U., 2006. Evaluation of transfection protocols for unmodified and modified peptide 
nucleic acid (PNA) oligomers. Oligonucleotides. 16(1): 43-57 
 
Rasmussen H., Kastrup J.S., Nielsen J.N., Nielsen J.M., Nielsen P.E., 1997. Crystal structure of a 
peptide nucleic acid (PNA) duplex at 1.7A resolution. Nat Struct Biol 4: 98-101 
 
Rodier G., Montagnoli A., Di Marcotullio L., Coulombe P., Draetta G.F., Pagano M., Meloche S., 2001. 
p27 cytoplasmic localization is regulated by phosphorylation on Ser10 and is not a prerequisite 
for its proteolysis. EMBO J. 20(23): 6672-6682 
 
Sahu B., Chenna V., Lathrop K.L., Thomas S.M., Zon G., Livak K.J., Ly D.H., 2009. Synthesis of 
conformational preorganized and cell-permeable guanidine-based γ-peptide nucleic acid 
(γGPNAs). Journal of Organic Chemistry. 74(4): 1509-1516 
 
Sanchez-Beato  M.,  Sanchez-Aguilera  A.,  Piris  M.A.,  2003.  Cell  cycle  deregulation  in  B-cell 
lymphomas. Blood 101: 1220-1235 
 
Schwartz D.S., Hutvágner G., Du T., Xu Z., Aronin N., Zamore P.D., 2003. Asymmetry in the assembly 
on the RNAi enzyme complex. Cell. 115: 199-208 
 
Scott  G.K.,  Goga  A.,  Bhaumik  D.,  Berger  C.E.,  Sullivan  C.S.,  Benz  C.C.,  2007.  Coordinate 
suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR- 
125b. J. Biol. Chem. 282: 1479-1486 
 
Serrano M., Hannon G.J., Beach D., 1993. A new regulatory motif in cell-cycle control causing specific 
inhibition of cyclin D/CDK4. Nature. 366(6456): 704-707 
 
Sforza S., Corradini R., Ghirardi S., Dossena A., Marchelli R., 2000. DNA Binding of a DLysine-Based 
Chiral PNA: Direction Control and Mismatch Recognition. European Journal of Organic 
Chemistry. 16: 2905-2913 
 
Sherr C.J., 1994. G1 phase progression: cycling on cue. Cell. 79(4): 551-555 
- 124 -  
Sherr C.J., Roberts J.M., 1999. CDK inhibitors: Positive and negative regulators of G1 phase 
progression. Genes Dev. 13: 1501-1512 
 
Sherr C.J., Roberts J.M., 2004. Living with or without cyclins and cyclin-dependent kinases. Genes 
Dev. 18: 2699-2711 
 
Shiraishi T., Eysturskarth J., Nielsen P.E., 2010. Modulation of mdm2 pre-mRNA splicing by 9 
aminoacridine-PNA (peptide nucleic acid) conjugates targeting intron-exon junctions. BMC 
Cancer 10: 342-351 
 
Shiraishi T., Hamzavi R., Nielsen P.E., 2008. Subnanomolar antisense activity of phosphonate-peptide 
nucleic acid (PNA) conjugates delivered by cationic lipids to HeLa cells. Nucleic Acids Res. 
36(13): 4424–4432 
 
Shiraishi T., Nielsen P.E., 2011. Enhanced cellular delivery of cell-penetrating peptide-peptide nucleic 
acid conjugates by photochemical internalization. Methods Mol. Biol. 683: 391–397 
 
Sibley C.R., Seow Y., Wood M.J., 2010. Novel RNA-based strategies for therapeutic gene silencing. 
Mol. Ther. 18: 466-476 
 
Soule H.D., Vazguez J., Long A., Albert S., Brennan M., 1973. A human cell line from a pleural 
effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 51(5): 1409-1416 
 
Stein C.A.,  1999.  Two  problems in antisense  biotechnology: in vitro delivery and the design  of 
antisense experiments. Biochim. Biophys. Acta. 1489: 45–52 
 
Subramanian S.,  Steer C.J.,  2010.  MicroRNAs as gatekeepers of  apoptosis. Journal  of  Cellular 
Physiology. 223(2): 289-298 
 
Takamizawa J., 2004. Reduced expression of the let-7 microRNAs in human lung cancers in 
association with shortened postoperative survival. Cancer Res. 64: 3753-3756 
 
Takuwa N., Takuwa Y., 1997. Ras activity late in G1 phase required for p27kip1 downregulation, 
passage through the restriction point, and entry into S phase in growth factor-stimulated NIH 
3T3 fibroblasts. Mol. Cell. Biol. 17: 5348-5358 
 
Tavazoie S.F., Alarcón C., Oskarsson T., Padua D., Wang Q., Bos P.D., Gerald W.L., Massagué J., 
2008. Endogenous human microRNAs that suppress breast cancer metastasis. Nature. 451: 
147-152 
 
Tedeschi T., Sforza S., Dossena A., Corradini R., Marchelli R., 2005. Lysine-based peptide nucleic 
acids (PNAs) with strong chiral constraint: control of helix handedness and DNA binding by 
chirality. Chirality 17: S196-S204 
 
Tomoda K., Kubota Y., Kato J., 1999. Degradation of the cyclin-dependent- kinase inhibitor p27Kip1 is 
instigated by Jab1. Nature .398: 160-165 
 
Tonelli R., Purgato S., Camerin C., Fronza R., Bologna F., Alboresi S., Franzoni M., Corradini R., 
Sforza S., Faccini A., Shohet J.M., Marchelli R., Pession A., 2005. Anti-gene peptide nucleic 
acid specifically inhibits MYCN expression in human neuroblastoma cells leading to cell growth 
inhibition and apoptosis. Mol. Cancer Ther. 4(5): 779-786 
 
Tsai L.M., Yu D., 2010. MicroRNAs in common diseases and potential therapeutic applications. Clin. 
Exp. Pharmacol. Physiol. 37:102–107 
 
Valastyan S., Reinhardt F., Benaich N., Calogrias D., Szász A.M., Wang Z.C., Brock J.E., Richardson 
A.L., Weinberg R.A., 2009. A pleiotropically acting microRNA, miR-31, inhibits breast cancer 
metastasis. Cell. 137:1032-1046 
 
Varnholt H., Drebber U., Schulze F., Wedemeyer I., Schirmacher P., Dienes H.P., Odenthal M., 2008. 
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. 
Hepatology 47: 1223-1232 
- 125 -  
Vasudevan S., Tong Y., Steitz J.A., 2007. Switching from repression to activation: microRNAs can up- 
regulate translation. Science 318, 1931–1934 
 
Volinia S., Calin G.A., Liu C.G., Ambs S., Cimmino A., Petrocca F., Visone R., Iorio M., Roldo C., 
Ferracin M., Prueitt R.L., Yanaihara N., Lanza G., Scarpa A., Vecchione A., Negrini M., Harris 
C.C., Croce C.M., 2006. A microRNA expression signature of human solid tumors defines 
cancer gene targets. Proc. Natl. Acad. Sci. USA 103: 2257-2261 
 
Voorhoeve P.M., 2006. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in 
testicular germ cell tumors. Cell 124: 1169-1181 
 
Wang Y.M., Blelloch R., 2009. Cell cycle regulation by MicroRNAs in embryonic stem cells. Cancer 
Research 69(10): 4093-4096 
 
Watanabe N., Hunter T., Ruoslahti E., 1996. Dependence of cyclin E-cdk2 kinase activity on cell 
anchorage. Science 271:499-502 
 
Wojciechowski F., Hudson R.H., 2007. Nucleobase modifications in peptide nucleic acids. Curr. Top 
Med. Chem. 7(7): 667-679 
 
Wojciechowski F., Hudson R.H.E., 2009. Peptide Nucleic Acid Containing a Meta- Substituted 
Phenylpyrrolocytosine Exhibits a Fluorescence Response and Increased Binding Affinity toward 
RNA. Organic Letters Vol. 11(21): 4878-4881 
 
Wuarin J., Nurse P., 1996. Regulating S phase: CDKs, licensing and proteolysis. Cell. 85(6): 785-787 
 
Xiong Y., Connolly T., Futcher B., Beach D., 1991. Human D-type cyclin. Cell. 65(4): 691-699 
 
Zeng Y., Hirano K., Hirano M., Nishimura J., Kanaide H., 2000. Minimal requirements for the nuclear 
localization of p27(Kip1), a cyclin-dependent kinase inhibitor. Biochem Biophys Res Commun. 
274(1): 37-42 
 
Zhang C., Kang C., You Y., Pu P., Yang W., Zhao P., Wang G., Zhang A., Jia Z., Han L., Jiang H., 
2009.  Co-suppression  of  miR-221/222  cluster  suppresses  human  glioma  cell  growth  by 
targeting p27kip1 in vitro and in vivo. Int. J. Oncol. 34(6):1653-1660 
 
Zhao J.J., Lin J., Yang H., Kong W., He L., Ma X., Coppola D., Cheng J.Q.,  2008. MicroRNA-221/222 
negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in 
breast cancer. J. Biol. Chem. 283: 31079-31086 
 
Zhou P., Dragulescu-Andrasi A., Bhattacharya B., 2006. Synthesis of cell-permeable peptide nucleic 
acids and characterization of their hybridization and uptake properties. Bioorg. Med. Chem. Lett. 
16: 4931-4935 
 
Zhou P., Wang M.M., Du L., Fisher G.W., Waggoner A., Ly D.H., 2003. Novel Binding and efficient 
Cellular Uptake of Guanidine-Based Peptide Nucleic Acids (GPNA). Journal of the American 
Chemical Society. 125(23): 6878-6879 
- 126 -  
- GENERAL CONCLUSIONS - 
 
 
 
 
 
The general conclusion of this PhD Thesis is related to the biomedical 
applications  of  the  final  product  of  PNA  synthesis  (the  PNA  itself)  and  the 
intermediate molecules obtained during the synthetic activity. In all the chemical 
synthesis  approach  of  any  pharmaceutical  laboratory  several  molecules  are 
produced, which are usually not considered for biological assays and technology 
transfer. 
The studies presented in this PhD Thesis teach that even intermediate 
synthetic molecules deserve attention in respect to possible biological effects on cells 
relevant to human pathologies. In our study we screened a set of C(5) uracil 
derivatives monomers, that were employed during the PNA synthesis, for activity on 
differentiated functions in K562 cells, a model system mimicking some features of 
chronic myelogenous leukemia (CML) (Gambari et al., 2007). We found that the 
highest antiproliferative effect and erythroid induction ability was exhibited by 
compound 9, a thymine derivative bearing a n-octyl chain on nitrogen N(1), whereas 
thymine (compound 2) did not show any effect, suggesting the importance of the 
linear alkil chain in N(1) position. We have also compared compound 9 with other two 
similar molecules, compound 10 (1-octyl-5-uracilcarboxilic acid) and compound 11 
(N-benzyl-1-octyl-5-uracilcarboxamide); these derivatives present the alkyl chain in 
N1 position but different groups in C(5) position. Compound 10 has an appreciable 
but much lower erythroid differentiation activity, suggesting the importance of C(5) 
position. Compound 9, furthermore, exhibits induce erythroid terminal differentiation 
without activation of apoptotic pathway. 
The interest in the context on anti-tumor differentiation therapy is related to the 
fact that, when compared to known erythroid differentiation antitumor inducers (such 
as for instance cytosine arabinoside, mithramycin, resveratrol), the lead compound 
we were able to identify is the most active agent. Therefore these molecules in our 
opinion deserves further research activity in order to define its possible application, 
for instance in the control of proliferation/differentiation of CML primary cells 
resistance to the commonly employed Imatinib (Gleevec®) therapy. 
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As far as the final product of the synthetic strategy (a PNA recognizing miR- 
 
221 and able to be internalized in target tumor cells thanking to a linked Arg-8 
peptide), the results here presented allows to conclude that (a) it is internalized at 
high  efficiency  into  target  tumor  cells;  (b)  inhibits  the  miR-221  hybridization 
availability and (c) has important effects on biological functions regulated by miR-221 
(i.e. expression of the p27Kip1 mRNA/protein). 
These results are in our opinion of interest, considering on one hand the role 
 
of miR-221 in cancer and, on the other hand, the role of p27Kip1. 
 
As far as miR-221, it was found to be up-regulated in several tumors; in breast 
cancer miR-221 is up-regulated in breast cancer cell line (such as MDA-MB-231) and 
in metastatic tumors. Taken together, miR-221 should be considered as an oncomiR 
and, for this reason, of great interest as molecular target of anticancer therapy. 
In the contest of breast cancer, it was identified p27kip1  mRNA as possible 
 
target of miR-221. The cyclin-kinase inhibitor p27kip1 is a tumor-suppressor protein, 
involved in the control of cell cycle during the G0/G1 check-point transition: the loss 
or decrease of p27
kip1
, together with others, is one of contributory causes of the 
“proliferating state” of invasive cancer, which remains in this growth phase without 
arrive to differentiation. It is of great interest since it was found to be down-regulated 
in several type of tumors. 
In conclusion, we have identify two reagents of possible interest for the 
development of anti-cancer protocols: N(1)-octyl-thymine for the treatment of CML 
cells and Rpep-PNA-a221 for possible use in the treatment of breast cancer cells. 
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